


Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update July 12 - July 18, 2021,

Dr. Peter J. Lansberg MD, PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 28 2021 1059 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click [here](#)

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

[WHO](#)

[Daily dashbord](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[German \(ICU\) bed capacity](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford Universtiy Press](#)

[Cambridge Univeristy Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[COVID reference \(Steinhauser Verlag\)](#)

[COVID-19 Projections tracker](#)

[Retracted papers](#)

[AAN - Neurology resources](#)

[COVID-19 risk tools - Apps](#)

[COVID-19 resources \(Harvard\)](#)

[Web app for SARS-CoV2 mutations](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRF\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

[COVID-19 calculators \(Medscape\)](#)

Guidelines

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

Trials & Registries

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

[COVID-19 prevention network](#)

[Covid-Plex trial - \(plasma exchange & convalescent plasma trial\)](#)

Mainstream Media

New York Times - Corona update

The Delta Variant Is the Symptom of a Bigger Threat: Vaccine Refusal

No Longer 'Hidden Victims,' Children Are Dying as Virus Surges in Indonesia

The Most Influential Spreader of Coronavirus Misinformation Online

Israeli Data Suggests Possible Waning in Effectiveness of Pfizer Vaccine

Persuasion vs. Coercion: Vaccine Debate in Europe Heats Up

The bubble bursts: New Zealand suspends quarantine-free travel from Australia.

Should Vaccinated People Start Wearing Masks Again?

Why Vaccinated People Are Getting 'Breakthrough' Infections

Washington Post - Corona update

If you got the J&J vaccine, should you get a booster dose of Pfizer or Moderna?

More than 4 million dead: Tracking global cases

Europe's hotels and restaurants are eager to welcome tourists — if they can find enough staff

Health experts discuss vaccines

Why some experts recommend upgrading to N95 masks to help fight the delta variant

Guardian - Corona update

Indonesia loosens Covid restrictions despite record deaths

Doctors warn over increasing number of young people with Covid in ICU

Under-30s reluctant to take Covid vaccine cite fertility and side-effect concerns

'Heart-wrenching': inside a hospital grappling with Delta and vaccine hesitancy.

PHE upgrade Delta variant's risk level due to reinfection risk

Key Articles

1. **Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know?** J. Clin. Med. Res. 2021; 13:317-325 Vasireddy D, Vanaparthi R, Mohan G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267839>
2. **The devil in the details: Herd immunity and pandemic response.** Cell Host Microbe 2021; 29:1048-1051 Schaeffer B, Taylor B, Bushman M, Hanage WP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265244>
3. **The effectiveness of Colchicine as an anti-inflammatory drug in the treatment of coronavirus disease 2019: Meta-analysis.** Int. J. Immunopathol. Pharmacol. 2021; 35:20587384211031763 Golpour M, Mousavi T, Alimohammadi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250834>
4. **Prior Statin Use and Risk of Mortality and Severe Disease From Coronavirus Disease 2019: A Systematic Review and Meta-analysis.**

Open Forum Infect Dis 2021; 8:ofab284Yetmar ZA, Chesdachai S, Kashour T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258316>

5. **Plausible Positive Effects of Statins in COVID-19 Patient.** Cardiovasc. Toxicol. 2021;1-9Vitiello A, Ferrara F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255300>
6. **Venous and arterial thromboembolic disease in COVID-19.** J. Thromb. Thrombolysis 2021;1-3Ten Berg J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255267>
7. **Outcome and death risk of diabetes patients with Covid-19 receiving pre-hospital and in-hospital metformin therapies.** Diabetol. Metab. Syndr. 2021; 13:76Tamura RE, Said SM, de Freitas LM, Rubio IGS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256824>
8. **A living mapping review for COVID-19 funded research projects: nine-month update.** Wellcome Open Res 2020; 5:209Norton A, Bucher A, Antonio E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117894>
9. **Self-infection with speech aerosol may contribute to COVID-19 severity.** J Intern Med 2021; Kushalnagar P, Chow CC, Bax A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268819>
10. **Effectiveness of contact tracing apps for SARS-CoV-2: a rapid systematic review.** BMJ Open 2021; 11:e050519Jenniskens K, Bootsma MCJ, Damen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253676>
11. **Recurrent massive pulmonary embolism following catheter directed thrombolysis in a 21-year-old with COVID-19: a case report.** Eur Heart J Case Rep 2021; 5:ytab140Hirschbaum JH, Bradley CP, Kingsford P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268475>
12. **An outline of SARS-CoV-2 pathogenesis and the complement cascade of immune system.** Bull Natl Res Cent 2021; 45:123Hembram P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257504>
13. **Addressing Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following COVID-19 Vaccination: A Mini-Review of Practical Strategies.** Acta Cardiol Sin 2021; 37:355-364Chen PW, Tsai ZY, Chao TH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257485>
14. **COVID-19 and cardiovascular system-a comprehensive review.** Rev Cardiovasc Med 2021; 22:343-351AlShahrani I, Hosmani J, Shankar VG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258902>
15. **Symptoms, complications and management of long COVID: a review.** J R Soc Med 2021;1410768211032850Aiyegbusi OL, Hughes SE, Turner G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265229>

Basic Science (32 articles)

1. **Recent advances in developing small-molecule inhibitors against SARS-CoV-2.** Acta Pharm Sin B 2021; Xiang R, Yu Z, Wang Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34249607>
2. **Transmission trend of the COVID-19 pandemic predicted by dendritic neural regression.** Appl Soft Comput 2021; 111:107683Dong M, Tang C, Ji J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34248448>
3. **Discovering common pathogenetic processes between COVID-19 and diabetes mellitus by differential gene expression pattern analysis.** Brief. Bioinform. 2021; Rahman MR, Islam T, Shahjaman M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34260684>
4. **An outline of SARS-CoV-2 pathogenesis and the complement cascade of immune system.** Bull Natl Res Cent 2021; 45:123Hembram P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34257504>
5. **Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses.** Cell 2021; Nathan A, Rossin EJ, Kaseke C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34265281>
6. **Metal Organic Frameworks as Biosensing Materials for COVID-19.** Cell. Mol. Bioeng. 2021;1-19Udourioh GA, Solomon MM, Epelle EI.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34249167>
7. **Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19.** Cell Rep. 2021:109414Neidleman J, Luo X, George AF *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34260965>
8. **Complement activation and increased expression of Syk, mucin-1 and CaMK4 in kidneys of patients with COVID-19.** Clin Immunol 2021; 229:108795Jamaly S, Tsokos MG, Bhargava R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252574>
9. **COVID-19 candidate genes and pathways potentially share the association with lung cancer.** Comb. Chem. High Throughput Screen. 2021; Alnajeebi AM, Alharbi HFH, Alelwani W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254909>
10. **Efficient machine learning model for predicting drug-target interactions with case study for Covid-19.** Comput. Biol. Chem. 2021; 93:107536El-Behery H, Attia AF, El-Feshawy N, Torkey H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271420>
11. **Unravelling the therapeutic potential of marine drugs as SARS-CoV-2 inhibitors: An insight from essential dynamics and free energy landscape.** Comput. Biol. Med. 2021; 135:104525Rampogu S, Gajula RG, Lee G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34252682>
12. **The Altered Anatomical Distribution of ACE2 in the Brain With Alzheimer's Disease Pathology.** Front Cell Dev Biol 2021; 9:684874Cui H, Su S, Cao Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34249938>
13. **Catalytic Dyad Residues His41 and Cys145 Impact the Catalytic Activity and Overall Conformational Fold of the Main SARS-CoV-2 Protease 3-**

- Chymotrypsin-Like Protease.** *Front Chem* 2021; 9:692168 Ferreira JC, Fadl S, Villanueva AJ, Rabeh WM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249864>
14. **Soluble Neuropilin-1 Response to Hypoglycemia in Type 2 Diabetes: Increased Risk or Protection in SARS-CoV-2 Infection?** *Front. Endocrinol. (Lausanne)* 2021; 12:665134 Moin ASM, Al-Qaissi A, Sathyapalan T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248841>
 15. **Interleukin-1- Receptor Kinase 4 Inhibition: Achieving Immunomodulatory Synergy to Mitigate the Impact of COVID-19.** *Front. Immunol.* 2021; 12:693085 Gupta A, Chun HJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248990>
 16. **A Computational Approach Identified Andrographolide as a Potential Drug for Suppressing COVID-19-Induced Cytokine Storm.** *Front. Immunol.* 2021; 12:648250 Rehan M, Ahmed F, Howladar SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248936>
 17. **Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets.** *Front. Immunol.* 2021; 12:694857 Riddell S, Goldie S, McAuley AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248993>
 18. **Severe COVID-19 Recovery Is Associated with Timely Acquisition of a Myeloid Cell Immune-Regulatory Phenotype.** *Front. Immunol.* 2021; 12:691725 Trombetta AC, Farias GB, Gomes AMC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248984>
 19. **Novel Highly Divergent SARS-CoV-2 Lineage With the Spike Substitutions L249S and E484K.** *Front Med (Lausanne)* 2021; 8:697605 Laiton-Donato K, Usme-Ciro JA, Franco-Muñoz C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262921>
 20. **In vitro Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms.** *Front. Microbiol.* 2021; 12:698944 Lassaunière R, Fonager J, Rasmussen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248922>
 21. **A protein interactions map of multiple organ systems associated with COVID-19 disease.** *Genomics Inform* 2021; 19:e14 Bharne D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261299>
 22. **Detection of Representative Mutant Strains and a Case of Prolonged Infection by SARS-CoV-2 with Spike 69/70 Deletion in Japan.** *Infect Drug Resist* 2021; 14:2579-2581 Takano K, Watanabe Y, Hariu M, Seki M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267528>
 23. **Computational drug repurposing study of antiviral drugs against main protease, RNA polymerase, and spike proteins of SARS-CoV-2 using molecular docking method.** *J. Basic Clin. Physiol. Pharmacol.* 2021; Jalalvand A, Khatouni SB, Najafi ZB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265888>
 24. **SARS-CoV-2 B.1.617 mutations L452 and E484Q are not synergistic for antibody evasion.** *J Infect Dis* 2021; Ferreira I, Kemp S, Datir R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260717>
 25. **HIV infection drives interferon signalling within intestinal SARS-CoV-2 target cells.** *JCI Insight* 2021; Fardoos R, Asowata OE, Herbert N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252054>
 26. **Synthetic Attempts Towards Eminent Anti-Viral Candidates of SARS-CoV.** *Mini Rev. Med. Chem.* 2021; Kundu S, Sarkar D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254915>

27. **Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines.** Mol. Pharm. 2021; Chatzikleanthous D, O'Hagan DT, Adamo R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264684>
28. **Periodic thermomechanical modulation of toll-like receptor expression and distribution in mesenchymal stromal cells.** MRS Commun 2021;1-7Xu X, Nie Y, Wang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258101>
29. **A synthetic defective interfering SARS-CoV-2.** PeerJ 2021; 9:e11686Yao S, Narayanan A, Majowicz SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249513>
30. **Platelet-leukocyte interactions in the pathogenesis of viral infections.** Platelets 2021;1-8Hottz ED, Quirino-Teixeira AC, Merij LB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260328>
31. **Genetic Control of Human Infection with SARS-CoV-2.** Russ J Genet 2021; 57:627-641Kucher AN, Babushkina NP, Sleptcov AA, Nazarenko MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248311>
32. **First detection and molecular analysis of SARS-CoV-2 from a naturally infected cat from Argentina.** Vet. Microbiol. 2021; 260:109179Fuentealba NA, Moré G, Bravi ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271305>

Biomarkers - Genetics (113 articles)

1. **Making a Difference: Adaptation of the Clinical Laboratory in Response to the Rapidly Evolving COVID-19 Pandemic.** Acad Pathol 2021; 8:23742895211023948Sahajpal NS, Mondal AK, Ananth S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263025>
2. **Dye-Loaded Polymersome-Based Lateral Flow Assay: Rational Design of a COVID-19 Testing Platform by Repurposing SARS-CoV-2 Antibody Cocktail and Antigens Obtained from Positive Human Samples.** ACS Sens 2021; Ghorbanizamani F, Tok K, Moulahoum H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34270230>
3. **Pulling-Force Spinning Top for Serum Separation Combined with Paper-Based Microfluidic Devices in COVID-19 ELISA Diagnosis.** ACS Sens 2021; Gong F, Wei HX, Qi J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263598>
4. **Reverse Transcription Polymerase Chain Reaction Pattern of SARS-CoV-2 Beta Variant.** Acta Med Port 2021; Fonseca ESD, Silva PD, Baldaque I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274029>
5. **Serum CK-MB, COVID-19 severity and mortality: An updated systematic review and meta-analysis with meta-regression.** Adv. Med. Sci. 2021; 66:304-314Zinellu A, Sotgia S, Fois AG, Mangoni AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256241>
6. **Enhanced lateral flow testing strategies in care homes are associated with poor adherence and were insufficient to prevent COVID-19 outbreaks: Results from a mixed methods implementation study.** Age Ageing 2021; Tulloch JSP, Micocci M, Buckle P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272866>
7. **Impaired semen parameters in patients with confirmed SARS-CoV-2 infection: A prospective cohort study.** Andrologia 2021:e14157Pazir Y, Eroglu T, Kose A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268784>
8. **Myeloid phenotypes in severe COVID-19 predict secondary infection and mortality: a pilot study.** Ann Intensive Care 2021; 11:111Marais C, Claude C,

- Semaan N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259942>
9. **Platelet activation in critically ill COVID-19 patients.** *Ann Intensive Care* 2021; 11:113Yatim N, Boussier J, Chocron R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273008>
 10. **A chemical-enhanced system for CRISPR-Based nucleic acid detection.** *Biosens. Bioelectron.* 2021; 192:113493Li Z, Zhao W, Ma S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271398>
 11. **A rapid, ultrasensitive voltammetric biosensor for determining SARS-CoV-2 spike protein in real samples.** *Biosens. Bioelectron.* 2021; 192:113497Liv L, Çoban G, Nakiboğlu N, Kocagöz T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274624>
 12. **The TDs/aptamer cTnI biosensors based on HCR and Au/Ti(3)C(2)-MXene amplification for screening serious patient in COVID-19 pandemic.** *Biosens. Bioelectron.* 2021; 192:113482Mi X, Li H, Tan R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256261>
 13. **A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae.** *BMC Infect. Dis.* 2021; 21:677LaVergne SM, Stromberg S, Baxter BA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256735>
 14. **Longitudinal trajectories of pneumonia lesions and lymphocyte counts associated with disease severity among convalescent COVID-19 patients: a group-based multi-trajectory analysis.** *BMC Pulm. Med.* 2021; 21:233Shi N, Huang C, Zhang Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256743>
 15. **COVID-19: a confirmed case of reinfection in a nurse.** *BMJ Case Rep.* 2021; 14Scarpati G, Piazza O, Pagliano P, Rizzo F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257135>
 16. **National cross-sectional survey of 1.14 million NHS staff SARS-CoV-2 serology tests: a comparison of NHS staff with regional community seroconversion rates.** *BMJ Open* 2021; 11:e049703Coltart CEM, Wells D, Sutherland E, Fowler A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257096>
 17. **Vulnerability of patients on immunosuppressive therapy to SARS-CoV-2 reinfection.** *BMJ Support Palliat Care* 2021; Pathania YS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257064>
 18. **Discovering common pathogenetic processes between COVID-19 and diabetes mellitus by differential gene expression pattern analysis.** *Brief. Bioinform.* 2021; Rahman MR, Islam T, Shahjaman M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260684>
 19. **An outline of SARS-CoV-2 pathogenesis and the complement cascade of immune system.** *Bull Natl Res Cent* 2021; 45:123Hembram P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257504>
 20. **Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19.** *Cell Rep.* 2021:109414Neidleman J, Luo X, George AF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260965>
 21. **Determination of camostat and its metabolites in human plasma - preservation of samples and quantification by a validated UHPLC-MS/MS method.** *Clin. Biochem.* 2021; Sørensen LK, Hasselstrøm JB, Gunst JD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252447>
 22. **A theoretical simulation of SARS-CoV-2 pooled testing: Pooled sample collection outperforms pooled RNA extraction.** *Clin Chim Acta* 2021; 521:155-157He Y, Tong Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274344>

23. **Calprotectin in viral systemic infections-COVID-19 versus hepatitis C virus.** Clin. Exp. Med. 2021;1-7Toma L, Dodot M, Zgura A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34254197>
24. **Complement activation and increased expression of Syk, mucin-1 and CaMK4 in kidneys of patients with COVID-19.** Clin Immunol 2021; 229:108795Jamaly S, Tsokos MG, Bhargava R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252574>
25. **The potential clinical utility of measuring SARS-CoV-2-specific T-cell responses.** Clin Microbiol Infect 2021; Goletti D, Petrone L, Manissero D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34256141>
26. **Duration of SARS-CoV-2 viral culture Positivity among different specimen types.** Clin Microbiol Infect 2021; Kojima N, Mores C, Farsai N, Klausner JD.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34274524>
27. **COVID-19 candidate genes and pathways potentially share the association with lung cancer.** Comb. Chem. High Throughput Screen. 2021; Alnajeebi AM, Alharbi HFH, Alelwani W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254909>
28. **Asystole During Nasopharyngeal Swab: Is COVID-19 to Blame?** Cureus 2021; 13:e15448Madanat L, Khalife A, Sims M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249579>
29. **Biomarkers Predictive of Extubation and Survival of COVID-19 Patients.** Cureus 2021; 13:e15462Topp G, Bouyea M, Cochran-Caggiano N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34258124>
30. **The Role of Antiphospholipid Antibodies in COVID-19.** Curr. Rheumatol. Rep. 2021; 23:72Stelzer M, Henes J, Saur S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259944>
31. **Higher admission activated partial thromboplastin time, neutrophil-lymphocyte ratio, serum sodium, and anticoagulant use predict in-hospital COVID-19 mortality in people with Diabetes: Findings from Two University Hospitals in the U.K.** Diabetes Res Clin Pract 2021; 178:108955Iqbal A, Greig M, Arshad MF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273452>
32. **Extractionless nucleic acid detection: a high capacity solution to COVID-19 testing.** Diagn. Microbiol. Infect. Dis. 2021; 101:115458Baksh S, Volodko N, Soucie M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274751>
33. **The efficiency of COVID-19 testing centers in Iran: A data envelopment analysis approach Hamed Seddighi, Hossein Baharmand, Ali Morovati Sharifabadi, Ibrahim Salmani, Saeideh Seddighi.** Disaster Med Public Health Prep 2021;1-13Seddighi H, Baharmand H, Morovati Sharifabadi A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34254576>
34. **Passive Sampling of SARS-CoV-2 for Wastewater Surveillance.** Environ. Sci. Technol. 2021; Schang C, Crosbie ND, Nolan M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34264643>
35. **The relative expression of miR-31, miR-29, miR-126, and miR-17 and their mRNA targets in the serum of COVID-19 patients with different grades during hospitalization.** Eur. J. Med. Res. 2021; 26:75Keikha R, Hashemi-Shahri SM, Jebali A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256840>
36. **Association of ABO and Rh blood groups with obstetric outcomes in SARS-CoV-2 infected pregnancies: A prospective study with a multivariate analysis.** Eur. J. Obstet. Gynecol. Reprod. Biol. 2021; 264:41-48Sainz Bueno JA, Cerrillos

- González L, Abascal-Saiz A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271364>
37. **Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021.** Euro Surveill 2021; 26:Alizon S, Haim-Boukobza S, Foulongne V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269174>
 38. **Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C).** Exp. Biol. Med. (Maywood). 2021;15353702211028560 Kuypers FA, Rostad CA, Anderson EJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255566>
 39. **COVID-19 vulnerabilities are intensified by declining Human Serum Albumin levels.** Exp. Physiol. 2021; Johnson AS, Winlow W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275164>
 40. **B-Type Natriuretic Peptide Concentrations, COVID-19 Severity, and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression.** Front Cardiovasc Med 2021; 8:690790 Zinellu A, Sotgia S, Carru C, Mangoni AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250044>
 41. **The Altered Anatomical Distribution of ACE2 in the Brain With Alzheimer's Disease Pathology.** Front Cell Dev Biol 2021; 9:684874 Cui H, Su S, Cao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249938>
 42. **PNPLA3 and TLL-1 Polymorphisms as Potential Predictors of Disease Severity in Patients With COVID-19.** Front Cell Dev Biol 2021; 9:627914 Grimaudo S, Amodio E, Pipitone RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249902>
 43. **The Gut Microbiota of Critically Ill Patients With COVID-19.** Front Cell Infect Microbiol 2021; 11:670424 Gaibani P, D'Amico F, Bartoletti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268136>
 44. **A Multiplex and Colorimetric Reverse Transcription Loop-Mediated Isothermal Amplification Assay for Sensitive and Rapid Detection of Novel SARS-CoV-2.** Front Cell Infect Microbiol 2021; 11:653616 Juscamayta-López E, Valdivia F, Horna H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268131>
 45. **Soluble Neuropilin-1 Response to Hypoglycemia in Type 2 Diabetes: Increased Risk or Protection in SARS-CoV-2 Infection?** Front. Endocrinol. (Lausanne) 2021; 12:665134 Moin ASM, Al-Qaissi A, Sathyapalan T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248841>
 46. **Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 Severity.** Front. Endocrinol. (Lausanne) 2021; 12:658304 Moin ASM, Al-Qaissi A, Sathyapalan T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248840>
 47. **Dyslipidemia Is Related to Mortality in Critical Patients With Coronavirus Disease 2019: A Retrospective Study.** Front. Endocrinol. (Lausanne) 2021; 12:611526 Yue J, Xu H, Zhou Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248834>
 48. **SARS-CoV-2/ACE2 Interaction Suppresses IRAK-M Expression and Promotes Pro-Inflammatory Cytokine Production in Macrophages.** Front. Immunol. 2021; 12:683800 Pantazi I, Al-Qahtani AA, Alhamlan FS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248968>
 49. **Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning.** Front. Immunol. 2021; 12:700782 Patterson BK, Guevara-Coto J, Yogendra R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262570>

50. **Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2.** *Front. Microbiol.* 2021; 12:676314Castonguay N, Zhang W, Langlois MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267735>
51. **Oral Microbiome Dysbiosis Is Associated With Symptoms Severity and Local Immune/Inflammatory Response in COVID-19 Patients: A Cross-Sectional Study.** *Front. Microbiol.* 2021; 12:687513Soffritti I, D'Accolti M, Fabbri C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248910>
52. **Epidemiology of SARS-CoV-2 Infection Evaluated by Immunochromatographic Rapid Testing for the Determination of IgM and IgG Against SARS-CoV-2 in a Cohort of Mask Wearing Workers in the Metal-Mechanical Sector in an Area With a High Incidence of COVID-19.** *Front Public Health* 2021; 9:628098Esposito S, Neglia C, Affanni P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249830>
53. **Rapid Point-Of-Care Serology and Clinical History Assessment Increase Protection Provided by RT-PCR Screening: A Pilot Study Involving Three Nursing Homes in Brescia, a Hotspot of Lombardy.** *Front Public Health* 2021; 9:649524Savio A, Calza S, Guerrini G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249831>
54. **A machine learning PROGRAM to identify COVID-19 and other diseases from hematology data.** *Future Sci OA* 2021; 7:Fso733Gladding PA, Ayar Z, Smith K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254032>
55. **Validation of red cell distribution width as a COVID-19 severity screening tool.** *Future Sci OA* 2021; 7:Fso712Pouladzadeh M, Safdarian M, Choghakabodi PM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254030>
56. **Blood system ABO antigens as risk factor for severity of SARS-CoV-2 infection.** *Gac Med Mex* 2021; 157:174-180Torres-Alarcón CG, García-Ruiz A, Cañete-Ibáñez CR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34270530>
57. **Relevance of vitamin D(3) in COVID-19 infection.** *Gene Rep* 2021; 24:101270UI Afshan F, Nissar B, Chowdri NA, Ganai BA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250314>
58. **Rhizopus homothallicus: An emerging pathogen in era of COVID-19 associated mucormycosis.** *Indian J. Med. Microbiol.* 2021; Kaur H, Kanaujia R, Rudramurthy SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266698>
59. **COVID-19: Zinc and Angiotensin-Converting Enzyme 2 (ACE2) Deficiencies as Determinants of Risk and Severity of Disease: A Narrative Review.** *Infect Dis Ther* 2021:1-11Salgo MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251655>
60. **Detection of Representative Mutant Strains and a Case of Prolonged Infection by SARS-CoV-2 with Spike 69/70 Deletion in Japan.** *Infect Drug Resist* 2021; 14:2579-2581Takano K, Watanabe Y, Hariu M, Seki M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267528>
61. **Genetic and evolutionary analysis of SARS-CoV-2 circulating in the region surrounding Islamabad, Pakistan.** *Infect Genet Evol* 2021:105003Tamim S, Trovao NS, Thielen P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271187>
62. **Glycemic control among children and adolescents with type 1 diabetes during COVID-19 pandemic in Egypt: a pilot study.** *Int. J. Diabetes Dev. Ctries.* 2021:1-7Elhenawy YI, Eltonbary KY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257483>
63. **Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case.** *Int J Infect Dis* 2021; Connor BA, Couto-Rodriguez M, Barrows JE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271202>

64. **nnAge significantly influences the sensitivity of SARS-CoV-2 rapid antibody assays.** *Int J Infect Dis* 2021; Irwin N, Murray L, Ozynski B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34271199>
65. **Analysis of SARS-CoV-2 RT-qPCR Ct values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region.** *Int J Infect Dis* 2021; Markewitz R, Torge A, Wandinger KP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273511>
66. **AuNP Coupled Rapid Flow-Through Dot-Blot Immuno-Assay for Enhanced Detection of SARS-CoV-2 Specific Nucleocapsid and Receptor Binding Domain IgG.** *Int J Nanomedicine* 2021; 16:4739-4753 Sil BK, Jamiruddin MR, Haq MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267520>
67. **Diagnostic performance of the Elecsys SARS-CoV-2 antigen assay in the clinical routine of a tertiary care hospital: Preliminary results from a single-center evaluation.** *J. Clin. Lab. Anal.* 2021:e23906 Mueller T, Kompatscher J, La Guardia M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251047>
68. **Low serum level of apolipoprotein A1 may predict the severity of COVID-19: A retrospective study.** *J. Clin. Lab. Anal.* 2021:e23911 Zhu Z, Yang Y, Fan L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34260764>
69. **Gut microbiota, inflammation, and molecular signatures of host response to infection.** *J Genet Genomics* 2021; Gou W, Fu Y, Yue L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34257044>
70. **COVID-19 diagnosis and testing in pediatric heart transplant recipients.** *J Heart Lung Transplant.* 2021; Bock MJ, Kuhn MA, Chinnock RE.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34253455>
71. **Does ABO Blood Groups Affect Outcomes in Hospitalized COVID-19 Patients?** *J Hematol* 2021; 10:98-105 Kumar G, Nanchal R, Herrera M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34267846>
72. **Blood cell morphology and COVID-19 clinical course, severity, and outcome.** *J Hematop.* 2021:1-8 Pezeshki A, Vaezi A, Nematollahi P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34249171>
73. **Is diffusion of SARS-CoV-2 variants of concern associated with different symptoms?: Symptoms of COVID-19.** *J Infect* 2021; Mattiuzzi C, Henry BM, Lippi G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274361>
74. **Accuracy of Rapid Point-of-Care Antibody Test in patients with suspected or confirmed COVID-19.** *J Infect* 2021; Vancheeswaran R, Willcox ML, Stuart B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34273411>
75. **SARS-CoV-2 B.1.617 mutations L452 and E484Q are not synergistic for antibody evasion.** *J Infect Dis* 2021; Ferreira I, Kemp S, Datir R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34260717>
76. **Cross-sectional assessment of SARS-CoV-2 viral load by symptom status in Massachusetts congregate living facilities.** *J Infect Dis* 2021; Lennon NJ, Bhattacharyya RP, Mina MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255846>
77. **Severe acute respiratory syndrome coronavirus 2 reinfection in a coronavirus disease 2019 recovered young adult: a case report.** *J Med Case Rep* 2021; 15:382 Awada H, Nassereldine H, Hajj Ali A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271967>
78. **Recurrent COVID-19 infection in a health care worker: a case report.** *J Med Case Rep* 2021; 15:363 Garg J, Agarwal J, Das A, Sen M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34253225>

79. **Probable viremia and positive placental swabs for SARS-CoV-2 in a preterm pregnant woman with mild COVID-19.** J Med Virol 2021; Akdemir Y, Haciseyitoglu D, Celebi G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260081>
80. **Cycle threshold values in RT-PCR to determine dynamics of SARS-CoV-2 viral load: An approach to reduce isolation period for COVID-19 patients.** J Med Virol 2021; Aranha C, Patel V, Bhor V, Gogoi D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264527>
81. **Cycle threshold values in RT-PCR to determine dynamics of SARS-CoV-2 viral load: An approach to reduce the isolation period for COVID-19 patients.** J Med Virol 2021; Aranha C, Patel V, Bhor V, Gogoi D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264527>
82. **Effect of Different Storage Conditions on Covid-19 RT-PCR Results.** J Med Virol 2021; Gulec EY, Cesur NP, Fazlioğlu GY, Kazezoğlu C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260086>
83. **Evaluation of Rapid Antibody Test and Chest Computed Tomography Results of COVID-19 Patients: A Retrospective Study.** J Med Virol 2021; Ozturk A, Bozok T, Bozok TS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260078>
84. **Dexamethasone treatment may mitigate adverse effects of vitamin D deficiency in hospitalised Covid-19 patients.** J Med Virol 2021; Wenban C, Heer RS, Baktash V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273116>
85. **The evolution of rapid antigen detection systems and their application for COVID-19 and other serious respiratory infectious diseases.** J Microbiol Immunol Infect 2021; C SP, M MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272205>
86. **Integrative Modeling of Plasma Metabolic and Lipoprotein Biomarkers of SARS-CoV-2 Infection in Spanish and Australian COVID-19 Patient Cohorts.** J. Proteome Res. 2021; Masuda R, Lodge S, Nitschke P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251833>
87. **Harmonized D-dimer levels upon admission for prognosis of COVID-19 severity: Results from a Spanish multicenter registry (BIOCOVID-Spain study).** J. Thromb. Thrombolysis 2021;1-10García de Guadiana-Romualdo L, Morell-García D, Favaloro EJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272635>
88. **Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay.** JCI Insight 2021; Lopez E, Haycroft ER, Adair A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251356>
89. **Clinical utility of biochemical markers for the prediction of COVID-19-related mortality in kidney transplant recipients.** Kidney Int Rep 2021; Caillard S, Chavarot N, Francois H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254049>
90. **The nasal and pharyngeal swab techniques during the COVID-19-pandemic - The ENT-perspective: SARS-CoV-2, Coronavirus, nasal swab, pharyngeal swab, complications.** Laryngo- Rhino- Otologie 2021; 100:517-525Deitmer T, Dietz A, Chaberny IF, Pietsch C.
91. **Highly expressed ACE-2 receptors during pregnancy: A protective factor for SARS-COV-2 infection?** Med. Hypotheses 2021; 153:110641Figueiro-Filho EA, Hobson SR, Farine D, Yudin MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256245>
92. **The considerable impact of the SARS-CoV-2 pandemic and COVID-19 on the UK National Mycology Reference Laboratory activities and workload.** Med.

- Mycol. 2021; Borman AM, Fraser M, Patterson Z *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34259872>
93. **Absolute quantification of SARS-CoV-2 with Clarity Plus™ digital PCR.** Methods 2021; Yi Han Tan S, Yi Milton Kwek S, Low H, Ling Joy Pang Y.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34273478>
 94. **Self-Collected Gargle Lavage Allows Reliable Detection of SARS-CoV-2 in an Outpatient Setting.** Microbiol Spectr 2021:e0036121Zander J, Scholtes S, Ottinger M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259547>
 95. **Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis.** Microvasc. Res. 2021:104224Andrianto, Al-Farabi MJ, Nugraha RA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34273359>
 96. **Serum Lateral Flow Assay with Digital Reader for the Diagnosis of Invasive Pulmonary Aspergillosis: A Two Center Mixed Cohort Study.** Mycoses 2021; Hoenigl M, Egger M, Boyer J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252244>
 97. **Serum Lateral Flow assay with digital reader for the diagnosis of invasive pulmonary aspergillosis: A two-centre mixed cohort study.** Mycoses 2021; Hoenigl M, Egger M, Boyer J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252244>
 98. **Performance and Operational Evaluation of the Access Bio CareStart Rapid Antigen Test in a High-Throughput Drive-Through Community Testing Site in Massachusetts.** Open Forum Infect Dis 2021; 8:ofab243Pollock NR, Tran K, Jacobs JR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250188>
 99. **First Experience Addressing the Prognostic Utility of Novel Urinary Biomarkers in Patients With COVID-19.** Open Forum Infect Dis 2021; 8:ofab274Tantry US, Bliden KP, Cho A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250193>
 100. **Oxidant and antioxidant balance in patients with COVID-19.** Pediatr Pulmonol 2021; Aykac K, Ozsurekci Y, Yayla BCC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265172>
 101. **Platelet-leukocyte interactions in the pathogenesis of viral infections.** Platelets 2021:1-8Hottz ED, Quirino-Teixeira AC, Merij LB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34260328>
 102. **COVID-19 pneumonia: relationship between initial chest X-rays and laboratory findings.** Radiologia (Roma) 2021; Nava-Muñoz Á, Gómez-Peña S, Fuentes-Ferrer ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253334>
 103. **C-Reactive protein and SOFA scale: A simple score as early predictor of critical care requirement in patients with COVID-19 pneumonia in Spain.** Rev. Esp. Anesthesiol. Reanim. 2021; Vaquero-Roncero LM, Sánchez-Barrado E, Escobar-Macias D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247837>
 104. **The effectiveness of non-contact thermal screening as a means of identifying cases of Covid-19: a rapid review of the evidence.** Rev Med Virol 2021; 31:e2192Cardwell K, Jordan K, Byrne P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260781>
 105. **Genetic Control of Human Infection with SARS-CoV-2.** Russ J Genet 2021; 57:627-641Kucher AN, Babushkina NP, Sleptcov AA, Nazarenko MS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34248311>

106. **COVID-19 and dysnatremia: A comparison between COVID-19 and non-COVID-19 respiratory illness.** *SAGE Open Med* 2021; 9:20503121211027778Voets PJ, Frölke SC, Vogtländer NP, Kaasjager KA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262763>
107. **Monitoring of SARS-CoV-2 RNA in wastewater as an epidemiological surveillance tool in Mendoza, Argentina.** *Sci Total Environ* 2021; 796:148887Giraud-Billoud M, Cuervo P, Altamirano JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274669>
108. **A direct capture method for purification and detection of viral nucleic acid enables epidemiological surveillance of SARS-CoV-2.** *Sci Total Environ* 2021; 795:148834Mondal S, Feirer N, Brockman M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252764>
109. **Sensitive and rapid on-site detection of SARS-CoV-2 using a gold nanoparticle-based high-throughput platform coupled with CRISPR/Cas12-assisted RT-LAMP.** *Sens. Actuators B Chem.* 2021; 345:130411Zhang Y, Chen M, Liu C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248284>
110. **Clinical characteristics and outcomes of COVID-19 long-term nucleic acid positive patients.** *Technol. Health Care* 2021; Zhu X, Zhu X, Wang M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250914>
111. **Elevated glycohemoglobin is linked to critical illness in CoVID-19: a retrospective analysis.** *Ther Adv Infect Dis* 2021; 8:20499361211027390Windham S, Wilson MP, Fling C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249357>
112. **Significance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation.** *Vaccine* 2021; Fujimoto AB, Keskinocak P, Yildirim I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274126>
113. **First detection and molecular analysis of SARS-CoV-2 from a naturally infected cat from Argentina.** *Vet. Microbiol.* 2021; 260:109179Fuentealba NA, Moré G, Bravi ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271305>

Children (31 articles)

1. **Kids are back in town: the return of high demand for paediatric emergency care.** *Arch. Dis. Child.* 2021; Jenner R, Walker A, Isba R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266875>
2. **Delayed diagnosis of ingested button battery leading to tracheoesophageal fistula in a child infected with SARS-CoV-2.** *BMJ Case Rep.* 2021; 14Goussard P, Janson J, Nel E, Schubert P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253535>
3. **Cardiac Implications of Multisystem Inflammatory Syndrome Associated with COVID-19 in Children under the age of Five Years.** *Cardiol. Young* 2021:1-15Rakha S, Sobh A, Hager AH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261560>
4. **Intraoperative Ultrasonographic Assessment of Vocal Cord motion under sedation, following pediatric thyroidectomy in the Era of COVID-19, a double-blinded preliminary study.** *Clin. Otolaryngol.* 2021; Zavdy O, Schwarz M, Gilony D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255927>
5. **Intraoperative Ultrasonographic Assessment of Vocal Cord motion under sedation, following paediatric thyroidectomy in the Era of COVID-19: A double-blinded preliminary study.** *Clin. Otolaryngol.* 2021; Zavdy O, Schwarz M, Gilony D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255927>

6. **Media use before, during and after COVID-19 lockdown according to parents in a clinically referred sample in child and adolescent psychiatry: Results of an online survey in Switzerland.** Compr. Psychiatry 2021; 109:152260Werling AM, Walitza S, Grünblatt E, Drechsler R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265597>
7. **SARS-CoV-2 infection and paediatric endocrine disorders: Risks and management considerations.** Endocrinol Diabetes Metab 2021; 4:e00262Miller R, Ashraf AP, Gourgari E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268455>
8. **Effect of the COVID-19 quarantine on metabolic control in children and adolescents with type 1 diabetes.** Endocrinol Diabetes Nutr 2021; Turan H, Güneş Kaya D, Tarçın G, Evliyaoğlu SO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274306>
9. **COVID-19 unmasked: preschool children's negative thoughts and worries during the COVID-19 pandemic in Australia.** Eur J Psychotraumatol 2021; 12:1924442Vasileva M, Alisic E, De Young A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249241>
10. **Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C).** Exp. Biol. Med. (Maywood). 2021:15353702211028560Kuypers FA, Rostad CA, Anderson EJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255566>
11. **Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy.** Front. Immunol. 2021; 12:680567Boudhabhay I, Rabant M, Roumenina LT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248962>
12. **Face Masks in Young Children During the COVID-19 Pandemic: Parents' and Pediatricians' Point of View.** Front Pediatr 2021; 9:676718Assathiany R, Salinier C, Béchet S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249814>
13. **Case Report: Acute Intracardiac Thrombosis in Children With Coronavirus Disease 2019 (COVID-19).** Front Pediatr 2021; 9:656720Bigdelian H, Sedighi M, Sabri MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249807>
14. **Influenza vs. COVID-19: Comparison of Clinical Characteristics and Outcomes in Pediatric Patients in Mexico City.** Front Pediatr 2021; 9:676611Laris-González A, Avilés-Robles M, Domínguez-Barrera C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249813>
15. **Association Between Pediatric Asthma and Positive Tests for SARS-CoV-2 in the District of Columbia.** J Allergy Clin Immunol Pract 2021; Margolis RHF, Patel SJ, Sheehan WJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265448>
16. **COVID-19 diagnosis and testing in pediatric heart transplant recipients.** J. Heart Lung Transplant. 2021; Bock MJ, Kuhn MA, Chinnock RE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253455>
17. **Presentation of a participatory approach to develop preventive measures to reduce COVID-19 transmission in child care.** J. Occup. Med. Toxicol. 2021; 16:26Diebig M, Gritzka S, Dragano N, Angerer P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261512>
18. **YouTube as a source of information about COVID-19 for children: Content quality, reliability, and audience participation analysis.** J. Pediatr. Nurs. 2021; Azak M, Şahin K, Korkmaz N, Yıldız S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247879>

19. **Room for Improvement: The Trephination Procedure for Pediatric Patients with Pilonidal Disease.** J. Surg. Res. 2021; 267:605-611 Metzger GA, Apfeld JC, Nishimura L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271267>
20. **Neurological manifestations of paediatric acute COVID infections: A single centre experience.** J. Trop. Pediatr. 2021; Dilber B, Aydın ZGG, Yeşilbaş O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254129>
21. **Systematic Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients with Chronic Kidney Disease.** Kidney Int Rep 2021; Carr EJ, Kronbichler A, Graham-Brown M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250319>
22. **Saliva Testing Is Accurate for Early-Stage and Presymptomatic COVID-19.** Microbiol Spectr 2021:e0008621 Johnson AJ, Zhou S, Hoops SL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259552>
23. **Leukaemia and lockdown: The delayed infection model of childhood acute lymphoblastic leukaemia and the COVID-19 pandemic.** Pediatr Blood Cancer 2021:e29194 Lillie K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251092>
24. **SARS-CoV-2 vaccination for adolescents and young adult patients treated at a specialist pediatric oncology unit.** Pediatr Blood Cancer 2021:e29240 Nigro O, Sironi G, Bergamaschi L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264546>
25. **Impact of nonpharmacological COVID-19 interventions in hospitalizations for childhood pneumonia in Brazil.** Pediatr Pulmonol 2021; Friedrich F, LC EG, Petry LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265188>
26. **Impact of COVID-19 on pediatric pulmonology healthcare practice.** Pediatr Pulmonol 2021; Nayir Buyuksahin H, Emiralioglu N, Ademhan Tural D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265185>
27. **Unaffected asthma control in children with mild asthma after COVID-19.** Pediatr Pulmonol 2021; Tosca MA, Crocco M, Gironi D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265183>
28. **COVID-19 pandemic lockdown in young people with type 1 diabetes: Positive results of an unprecedented challenge for patients through telemedicine and change in use of continuous glucose monitoring.** Prim. Care Diabetes 2021; Salabelle C, Ly Sall K, Eroukmanoff J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257050>
29. **Parents' Perceived Impact of the Societal Lockdown of COVID-19 on Family Well-Being and on the Emotional and Behavioral State of Walloon Belgian Children Aged 4 to 13 Years: An Exploratory Study.** Psychol. Belg. 2021; 61:186-199 Stassart C, Wagener A, Etienne AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249370>
30. **Short-term outcomes in children recovered from multisystem inflammatory syndrome associated with SARS-CoV-2 infection.** Rheumatol. Int. 2021:1-6 Patnaik S, Jain MK, Ahmed S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259880>
31. **Comment on: Emerging Evidence on Multisystem Inflammatory Syndrome in Children Associated with SARS-CoV-2 Infection.** SN Compr Clin Med 2021:1-2 Mantina NM, Madhivanan P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250445>

Clinical Features (28 articles)

1. **Phlegmasia cerulea dolens during the SARS-COV-2 pandemic: What management ?** Ann Med Surg. (Lond) 2021; 67:102541 Anane O, Rezziki A, Benzirar A, El Mahi O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249354>
2. **Clinical features and survival analysis of 97 coronavirus disease 2019 (COVID-19) patients.** Ann Palliat Med 2021; Li A, Chen F, Gao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263633>
3. **Enteroviruses and coronaviruses: Similarities and therapeutic targets.** Expert Opin. Ther. Targets 2021; Marjomäki V, Kalander K, Hellman M, Permi P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253126>
4. **Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review.** Fam. Pract. 2021; van Kessel SAM, Olde Hartman TC, Lucassen P, van Jaarsveld CHM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268556>
5. **Symptom Prediction and Mortality Risk Calculation for COVID-19 Using Machine Learning.** Front Artif Intell 2021; 4:673527 Jamshidi E, Asgary A, Tavakoli N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250465>
6. **Influenza vs. COVID-19: Comparison of Clinical Characteristics and Outcomes in Pediatric Patients in Mexico City.** Front Pediatr 2021; 9:676611 Laris-González A, Avilés-Robles M, Domínguez-Barrera C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249813>
7. **Dissociation between the clinical course and chest imaging in severe COVID-19 pneumonia: A series of five cases.** Heart Lung 2021; 50:818-824 Basille D, Auquier MA, Andréjak C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271253>
8. **Post Viral Olfactory Dysfunction After SARS-CoV-2 Infection: Anticipated Post-pandemic Clinical Challenge.** Indian J Otolaryngol Head Neck Surg 2021; 1-8 Kapoor D, Verma N, Gupta N, Goyal A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249668>
9. **New Onset Vertigo After COVID-19 Infection. A Case Report.** Indian J Otolaryngol Head Neck Surg 2021; 1-3 Motawea KR, Monib FA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249665>
10. **Clinical Features and Outcomes of COVID-19 Infection among Pregnant Women in South Africa.** Int J MCH AIDS 2021; 10:1-9 Basu JK, Chauke L, Magoro T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262795>
11. **Discriminatory Value of Self-reported Olfactory Dysfunction in the Prediction of Coronavirus Disease 2019.** Intern Med 2021; Akaishi T, Kushimoto S, Katori Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248118>
12. **Validity of the Use of Wrist and Forehead Temperatures in Screening the General Population for COVID-19: A Prospective Real-World Study.** Iran J. Public Health 2020; 49:57-66 Chen G, Xie J, Dai G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268206>
13. **Challenges of Differential Diagnosis, Symptoms of Coronavirus Disease 2019 (COVID-19) or Cannabinoid Hyperemesis Syndrome (CHS)? A Rare Case Report.** Iran J. Public Health 2020; 49:109-111 Pirnia B, Pirnia K, Malekanmehr P, Zahiroddin A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268213>
14. **"Five-Early" Model: The Magic Weapon against COVID-19.** Iran J. Public Health 2020; 49:82-86 Yi Q, Fang W, Lang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268209>
15. **Characteristics of Patients Presenting with COVID-19 from Balochistan Province and Lessons Learnt.** J. Coll. Physicians Surg. Pak. 2021; 31:104-

- 108Badini AM, Badini A, Mengal NM, Nanji K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271805>
16. **Fixed dilated pupils in Covid-19 ARDS patients under rocuronium, reversed after discontinuation.** *J Crit Care* 2021; 65:259-260Zakynthinos GE, Tsolaki V, Bardaka F, Makris D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274833>
 17. **Study of clinical features of patients with COVID-19 hospitalized in an educational hospital in Iran.** *J Educ Health Promot* 2021; 10:202Homauni A, Ghadami L, Abdollahi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250136>
 18. **Blood cell morphology and COVID-19 clinical course, severity, and outcome.** *J. Hematop.* 2021;1-8Pezeshki A, Vaezi A, Nematollahi P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249171>
 19. **Is diffusion of SARS-CoV-2 variants of concern associated with different symptoms?: Symptoms of COVID-19.** *J Infect* 2021; Mattiuzzi C, Henry BM, Lippi G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274361>
 20. **Taste alteration in COVID-19: Significant geographical differences exist in the prevalence of the symptom.** *J Infect Public Health* 2021; 14:1099-1105Cirillo N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274859>
 21. **Future Challenges of Covid-19 and Oral Manifestations in Daily Dental Practice: A Literature Review.** *J Int Soc Prev Community Dent* 2021; 11:242-247Riofrio G, Castillo S, Salcedo G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268185>
 22. **Symptoms, complications and management of long COVID: a review.** *J R Soc Med* 2021;1410768211032850Aiyegbusi OL, Hughes SE, Turner G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265229>
 23. **Pathogenesis of taste impairment and salivary dysfunction in COVID-19 patients.** *Jpn. Dent. Sci. Rev.* 2021; Okada Y, Yoshimura K, Toya S, Tsuchimochi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257762>
 24. **Anthropometric analysis of body habitus and outcomes in critically ill COVID-19 patients.** *Obes Med* 2021; 25:100358Poros B, Becker-Pennrich AS, Sabel B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250312>
 25. **All That Coughs Is Not COVID-19: A Delayed Diagnosis of Disseminated Coccidioidomycosis Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection.** *Open Forum Infect Dis* 2021; 8:ofab246Chen JC, Wong D, Rabi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258312>
 26. **Clinical Features of COVID-19 Patients in Jordan: A Study of 508 Patients.** *Open Respir. Med. J.* 2021; 15:28-34Al-Balas M, Al-Balas HI, Alqassieh R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249180>
 27. **A Narrative Review of Current Understanding and Classification of Dry Eye Disease with New Insights on the Impact of Dry Eye during the COVID-19 Pandemic.** *Ophthalmol Ther* 2021;1-13Barabino S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275088>
 28. **Risk Factors and Clinical Phenotypes Associated with Severity in Patients with COVID-19 in Northeast Mexico.** *Vector Borne Zoonotic Dis.* 2021; García-Alvarado FJ, Muñoz-Hernández MA, Moran Guel E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255563>

CNS (32 articles)

1. **Neurological Manifestations in COVID-19 Patients: A Meta-Analysis.** ACS Chem Neurosci 2021; D V, Sharma A, Kumar A, Flora SJS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34260855>
2. **Neurological Manifestations in COVID-19: An Unrecognized Crisis in Our Elderly?** Adv Geriatr Med Res 2021; 3Krupp K, Madhivanan P, Killgore WDS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34268500>
3. **Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar.** Ann Med Surg (Lond) 2021; 67:102540Razok A, Shams A, Almeer A, Zahid M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249353>
4. **Management of a COVID-19-infected critically ill patient treated by extracorporeal membrane oxygenation: a case report.** Ann Palliat Med 2021; Fu Q, Li D, He W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263609>
5. **The rationale for the use of corticosteroids in early severe Guillain-Barré syndrome.** Autoimmun Rev 2021; 20:102907Berciano J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34274541>
6. **Fatal Case of COVID-19 Pneumonia Associated with Acute Myelopathy.** Case Rep. Neurol. 2021; 13:398-404Hassoun HK, Radeef MR, Aljid Z, Allebban Z.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34248577>
7. **Hyponatremia and extrapontine myelinolysis in a patient with COVID-19: A case report.** Clin Case Rep 2021; 9:e04463Abd Ur Rehman M, Abdulrahman AF, Zainab A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267918>
8. **Post-COVID worsening of a Parkinson's disease patient.** Clin Case Rep 2021; 9:e04409Boika AV, Sialitski MM, Chyzyk VA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34257979>
9. **Can COVID-19 accelerate neurodegeneration?** Clin Case Rep 2021; 9:e04433Salari M, Etemadifar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267913>
10. **Efficacy of Intratympanic Glucocorticoid Steroid Administration Therapy as an Initial Treatment for Idiopathic Sudden Sensorineural Hearing Loss During the COVID-19 Pandemic.** Ear Nose Throat J 2021:1455613211032534Tsuda T, Hanada Y, Wada K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247535>
11. **Is SARS-CoV-2 responsible for relapses of Parkinson's disease?** Egypt J Neurol Psychiatr Neurosurg 2021; 57:90Scorza FA, Finsterer J, Fiorini AC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34248349>
12. **Challenges faced by people with epilepsy on ketogenic diet therapy and their caregivers during the COVID-19 pandemic in Brazil.** Epilepsy Behav. 2021; 122:108193Alencastro Veiga Domingues Carneiro R, Dos Santos Lunardi M, Matheus Uberna Giacomini F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256342>
13. **A follow-up study of patients with COVID-19 presenting with seizures.** Epilepsy Behav. 2021; 122:108207Asadi-Pooya AA, Kouhanjani MF, Nemati H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34273743>
14. **Patients with epilepsy during the COVID-19 pandemic: Depressive symptoms and their association with healthcare access.** Epilepsy Behav. 2021; 122:108178Dos Santos Lunardi M, Marin de Carvalho R, Alencastro Veiga Domingues Carneiro R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252830>
15. **Considering temporality in causal relationship between seizure worsening and psychological stress in patients with epilepsy during the COVID-19 pandemic:**

- A systematic review.** Epilepsy Behav. 2021; 122:108184Kuroda N, Fujimoto A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252833>
16. **Importance of access to epilepsy monitoring units during the COVID-19 pandemic: consensus statement of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology.** Epileptic Disord. 2021; Beniczky S, Husain A, Ikeda A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266813>
 17. **SARS-CoV-2: is there neuroinvasion?** Fluids Barriers CNS 2021; 18:32McQuaid C, Brady M, Deane R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261487>
 18. **Dementia as Risk Factor for Severe Coronavirus Disease 2019: A Case-Control Study.** Front. Aging Neurosci. 2021; 13:698184Pisaturo M, Calò F, Russo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267649>
 19. **Review article on COVID-19 and Guillain-Barré syndrome.** Front Biosci (Schol Ed) 2021; 13:97-104Patnaik UJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256532>
 20. **New Onset Vertigo After COVID-19 Infection. A Case Report.** Indian J Otolaryngol Head Neck Surg 2021;1-3Motawea KR, Monib FA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249665>
 21. **Deaths of people with intellectual disabilities: Analysis of deaths in England from COVID-19 and other causes.** J Appl Res Intellect Disabil 2021; Heslop P, Byrne V, Calkin R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272793>
 22. **Acute motor-sensory axonal polyneuropathy variant of Guillain-Barre syndrome complicating the recovery phase of coronavirus disease 2019 infection: a case report.** J Med Case Rep 2021; 15:379Haidary AM, Noor S, Hamed E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271989>
 23. **Complex movement disorders in SARS-CoV-2 infection induced acute disseminated encephalomyelitis.** J. Neuroimmunol. 2021; 358:577655Ghosh R, Dubey S, Mandal A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265625>
 24. **Commentary: The spectrum of neurological manifestations related to COVID-19 and vaccinations.** J. Neuroimmunol. 2021; 358:577660Samudralwar RD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274719>
 25. **Neurological manifestations of paediatric acute COVID infections: A single centre experience.** J. Trop. Pediatr. 2021; Dilber B, Aydın ZGG, Yeşilbaş O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254129>
 26. **Acute facial paresis as a possible complication of vaccination against SARS-CoV-2.** Laryngo- Rhino- Otologie 2021; 100:526-528Volk GF, Kutenreich AM, Geitner M, Guntinas-Lichius O.
 27. **Encephalitis as a neurological manifestation of COVID-19.** Med Clin (Engl Ed) 2021; Lozano Gómez H, Pascual Bielsa A, Abansés Moreno P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250243>
 28. **Neurological symptoms and findings in COVID-19: a prospective clinical study.** Neurol. Res. 2021;1-6Köseoglu Toksoy C, Yavuz T, Orhan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269161>
 29. **New daily persistent headache after SARS-CoV-2 infection: a report of two cases.** Neurol Sci 2021; Dono F, Consoli S, Evangelista G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264414>
 30. **A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine.** Neurol Sci 2021;1-3Nasuelli NA, De Marchi F, Cecchin M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272622>

31. **Parkinson's disease patients may have higher rates of Covid-19 mortality in Iran.** Parkinsonism Relat. Disord. 2021; 89:90-92 Salari M, Etemadifar M, Ashrafi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256334>
32. **The impact of Parkinson's disease on manifestations and outcomes of Covid-19 patients: A systematic review and meta-analysis.** Rev Med Virol 2021:e2278 El-Qushayri AE, Ghozy S, Reda A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260773>

Coagulation (36 articles)

1. **Addressing Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following COVID-19 Vaccination: A Mini-Review of Practical Strategies.** Acta Cardiol Sin 2021; 37:355-364 Chen PW, Tsai ZY, Chao TH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257485>
2. **Large hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: A case report.** Acta Neurol. Scand. 2021; de Mello Silva ML, Jr., Lopes DP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273119>
3. **Platelet activation in critically ill COVID-19 patients.** Ann Intensive Care 2021; 11:113 Yatim N, Boussier J, Chocron R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273008>
4. **Thromboprophylaxis strategies for COVID-19 patients.** Arch Med Res 2021; Porres-Aguilar M, Pérez-Nieto OR, Zamarrón-López É I, Ñamendys-Silva SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274156>
5. **Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine.** BMJ Case Rep. 2021; 14 Malik B, Kalantary A, Rikabi K, Kunadi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261635>
6. **Clinical patterns of endothelial damage and thrombotic events in two patients with COVID-19: A case report.** Clin Case Rep 2021; 9:e04406 Moghimi M, Khodadadi K, Sarvandi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257978>
7. **Aortic Thrombosis and Acute Limb Ischemia Secondary to COVID Hypercoagulability.** Cureus 2021; 13:e16171 Burley NB, Dy PS, Kalantri S, Razzaq K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258131>
8. **A Case Report on Extensive Arterial Thrombosis: A Rare Complication of COVID-19 Infection.** Cureus 2021; 13:e15378 Mandal S, Gami S, Khadka S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249531>
9. **The Role of Antiphospholipid Antibodies in COVID-19.** Curr. Rheumatol. Rep. 2021; 23:72 Stelzer M, Henes J, Saur S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259944>
10. **Left ventricular mural thrombi with multisystem thrombosis in patients with COVID-19 and myocardial injury: a case series.** Eur Heart J Case Rep 2021; 5:ytab239 Garg A, Hakeem H, Chennu G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263128>
11. **Recurrent massive pulmonary embolism following catheter directed thrombolysis in a 21-year-old with COVID-19: a case report.** Eur Heart J Case Rep 2021; 5:ytab140 Hirschbaum JH, Bradley CP, Kingsford P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268475>
12. **Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT).** Eur J

- Intern Med 2021; Varona JF, García-Isidro M, Moeinvaziri M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34256983>
13. **COVID-19 vaccination associated severe immune thrombocytopenia.** Exp Hematol Oncol 2021; 10:42Shah SRA, Dolkar S, Mathew J, Vishnu P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34266487>
 14. **Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines.** Expert Opin. Drug Saf. 2021; Sessa M, Kragholm K, Hviid A, Andersen M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264151>
 15. **Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 Severity.** Front. Endocrinol. (Lausanne) 2021; 12:658304Moin ASM, Al-Qaissi A, Sathyapalan T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34248840>
 16. **Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy.** Front. Immunol. 2021; 12:680567Boudhabhay I, Rabant M, Roumenina LT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248962>
 17. **Case Report: Acute Intracardiac Thrombosis in Children With Coronavirus Disease 2019 (COVID-19).** Front Pediatr 2021; 9:656720Bigdelian H, Sedighi M, Sabri MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249807>
 18. **A proposal for the management of COVID-19-induced coagulopathy in adults.** Gac Med Mex 2021; 157:201-206Ignacio-Ibarra G, García-Lee MT, González-Ávila AI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34270538>
 19. **Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine.** Int. J. Hematol. 2021; Waqar SHB, Khan AA, Memon S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34264514>
 20. **Adverse rare events to vaccines for COVID-19: From hypersensitivity reactions to thrombosis and thrombocytopenia.** Int. Rev. Immunol. 2021:1-10Novak N, Tordesillas L, Cabanillas B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251972>
 21. **Left ventricular thrombus with normal systolic function secondary to the novel prothrombotic association of acute on chronic calcific pancreatitis and COVID-19.** J Cardiol Cases 2021; Jariwala PV, Jadhav KP, Aurangabadkar H, Dommata RR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257751>
 22. **Questions about COVID-19 associated coagulopathy: possible answers from the viscoelastic tests.** J. Clin. Monit. Comput. 2021; Pavoni V, Ganesello L, Pazzi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264472>
 23. **Predicted and Observed Incidence of Thromboembolic Events among Koreans Vaccinated with ChAdOx1 nCoV-19 Vaccine.** J Korean Med Sci 2021; 36:e197Huh K, Na Y, Kim YE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254476>
 24. **Cerebral venous thrombosis in a patient with Down syndrome and coronavirus disease 2019: a case report.** J Med Case Rep 2021; 15:364Robayo-Amortegui H, Valenzuela-Faccini N, Quecano-Rosas C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34253238>
 25. **Physician Experiences in Management of COVID-19-Associated Coagulopathy in Pregnancy: Communication from the ISTH SSC Subcommittee on Women's Health Issues in Thrombosis and Haemostasis.** J Thromb Haemost 2021; Jevtic SD, Malinowski AK, Othman M, Kadir RAA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260818>

26. **The CoVID-TE Risk Assessment Model for Venous Thromboembolism in Hospitalized Patients with Cancer and COVID-19.** J Thromb Haemost 2021; Li A, Kuderer NM, Hsu CY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260813>
27. **Heparin -Messias or Verschlimmbesserung?** J Thromb Haemost 2021; Swan D, Carrier M, Lisman T, Thachil J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272818>
28. **Evaluation of coagulation status using clot waveform analysis in general ward patients with COVID-19.** J. Thromb. Thrombolysis 2021; Ichikawa J, Okazaki R, Fukuda T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263423>
29. **Venous and arterial thromboembolic disease in COVID-19.** J. Thromb. Thrombolysis 2021:1-3 Ten Berg J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255267>
30. **A Unique Case of Branch Retinal Artery Occlusion Associated with a Relatively Mild Coronavirus Disease 2019.** Ocul Immunol Inflamm 2021:1-4 Uzun A, Keles Sahin A, Bektas O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252339>
31. **Platelet-leukocyte interactions in the pathogenesis of viral infections.** Platelets 2021:1-8 Hottz ED, Quirino-Teixeira AC, Merij LB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260328>
32. **Thrombotic risk in patients with COVID-19.** Rev Cardiovasc Med 2021; 22:277-286 Pancaldi E, Pascariello G, Cimino G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258896>
33. **Warfarin anticoagulation in the Covid-19 pandemic: Telephone-based management at a regional hematology outpatient center in Joinville, Brazil.** Thromb Res 2021; 205:81-83 Machado KLC, Rosa STD, Dobner S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265606>
34. **Racial disparities in COVID-19 associated pulmonary embolism: A multicenter cohort study.** Thromb Res 2021; 205:84-91 Metra B, Summer R, Brooks SE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274560>
35. **Henoch-Schönlein purpura presenting post COVID-19 vaccination.** Vaccine 2021; Hines AM, Murphy N, Mullin C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247902>
36. **Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia.** Vaccine 2021; MacIntyre CR, Veness B, Berger D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272095>

Complications (40 articles)

1. **Penile Mondor's in a Covid-19 patient on prophylactic anti-thrombosis with rivaroxaban: a case report.** Afr J Urol 2021; 27:97 Eren MT, Özveri H, Kurtoğlu H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248351>
2. **Platypnoea-orthodeoxia syndrome in an older patient with COVID-19 pneumonia and orthostatic hypotension-A case of prolonged hospital admission.** Age Ageing 2021; Ismail MA, Trevest K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272845>
3. **Outbreak of NDM-1-producing Klebsiella pneumoniae in the intensive care unit during the COVID-19 pandemic: another nightmare.** Am. J. Infect. Control 2021; Amarsy R, Jacquier H, Munier AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273465>

4. **French Multicentre Observational Study on SARS-CoV-2 infections Intensive care initial management: the FRENCH CORONA Study.** Anaesth Crit Care Pain Med 2021;100931 Roger C, Collange O, Mezzarobba M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256165>
5. **Management of a COVID-19-infected critically ill patient treated by extracorporeal membrane oxygenation: a case report.** Ann Palliat Med 2021; Fu Q, Li D, He W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263609>
6. **Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France.** Arthritis Res. Ther. 2021; 23:188 Felten R, Scherlinger M, Guffroy A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256812>
7. **Similarities between COVID-19 and systemic sclerosis early vasculopathy: A "viral" challenge for future research in scleroderma.** Autoimmun Rev 2021; 20:102899 Matucci-Cerinic M, Hughes M, Taliani G, Kahaleh B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274540>
8. **Corona virus disease 2019-associated Stevens-Johnson syndrome: a case report.** BMC Ophthalmol. 2021; 21:274 Shahraki T, Hassanpour K, Arabi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253167>
9. **Coinfection of SARS-CoV-2 and MTB: how not to miss the wood for the trees.** BMJ Case Rep. 2021; 14 Jacob J, Venkataram R, Hosmane GB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257109>
10. **COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies.** Br. J. Haematol. 2021; Passamonti F, Romano A, Salvini M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272724>
11. **Cerebral Vasculitis in a COVID-19 Confirmed Postpartum Patient: A Case Report.** Case Rep. Neurol. 2021; 13:324-328 Chua AMU, Jamora RDG, Jose ACE, Anlacan VMM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248564>
12. **Two episodes of acute dyspnea that were induced by COVID-19 in a peritoneal dialysis patient.** CEN Case Rep 2021; Toda N, Takeoka J, Tanigaki K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269997>
13. **COVID-19 in a pregnant patient with beta-thalassemia major: A case report.** Clin Case Rep 2021; 9:e04331 Hailan YMA, Sayed G, Yassin MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267898>
14. **Acute epiglottitis after COVID-19 infection.** Clin Case Rep 2021; 9:e04419 Renner A, Lamminmäki S, Ilmarinen T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267905>
15. **Longitudinal changes in compliance, oxygenation and ventilatory ratio in COVID-19 versus non-COVID-19 pulmonary acute respiratory distress syndrome.** Crit Care 2021; 25:248 Beloncle F, Studer A, Seegers V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266454>
16. **Clinical Presentations and Outcomes of Coronavirus Disease 2019 in Patients With Solid Tumors.** Cureus 2021; 13:e15452 Farooque I, Farooque U, Karimi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262803>
17. **Characteristics of COVID-19 in cancer patients: a cross-sectional study in Peru.** Ecancermedicalscience 2021; 15:1246 Payet E, Perez J, Sarria G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267802>
18. **Case Report: Systemic Sclerosis After Covid-19 Infection.** Front. Immunol. 2021; 12:686699 Fineschi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262566>

19. **COVID-19 and Influenza Co-infection: A Systematic Review and Meta-Analysis.** Front Med (Lausanne) 2021; 8:681469 Dadashi M, Khaleghnejad S, Abedi Elkhichi P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249971>
20. **Cancer and COVID-19: analysis of patient outcomes.** Future Oncol 2021; Aboueshia M, Hussein MH, Attia AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263660>
21. **Rhizopus homothallicus: An emerging pathogen in era of COVID-19 associated mucormycosis.** Indian J. Med. Microbiol. 2021; Kaur H, Kanaujia R, Rudramurthy SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266698>
22. **Acute Fulminant Mucormycosis Triggered by Covid 19 Infection in a Young Patient.** Indian J Otolaryngol Head Neck Surg 2021;1-5 Eswaran S, Balan SK, Saravanam PK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258246>
23. **The Efficacy of Tracheotomy for Covid-19 Pneumonia: Impacts on Survival and Prognostic Factors.** Indian J Otolaryngol Head Neck Surg 2021;1-6 Tuna B, Birdane L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249667>
24. **Epidemiology and Incidence of COVID-19-Associated Pulmonary Aspergillosis (CAPA) in a Greek Tertiary Care Academic Reference Hospital.** Infect Dis Ther 2021;1-14 Paramythiotou E, Dimopoulos G, Koliakos N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260038>
25. **Bacterial infections in critically ill patients with SARS-2-COVID-19 infection: results of a prospective observational multicenter study.** Infection 2021;1-10 De Santis V, Corona A, Vitale D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260055>
26. **An Increase in Respiratory Protection Device Injuries Associated with the COVID-19 Pandemic.** J Am Acad Dermatol 2021; McGwin G, Jr., McGwin M, Griffin RL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274413>
27. **Coinfection with severe acute respiratory syndrome coronavirus-2 and other respiratory viruses at a tertiary hospital in Korea.** J. Clin. Lab. Anal. 2021:e23868 Kim Z, Lee JH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273182>
28. **Hospitalisation and mortality from COVID-19 in Mexican indigenous people: a cross-sectional observational study.** J. Epidemiol. Community Health 2021; Serván-Mori E, Seiglie JA, Gómez-Dantés O, Wirtz VJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266980>
29. **Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors.** J Immunother Cancer 2021; 9 Switzer B, Haanen J, Lorigan PC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272309>
30. **Cytomegalovirus infection in critically ill patients with COVID-19.** J Infect 2021; Niitsu T, Shiroyama T, Hirata H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252496>
31. **Mucormycosis or black fungus infection is a new scare in South Asian countries during COVID-19 pandemic: Associated risk factors and preventive measures.** J Med Virol 2021; Rahman FI, Islam MR, Bhuiyan MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260073>
32. **Increased risk of severe malaria in travellers during the COVID-19 pandemic.** J Travel Med 2021; de Laval F, Maugey N, de Bonet d'Oléon A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254146>
33. **Increased incidence of rhino-orbital mucormycosis in an educational therapeutic hospital during the COVID-19 pandemic in western Iran: An**

- observational study.** Mycoses 2021; Avatef Fazeli M, Rezaei L, Javadirad E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34252988>
34. **Mucormycosis and COVID-19: An Epidemic within a Pandemic in India.**
Mycoses 2021; Selarka L, Sharma S, Saini D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34255907>
 35. **Endogenous Endophthalmitis A Complication of COVID-19 Pandemic: A Case Series.** Ocul Immunol Inflamm 2021;1-4Agarwal M, Sachdeva M, Pal S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34255587>
 36. **Outcomes of Continuous Positive Airway Pressure in the Management of Patients with Coronavirus (COVID-19) Pneumonia who are not Suitable for Invasive Ventilation.** Open Respir. Med. J. 2021; 15:23-27Aung H, Avraam E, Ashraf M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249179>
 37. **Henoch-Schönlein purpura: Another COVID-19 complication.** Pediatr. Dermatol. 2021; El Hasbani G, Taher AT, Jawad ASM, Uthman I.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34272762>
 38. **COVID-19 in the Intensive Care Unit: Medical, Nursing, and Physical Therapy Challenges.** Praxis 2021; 110:512-516Jakob SM, Michel K, Kindler A.
 39. **Pre and retroperitoneal necrotizing fasciitis after COVID-19 infection: a case report.** Radiol Case Rep 2021; Elashry M, Alagha M, Salama M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34254011>
 40. **Secondary spontaneous pneumothorax: a time to re-evaluate management.**
Respirol Case Rep 2021; 9:e00749Cortes-Telles A, Ortiz-Farias DL, Perez-Hernandez F, Rodriguez-Morejon D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262774>

Cured – Recovered (20 articles)

1. **Pulmonary Fibrosis Caused by Severe COVID-19 Infection: Discharge May Not Be The End of Treatment.** Acta Med Indones 2021; 53:141-142Rumende CM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34251340>
2. **Dynamic changes of functional fitness, antibodies to SARS-CoV-2 and immunological indicators within 1 year after discharge in Chinese health care workers with severe COVID-19: a cohort study.** BMC Med 2021; 19:163Xiong L, Li Q, Cao X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256745>
3. **COVID-19: a confirmed case of reinfection in a nurse.** BMJ Case Rep. 2021; 14Scarpati G, Piazza O, Pagliano P, Rizzo F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257135>
4. **Vulnerability of patients on immunosuppressive therapy to SARS-CoV-2 reinfection.** BMJ Support Palliat Care 2021; Pathania YS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34257064>
5. **Post-COVID worsening of a Parkinson's disease patient.** Clin Case Rep 2021; 9:e04409Boika AV, Sialitski MM, Chyzyk VA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34257979>
6. **Aortic Thrombosis and Acute Limb Ischemia Secondary to COVID Hypercoagulability.** Cureus 2021; 13:e16171Burley NB, Dy PS, Kalantri S, Razzaq K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258131>
7. **Development of a Large Pneumatocoele in a Patient Recovering from COVID-19 Pneumonitis.** Eur J Case Rep Intern Med 2021; 8:002605Hampson F, Salih W, Helm J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268263>

8. **Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review.** Fam. Pract. 2021; van Kessel SAM, Olde Hartman TC, Lucassen P, van Jaarsveld CHM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268556>
9. **Comparison of Residual Pulmonary Abnormalities 3 Months After Discharge in Patients Who Recovered From COVID-19 of Different Severity.** Front Med (Lausanne) 2021; 8:682087Zhou M, Xu J, Liao T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249973>
10. **Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms.** Front. Microbiol. 2021; 12:698169Proal AD, VanElzakker MB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248921>
11. **Post Viral Olfactory Dysfunction After SARS-CoV-2 Infection: Anticipated Post-pandemic Clinical Challenge.** Indian J Otolaryngol Head Neck Surg 2021;1-8Kapoor D, Verma N, Gupta N, Goyal A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249668>
12. **The Long-Term Impact of COVID-19 Pneumonia on the Pulmonary Function of Survivors.** Int. J. Gen. Med. 2021; 14:3271-3280Salem AM, Al Khathlan N, Alharbi AF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267545>
13. **Pulmonary Covid Fibrosis a New Pharmaceutical Approach.** Int. J. Prev. Med. 2021; 12:35Menicagli R, Limodio M, Limodio M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249284>
14. **Severe acute respiratory syndrome coronavirus 2 reinfection in a coronavirus disease 2019 recovered young adult: a case report.** J Med Case Rep 2021; 15:382Awada H, Nassereldine H, Hajj Ali A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271967>
15. **Recurrent COVID-19 infection in a health care worker: a case report.** J Med Case Rep 2021; 15:363Garg J, Agarwal J, Das A, Sen M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253225>
16. **Post-covid Syndrome: A Single-Center Questionnaire Study On 1007 Participants Recovered from COVID-19.** J Med Virol 2021; Kayaaslan B, Eser F, Kalem AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255355>
17. **Symptoms, complications and management of long COVID: a review.** J R Soc Med 2021;1410768211032850Aiyegbusi OL, Hughes SE, Turner G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265229>
18. **Health consequences of covid-19 disease in adults and children and their long-term rehabilitative treatment consequences.** Pravention und Rehabilitation 2021; 33:66-76Steuernagel T, Wiesner C, Doering TJ.
19. **Prevalence of exercise-induced oxygen desaturation after recovery from SARS-CoV-2 pneumonia and use of lung ultrasound to predict need for pulmonary rehabilitation.** Pulmonology 2021; Carlucci A, Paneroni M, Carotenuto M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247995>
20. **Clinical characteristics and outcomes of COVID-19 long-term nucleic acid positive patients.** Technol. Health Care 2021; Zhu X, Zhu X, Wang M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250914>

Cardiovascular disease (60 articles)

1. **Comparison of ventricular repolarization parameters of Covid-19 patients diagnosed with chest CT and RT-PCR.** Acta Cardiol. 2021;1-6Ibisoglu E, Boyraz B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254875>
2. **Large hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: A case report.** Acta Neurol. Scand. 2021; de M lo Silva ML, Jr., Lopes DP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273119>
3. **Brugada pattern in an afebrile patient with acute COVID-19.** BMJ Case Rep. 2021; 14Adedeji OM, Falk Z, Tracy CM, Batarseh A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257116>
4. **COVID-19-associated myocarditis presenting as new-onset heart failure and atrial fibrillation.** BMJ Case Rep. 2021; 14Gaine S, Devitt P, Coughlan JJ, Pearson I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253533>
5. **Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine.** BMJ Case Rep. 2021; 14Malik B, Kalantary A, Rikabi K, Kunadi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261635>
6. **Intracerebral bleeding after janus-kinase inhibitor baricitinib for COVID-19.** Brain Hemorrhages 2021; Finsterer J, Scorza FA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250455>
7. **Cardiac Implications of Multisystem Inflammatory Syndrome Associated with COVID-19 in Children under the age of Five Years.** Cardiol. Young 2021;1-15Rakha S, Sobh A, Hager AH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261560>
8. **Plausible Positive Effects of Statins in COVID-19 Patient.** Cardiovasc. Toxicol. 2021;1-9Vitiello A, Ferrara F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255300>
9. **Cerebral Vasculitis in a COVID-19 Confirmed Postpartum Patient: A Case Report.** Case Rep. Neurol. 2021; 13:324-328Chua AMU, Jamora RDG, Jose ACE, Anlacan VMM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248564>
10. **Intensive Care Unit Admission for Moderate-to-Severe COVID-19 Patients With Known Cardiovascular Diseases or Their Risk Factors - Insights From a Nationwide Japanese Cohort Study.** Circ Rep 2021; 3:375-380Yoshida N, Iwata S, Ogawa M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250278>
11. **Clinical patterns of endothelial damage and thrombotic events in two patients with COVID-19: A case report.** Clin Case Rep 2021; 9:e04406Moghimi M, Khodadadi K, Sarvandi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257978>
12. **An Unusual Case of Acute Hemorrhagic Necrotizing Encephalomyelitis in a COVID-19 Patient.** Cureus 2021; 13:e15542Baghal M, Ahmed M, Ibrahim M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268057>
13. **Fulminant Myocarditis With ST Elevation and Cardiogenic Shock in a SARS-CoV-2 Patient.** Cureus 2021; 13:e16149Ghafoor K, Ahmed A, Abbas M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262828>
14. **A Case Report on Extensive Arterial Thrombosis: A Rare Complication of COVID-19 Infection.** Cureus 2021; 13:e15378Mandal S, Gami S, Khadka S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249531>
15. **Cardiovascular Risk Factors and the Severity of COVID-19 Disease.** Cureus 2021; 13:e15486Motaib I, Zbiri S, Elamari S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262822>
16. **The Role and Impact of Social Media in Cardio-oncology During the COVID-19 Pandemic.** Curr. Oncol. Rep. 2021; 23:99Kwan JM, Henry ML, Christophers B *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34259950>

17. **Myocarditis after mRNA vaccination: Discussions about risks of the new COVID-19 vaccines for younger men.** Deutsche Apotheker Zeitung 2021; 161 Blasius H.
18. **Recent trends in hypertension and diabetes therapy.** Diabetologe 2021; Lindner TH.
19. **Left ventricular mural thrombi with multisystem thrombosis in patients with COVID-19 and myocardial injury: a case series.** Eur Heart J Case Rep 2021; 5:ytab239 Garg A, Hakeem H, Chennu G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34263128>
20. **Recurrent massive pulmonary embolism following catheter directed thrombolysis in a 21-year-old with COVID-19: a case report.** Eur Heart J Case Rep 2021; 5:ytab140 Hirschbaum JH, Bradley CP, Kingsford P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34268475>
21. **COVID-19 mRNA Vaccine and Myocarditis.** Eur J Case Rep Intern Med 2021; 8:002681 Singh B, Kaur P, Cedeno L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268277>
22. **HFpEF and COVID-19: which comes first, the chicken or the egg? REPLY.** Eur J Heart Fail 2021; Anker MS, Tschöpe C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263996>
23. **Case Report: Acute Intracardiac Thrombosis in Children With Coronavirus Disease 2019 (COVID-19).** Front Pediatr 2021; 9:656720 Bigdelian H, Sedighi M, Sabri MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249807>
24. **Association Between Air Pollution and Acute Coronary Syndromes During Lockdown for COVID-19: Results From the Terni Hub Center.** Front Public Health 2021; 9:683683 Arrivi A, Dominici M, Bier N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34249847>
25. **Mortality rate and biomarker expression within COVID-19 patients who develop acute ischemic stroke: a systematic review and meta-analysis.** Future Sci OA 2021; 7:Fso713 Yassin A, Ghzawi A, Al-Mistarehi AH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34254031>
26. **The hidden interplay between sex and COVID-19 mortality: the role of cardiovascular calcification.** Geroscience 2021; 1-15 Cereda A, Toselli M, Palmisano A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260010>
27. **Impact of cardiovascular disease on clinical outcomes in hospitalized patients with Covid-19: a systematic review and meta-analysis.** Intern Emerg Med 2021; 1-11 Maddaloni E, D'Onofrio L, Siena A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34273056>
28. **Exploring the Rescue Strategy for Cardiac Arrest in Makeshift (FangCang) Hospital Workers during the Pneumonia Outbreak Associated with COVID-19.** Iran J. Public Health 2020; 49:76-81 Feng K, Mei B, Chen Z, Fu X.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34268208>
29. **Left ventricular thrombus with normal systolic function secondary to the novel prothrombotic association of acute on chronic calcific pancreatitis and COVID-19.** J Cardiol Cases 2021; Jariwala PV, Jadhav KP, Aurangabadkar H, Dommata RR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257751>
30. **COVID-19 diagnosis and testing in pediatric heart transplant recipients.** J. Heart Lung Transplant. 2021; Bock MJ, Kuhn MA, Chinnock RE.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34253455>

31. **Predicted and Observed Incidence of Thromboembolic Events among Koreans Vaccinated with ChAdOx1 nCoV-19 Vaccine.** J Korean Med Sci 2021; 36:e197Huh K, Na Y, Kim YE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254476>
32. **Cerebral venous thrombosis in a patient with Down syndrome and coronavirus disease 2019: a case report.** J Med Case Rep 2021; 15:364Robayo-Amortegui H, Valenzuela-Faccini N, Quecano-Rosas C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253238>
33. **The CoVID-TE Risk Assessment Model for Venous Thromboembolism in Hospitalized Patients with Cancer and COVID-19.** J Thromb Haemost 2021; Li A, Kuderer NM, Hsu CY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260813>
34. **Venous and arterial thromboembolic disease in COVID-19.** J. Thromb. Thrombolysis 2021;1-3Ten Berg J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255267>
35. **Impact of the COVID-19 pandemic on drug treatment of patients with peripheral arterial disease: an observational cross-sectional study.** J Vasc Bras 2021; 20:e20210021Braghieri HA, Correia MA, de Carvalho JF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249118>
36. **Reduction of hospitalisations and increased mortality for acute coronary syndromes during covid-19 era: Not all countries are equal.** Lancet Reg Health West Pac 2021; 12:100155Spaccarotella C, Sorrentino S, Indolfi C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250516>
37. **Increased Incidence of In-Hospital Ischemic Stroke During SARS-CoV-2 Outbreak: A Single-Center Study.** Neurocrit. Care 2021; Sierra-Hidalgo F, Aragón Revilla E, Arranz García P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268645>
38. **A Unique Case of Branch Retinal Artery Occlusion Associated with a Relatively Mild Coronavirus Disease 2019.** Ocul Immunol Inflamm 2021;1-4Uzun A, Keles Sahin A, Bektas O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252339>
39. **Prior Statin Use and Risk of Mortality and Severe Disease From Coronavirus Disease 2019: A Systematic Review and Meta-analysis.** Open Forum Infect Dis 2021; 8:ofab284Yetmar ZA, Chesdachai S, Kashour T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258316>
40. **COVID-19 and cardiovascular system-a comprehensive review.** Rev Cardiovasc Med 2021; 22:343-351AlShahrani I, Hosmani J, Shankar VG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258902>
41. **Chronic disease management in heart failure: focus on telemedicine and remote monitoring.** Rev Cardiovasc Med 2021; 22:403-413Alvarez P, Sianis A, Brown J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258907>
42. **Cardiac manifestations of COVID-19.** Rev Cardiovasc Med 2021; 22:365-371Bielecka-Dabrowa A, Cichocka-Radwan A, Lewek J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258904>
43. **COVID-19 infection and cardiometabolic complications: short- and long-term treatment and management considerations.** Rev Cardiovasc Med 2021; 22:263-265Stoner L, Faghy M, Conners R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258892>
44. **Impact of SARS-CoV-2 pandemic on ST-elevation myocardial infarction admissions and outcomes in a Portuguese primary percutaneous coronary intervention center: Preliminary Data.** Rev Port Cardiol (Engl Ed) 2021; 40:465-

- 471Azul Freitas A, Baptista R, Gonçalves V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34274091>
45. **Telestroke: Maintaining Quality Acute Stroke Care During the COVID-19 Pandemic.** Telemed J E Health 2021; Sevilis T, McDonald M, Avila A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34265222>
46. **Racial disparities in COVID-19 associated pulmonary embolism: A multicenter cohort study.** Thromb Res 2021; 205:84-91Metra B, Summer R, Brooks SE *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34274560>
47. **Sinus bradycardia is associated with poor outcome in critically ill patients with COVID-19 due to the B.1.1.7 Lineage.** Toxicol Rep 2021; 8:1394-1398Chalkias A, Pantazopoulos I, Papagiannakis N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34258235>

Diagnosis (7 articles)

1. **Similarities between COVID-19 and systemic sclerosis early vasculopathy: A "viral" challenge for future research in scleroderma.** Autoimmun Rev 2021; 20:102899Matucci-Cerinic M, Hughes M, Taliani G, Kahaleh B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34274540>
2. **Synopsis on Pharmotechnological Approaches in Diagnostic to Management Strategies in Fighting Against COVID-19.** Curr. Pharm. Des. 2021; Azhar A, Hassan N, Singh M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269664>
3. **Left ventricular mural thrombi with multisystem thrombosis in patients with COVID-19 and myocardial injury: a case series.** Eur Heart J Case Rep 2021; 5:ytab239Garg A, Hakeem H, Chennu G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34263128>
4. **A machine learning PROGRAM to identify COVID-19 and other diseases from hematology data.** Future Sci OA 2021; 7:Fso733Gladding PA, Ayar Z, Smith K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254032>
5. **Challenges of Differential Diagnosis, Symptoms of Coronavirus Disease 2019 (COVID-19) or Cannabinoid Hyperemesis Syndrome (CHS)? A Rare Case Report.** Iran J. Public Health 2020; 49:109-111Pirnia B, Pirnia K, Malekanmehr P, Zahiroddin A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268213>
6. **COVID-19 diagnosis and testing in pediatric heart transplant recipients.** J. Heart Lung Transplant. 2021; Bock MJ, Kuhn MA, Chinnock RE.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34253455>
7. **All That Coughs Is Not COVID-19: A Delayed Diagnosis of Disseminated Coccidioidomycosis Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection.** Open Forum Infect Dis 2021; 8:ofab246Chen JC, Wong D, Rabi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258312>

DM-MS-Obesity (24 articles)

1. **REPLY TO: What is the effect of obesity on the natriuretic peptide pathway?** AACE Clin Case Rep 2021; Rao AN, Al-Ward RY, Gaba R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34250225>
2. **Discovering common pathogenetic processes between COVID-19 and diabetes mellitus by differential gene expression pattern analysis.** Brief.

- [Bioinform. 2021; Rahman MR, Islam T, Shahjaman M *et al.* \[http://www.ncbi.nlm.nih.gov/pubmed/?term=34260684\]\(https://pubmed.ncbi.nlm.nih.gov/34260684/\)](https://pubmed.ncbi.nlm.nih.gov/34260684/)
3. **COVID-19 Self-quarantine and Weight Gain Risk Factors in Adults.** [Curr Obes Rep 2021;1-11](https://pubmed.ncbi.nlm.nih.gov/34251647/) Zeigler Z. [http://www.ncbi.nlm.nih.gov/pubmed/?term=34251647](https://pubmed.ncbi.nlm.nih.gov/34251647/)
 4. **Assessment and Management of Diabetic Patients During the COVID-19 Pandemic.** [Diabetes Metab. Syndr. Obes. 2021; 14:3131-3146](https://pubmed.ncbi.nlm.nih.gov/34262317/) Verma AK, Beg MMA, Bhatt D *et al.* [http://www.ncbi.nlm.nih.gov/pubmed/?term=34262317](https://pubmed.ncbi.nlm.nih.gov/34262317/)
 5. **Higher admission activated partial thromboplastin time, neutrophil-lymphocyte ratio, serum sodium, and anticoagulant use predict in-hospital COVID-19 mortality in people with Diabetes: Findings from Two University Hospitals in the U.K.** [Diabetes Res Clin Pract 2021; 178:108955](https://pubmed.ncbi.nlm.nih.gov/34273452/) Iqbal A, Greig M, Arshad MF *et al.* [http://www.ncbi.nlm.nih.gov/pubmed/?term=34273452](https://pubmed.ncbi.nlm.nih.gov/34273452/)
 6. **Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States.** [Diabetes Ther. 2021:1-17](https://pubmed.ncbi.nlm.nih.gov/34275115/) Boye KS, Tokar Erdemir E, Zimmerman N *et al.* [http://www.ncbi.nlm.nih.gov/pubmed/?term=34275115](https://pubmed.ncbi.nlm.nih.gov/34275115/)
 7. **Outcome and death risk of diabetes patients with Covid-19 receiving pre-hospital and in-hospital metformin therapies.** [Diabetol. Metab. Syndr. 2021; 13:76](https://pubmed.ncbi.nlm.nih.gov/34256824/) Tamura RE, Said SM, de Freitas LM, Rubio IGS. [http://www.ncbi.nlm.nih.gov/pubmed/?term=34256824](https://pubmed.ncbi.nlm.nih.gov/34256824/)
 8. **Recent trends in hypertension and diabetes therapy.** [Diabetologe 2021; Lindner TH.](https://pubmed.ncbi.nlm.nih.gov/34250875/)
 9. **Insulin therapy and outcome from coronavirus disease 2019 (COVID-19): A Systematic Review, Meta-Analysis, and Meta-Regression.** [Endocr. Metab. Immune Disord. Drug Targets 2021; Hariyanto TI, Lugito NPH, Yanto TA *et al.* \[http://www.ncbi.nlm.nih.gov/pubmed/?term=34250875\]\(https://pubmed.ncbi.nlm.nih.gov/34250875/\)](https://pubmed.ncbi.nlm.nih.gov/34250875/)
 10. **The Impact of COVID-19 Pandemic on Prevalence of Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes: A Single-Centre Study in Central Pennsylvania.** [Endocrinol Diabetes Metab 2021; 4:e00235](https://pubmed.ncbi.nlm.nih.gov/34268453/) Bogale KT, Urban V, Schaefer E, Bangalore Krishna K. [http://www.ncbi.nlm.nih.gov/pubmed/?term=34268453](https://pubmed.ncbi.nlm.nih.gov/34268453/)
 11. **The excess insulin requirement in severe COVID-19 compared to non-COVID-19 viral pneumonitis is related to the severity of respiratory failure and pre-existing diabetes.** [Endocrinol Diabetes Metab 2021; 4:e00228](https://pubmed.ncbi.nlm.nih.gov/34268452/) Lockhart SM, Griffiths H, Petrisor B *et al.* [http://www.ncbi.nlm.nih.gov/pubmed/?term=34268452](https://pubmed.ncbi.nlm.nih.gov/34268452/)
 12. **Effect of the COVID-19 quarantine on metabolic control in children and adolescents with type 1 diabetes.** [Endocrinol Diabetes Nutr 2021; Turan H, Güneş Kaya D, Tarçın G, Evliyaoğlu SO. \[http://www.ncbi.nlm.nih.gov/pubmed/?term=34274306\]\(https://pubmed.ncbi.nlm.nih.gov/34274306/\)](https://pubmed.ncbi.nlm.nih.gov/34274306/)
 13. **Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 Severity.** [Front. Endocrinol. \(Lausanne\) 2021; 12:658304](https://pubmed.ncbi.nlm.nih.gov/34248840/) Moin ASM, Al-Qaissi A, Sathyapalan T *et al.* [http://www.ncbi.nlm.nih.gov/pubmed/?term=34248840](https://pubmed.ncbi.nlm.nih.gov/34248840/)
 14. **Is obesity a risk factor in cancer patients with COVID-19?** [Future Oncol 2021; Park R, Wulff-Burchfield E, Sun W, Kasi A. \[http://www.ncbi.nlm.nih.gov/pubmed/?term=34254528\]\(https://pubmed.ncbi.nlm.nih.gov/34254528/\)](https://pubmed.ncbi.nlm.nih.gov/34254528/)
 15. **A protein interactions map of multiple organ systems associated with COVID-19 disease.** [Genomics Inform 2021; 19:e14](https://pubmed.ncbi.nlm.nih.gov/34261299/) Bharne D. [http://www.ncbi.nlm.nih.gov/pubmed/?term=34261299](https://pubmed.ncbi.nlm.nih.gov/34261299/)

16. **Acute Fulminant Mucormycosis Triggered by Covid 19 Infection in a Young Patient.** Indian J Otolaryngol Head Neck Surg 2021;1-5Eswaran S, Balan SK, Saravanam PK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258246>
17. **Glycemic control among children and adolescents with type 1 diabetes during COVID-19 pandemic in Egypt: a pilot study.** Int. J. Diabetes Dev. Ctries. 2021;1-7Elhenawy YI, Eltonbary KY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257483>
18. **Mucormycosis and COVID-19: An Epidemic within a Pandemic in India.** Mycoses 2021; Selarka L, Sharma S, Saini D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255907>
19. **COVID-19 infection, progression, and vaccination: Focus on obesity and related metabolic disturbances.** Obes Rev 2021; Westheim AJF, Bitorina AV, Theys J, Shiri-Sverdlov R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269511>
20. **Visceral Adiposity and Severe COVID-19 Disease: Application of an Artificial Intelligence Algorithm to Improve Clinical Risk Prediction.** Open Forum Infect Dis 2021; 8:ofab275Goehler A, Hsu TH, Seiglie JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258315>
21. **COVID-19 pandemic lockdown in young people with type 1 diabetes: Positive results of an unprecedented challenge for patients through telemedicine and change in use of continuous glucose monitoring.** Prim. Care Diabetes 2021; Salabelle C, Ly Sall K, Eroukhmanoff J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257050>
22. **The Association Between Body Mass Index, Emotional Eating and Perceived Stress during COVID-19 Partial Quarantine in Healthy Adults.** Public Health Nutr. 2021;1-23Barcin-Güzeldere HK, Devrim-Lanpir A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261563>
23. **COVID-19 infection and cardiometabolic complications: short- and long-term treatment and management considerations.** Rev Cardiovasc Med 2021; 22:263-265Stoner L, Faghy M, Connors R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258892>
24. **Elevated glycohemoglobin is linked to critical illness in CoVID-19: a retrospective analysis.** Ther Adv Infect Dis 2021; 8:20499361211027390Windham S, Wilson MP, Fling C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249357>

Education and training and science (61 articles)

1. **Laboratory Medicine and Pathology Education During the COVID-19 Pandemic-Lessons Learned.** Acad Pathol 2021; 8:23742895211020487Patel R, Hoppman NL, Gosse CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263023>
2. **Impact of the COVID-19 pandemic on surgical trainee education and well-being spring 2020-winter 2020: A path forward.** Am. J. Surg. 2021; Ellison EC, Nagler A, Stain SC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272062>
3. **Is remote near-peer anatomy teaching an effective teaching strategy? Lessons learned from the transition to online learning during the Covid-19 pandemic.** Anat Sci Educ 2021; Thom ML, Kimble BA, Qua K, Wish-Baratz S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268899>
4. **Anaphylaxis-related knowledge and concerns in Canadian families during COVID-19.** Ann. Allergy. Asthma. Immunol. 2021; Gabrielli S, Protudjer JL, Gooding G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260902>

5. **Sandwiches, 6 Feet Apart: Reflections on Community (and Medical School) During COVID-19.** Ann. Fam. Med. 2021; 19:368-370 Fessler MM, Bishop RA, Jabour SM, Vasudevan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264845>
6. **Impact of the COVID-19 pandemic on Caribbean Medical Students: A cross-sectional study.** Ann Med Surg (Lond) 2021; 67:102515 Thind AS, Singh H, Yerramsetty DL, Pandeya DR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257958>
7. **Can being a 'frontline doctor' in the COVID-19 pandemic be a positive experience?** Asian J Psychiatr 2021; 63:102769 Mohindra R, Goyal M, Suri V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274630>
8. **Willingness to Donate Remnant Human Biospecimens in the Context of the COVID-19 Pandemic.** Biopreserv. Biobank. 2021; Gao L, Li D, Liu X, Ren H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271844>
9. **A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae.** BMC Infect. Dis. 2021; 21:677 La Vergne SM, Stromberg S, Baxter BA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256735>
10. **Health authorities' health risk communication with the public during pandemics: a rapid scoping review.** BMC Public Health 2021; 21:1401 Berg SH, O'Hara JK, Shortt MT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266403>
11. **Gender disparity between authors in leading medical journals during the COVID-19 pandemic: a cross-sectional review.** BMJ Open 2021; 11:e051224 Misra V, Safi F, Brewerton KA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261692>
12. **Surgical training during the COVID-19 pandemic: preparing for future uncertainty.** Br. J. Oral Maxillofac. Surg. 2020; Ellis R, Scrimgeour DSG, Brennan PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256956>
13. **Gender Disparities in Cardiology-Related COVID-19 Publications.** Cardiol Ther 2021; Vasti EC, Ouyang D, Ngo S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268712>
14. **The Value of Medical Registries and Observational Studies Early in Pandemics: The COVID-19 Experience.** Clin Infect Dis 2021; Albhaisi S, Wenzel RP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34270715>
15. **You Only Find What You Look for: Anchor Bias During the COVID-19 Pandemic.** Cureus 2021; 13:e15416 Abu-Rumaleh MA, Alsharif NM, Abdulelah M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249563>
16. **Content and Functionality of United States Medical School Websites.** Cureus 2021; 13:e15534 Pollock JR, Moore ML, Smith JF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268052>
17. **Generation Z undergraduate students' resilience during the COVID-19 pandemic: a qualitative study.** Curr. Psychol. 2021:1-15 Ang WHD, Shorey S, Lopez V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253948>
18. **Occupational Commitment of Chinese Kindergarten Teachers During the COVID-19 Pandemic: Predictions of Anti-Epidemic Action, Income Reduction, and Career Confidence.** Early Child Educ J 2021:1-15 Wei Y, Wang L, Tan L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248326>
19. **"Working from home is one major disaster": An analysis of student feedback at a South African university during the Covid-19 lockdown.** Educ Inf Technol (Dordr) 2021:1-23 Fouche I, Andrews G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248388>

20. **Design, implementation and initial findings of COVID-19 research in the Rotterdam Study: leveraging existing infrastructure for population-based investigations on an emerging disease.** Eur. J. Epidemiol. 2021;1-6 Licher S, Terzikhan N, Splinter MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275020>
21. **Transitioning Nursing Students' Education from Traditional Classroom to Online Education during the COVID-19 Pandemic: A Case Study Applied to the Meleis Trial.** Florence Nightingale J Nurs 2021; 29:124-127 Jallad ST, Işık B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263230>
22. **The Yin and the Yang of Transformative Research During the COVID-19 Pandemic-A Perspective.** Front Pediatr 2021; 9:650302 Sampath V, Ramchandran R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249804>
23. **Extra-Curricular Activities and Well-Being: Results From a Survey of Undergraduate University Students During COVID-19 Lockdown Restrictions.** Front. Psychol. 2021; 12:647402 Finnerty R, Marshall SA, Imbault C, Trainor LJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262502>
24. **Assessment of Knowledge and Practices Toward COVID-19 Prevention Among Healthcare Workers in Tigray, North Ethiopia.** Front Public Health 2021; 9:614321 Gebremeskel TG, Kiros K, Gesesew HA, Ward PR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249827>
25. **Editorial: Coronavirus Research Landscape: Resources, Utilities, and Analytic Studies.** Front Res Metr Anal 2021; 6:712672 Chen C, Chavalarias D, Smalheiser NR, Wolfram D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250436>
26. **A call to action: Antiracist patient engagement in adolescent and young adult oncology research and advocacy.** Future Oncol 2021; Cheung CK, Tucker-Seeley R, Davies S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263658>
27. **The Impact of the SARS-CoV-2 (COVID-19) Pandemic on Gastroenterology Training.** GE Port J Gastroenterol 2021; 92:1-6 Pisani A, Cremers I, Ellul P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254042>
28. **COVID-19 and the Authority of Science.** HEC Forum 2021;1-28 Trotter G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251565>
29. **Impact of online education on fear of academic delay and psychological distress among university students following one year of COVID-19 outbreak in Bangladesh.** Heliyon 2021; 7:e07388 Hossain MJ, Ahmmed F, Rahman SMA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258456>
30. **Infection control professionals' and infectious diseases physicians' knowledge, preparedness, and experiences of managing COVID-19 in Australian healthcare settings.** Infect Dis Health 2021; Sotomayor-Castillo C, Nahidi S, Li C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266812>
31. **Impact of school reopening on pandemic spread: A case study using an agent-based model for COVID-19.** Infect Dis Model 2021; 6:839-847 Tatapudi H, Das TK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258483>
32. **Value-Added Roles of Medical Students During the COVID-19 Pandemic: Assessment of Medical Students' Perceptions and Willingness in Sri Lanka.** Int. J. Gen. Med. 2021; 14:3187-3196 Wickramasinghe ND, Jayarathne SW, Pilapitiya SD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262332>
33. **Remote learning and online teaching in Fiji during COVID-19: The challenges and opportunities: Correspondence.** Int J Surg 2021:106019 Chand AA, Lal PP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252594>

34. **Remote learning and online teaching in Fiji during COVID-19: The challenges and opportunities.** Int J Surg. 2021;106019Chand AA, Lal PP, Chand KK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34252594>
35. **Community Health Education for Health Crisis Management: The Case of COVID-19 in Cameroon.** Int. Q. Community Health Educ. 2021;272684x211031106Mbah M, Bang H, Ndi H, Ndzo JA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34264140>
36. **COVID-19: Learning from experience.** Internist 2021; 62:695-696Salzberger B, Schellong S.
37. **#COVID#BACKTOSCHOOL: Qualitative study based on the voice of Portuguese adolescents.** J. Community Psychol. 2021; Branquinho C, Santos AC, Ramiro L, Gaspar de Matos M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252981>
38. **Learning with lockdown: Utility of whatsApp status-based multiple-choice question discussion on COVID-19 among medical students and teaching faculty.** J Educ Health Promot 2021; 10:168Doddaiah SK, Kulkarni P, Mohandas A, Murthy MRN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250102>
39. **Effectiveness of video modules in infection control trainings during COVID-19 pandemic: A quasi-experimental study in tertiary care institute.** J Educ Health Promot 2021; 10:183Singh V, Supehia S, Gupta PK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34250117>
40. **In-person vs. home schooling during the COVID-19 pandemic: Differences in sleep, circadian timing, and mood in early adolescence.** J. Pineal Res. 2021:e12757Stone JE, Phillips AJK, Chachos E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34273194>
41. **Instilling resiliency in surgical education: The benefits of longitudinal medical student learning.** J. Surg. Res. 2021; 267:512-515Abel MK, Collins C, Lancaster EM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256193>
42. **Mentorship: a millennia-old remedy for learner success amidst the COVID-19 pandemic.** J. Surg. Res. 2021; 267:593-597Santiesteban L, McKenney M, Elkbuli A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265603>
43. **Preservice teachers' perceptions of learning environments before and after pandemic-related course disruption.** Learn Environ Res 2021;1-15Long CS, Sinclair BB, Fraser BJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248400>
44. **The landscape of COVID-19 trials in Australia.** Med. J. Aust. 2021; 215:58-61.e51Seidler AL, Aberoumand M, Williams JG *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34275134>
45. **Dry Eye and Visual Display Terminal-Related Symptoms among University Students during the Coronavirus Disease Pandemic.** Ophthalmic Epidemiol. 2021;1-7Cartes C, Segovia C, Salinas-Toro D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34251964>
46. **Urgent need to strengthen school health in Asia and the Pacific Islands.** Pediatr. Int. 2021; Kobayashi J, Takeuchi R, Toyama Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34258829>
47. **Impact of the COVID-19 pandemic on surgical skills training in pediatric surgery residents.** Pediatr. Surg. Int. 2021;1-6Lerendegui L, Boudou R, Percul C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272598>
48. **Health Beliefs and Preventive Behaviors Among Adults During the Early COVID-19 Pandemic in the United States: a Latent Class Analysis.** Prev Sci

- 2021;1-10Smail E, Schneider KE, DeLong SM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34275054>
49. **Implications for social work teaching and learning in Universiti Sains Malaysia, Penang, due to the COVID-19 pandemic: A reflection.** Qual Soc Work 2021; 20:553-560Azman A, Singh PSJ, Isahaque A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34253996>
 50. **"Thanks for hearing me out": Voices of social work students during COVID-19.** Qual Soc Work 2021; 20:63-66Cole SJ, Mitra SS, Robinson JA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34253955>
 51. **Experiences of the Covid-19 pandemic: From the perspective of an MSW student.** Qual Soc Work 2021; 20:604-609Hugo T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34253999>
 52. **A sanctuary: Mourning the loss of the classroom during COVID.** Qual Soc Work 2021; 20:162-167Mitchell Dove L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253962>
 53. **An evaluation of the experiences of academics and practice educators who supported radiography students working on the temporary HCPC register during the COVID-19 pandemic.** Radiography (Lond) 2021; Strudwick RM, Cushen-Brewster N, Doolan C, Driscoll-Evans P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34274227>
 54. **Covid-19 Knowledge and Perceptions Among Dental Specialists: A Cross-Sectional Online Questionnaire Survey.** Risk Manag. Healthc. Policy 2021; 14:2851-2861Aldhuwayhi S, Mallineni SK, Sakhamuri S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34262372>
 55. **COVID-19 and aging: Identifying measures of severity.** SAGE Open Med 2021; 9:20503121211027462Neves MT, de Matos LV, Vasques AC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34249362>
 56. **Flipped classroom: How higher education institutions (HEIs) of Bangladesh could move forward during COVID-19 pandemic.** Soc Sci Humanit Open 2021; 4:100187Khan MSH, Abdou BO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250462>
 57. **A living mapping review for COVID-19 funded research projects: nine-month update.** Wellcome Open Res 2020; 5:209Norton A, Bucher A, Antonio E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33117894>
 58. **Make nursing practice visible through nursing science in times of COVID-19.** Wien. Med. Wochenschr. 2021; Hödl M, Bauer S, Eglseer D *et al.*
 59. **The impact of the coronavirus pandemic on European Neurosurgery Trainees.** World Neurosurg 2021; Tzerefos C, Meling TR, Lafuente J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34252632>

Elderly (15 articles)

1. **Neurological Manifestations in COVID-19: An Unrecognized Crisis in Our Elderly?** Adv Geriatr Med Res 2021; 3Krupp K, Madhivanan P, Killgore WDS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34268500>
2. **COVID-19 Associated Suicidal Ideation in Older Adults: Two Case Reports With a Review of the Literature.** Am J Geriatr Psychiatry 2021; Asthana NK, Mehaffey E, Sewell DD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266752>

3. **Health service experiences and preferences of frail home care clients and their family and friend caregivers during the COVID-19 pandemic.** BMC Res. Notes 2021; 14:271Weeks LE, Nesto S, Hiebert B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34261523>
4. **Trends in emergency department use by older people during the COVID-19 pandemic.** Eur. Geriatr. Med. 2021;1-9Howley F, Lavan A, Connolly E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34273092>
5. **Comorbidities predict 30-day hospital mortality of older adults with COVID-19.** Geriatr. Nurs. 2021; 42:1024-1028Pott Junior H, Cominetti MR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34256151>
6. **Frailty as a mortality predictor in older adults with COVID-19: A systematic review and meta-analysis of cohort studies.** Geriatr. Nurs. 2021; 42:983-992Saragih ID, Advani S, Saragih IS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256158>
7. **Therapeutic prevention of COVID-19 in elderly: a case-control study.** Geroscience 2021;1-11Blanc F, Waechter C, Vogel T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34273049>
8. **Effects of social prescribing pilot project for the elderly in rural area of South Korea during COVID-19 pandemic.** Health Sci Rep 2021; 4:e320Kim JE, Lee YL, Chung MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250272>
9. **Ageism in the COVID-19 pandemic: age-based discrimination in triage decisions and beyond.** Hist Philos Life Sci 2021; 43:91Rueda J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34258692>
10. **Surviving older patients show preserved cellular and humoral immunological memory several months after SARS-CoV-2 infection.** J Gerontol A Biol Sci Med Sci 2021; García-Torre A, Bueno-García E, López-Martínez R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34252180>
11. **Association between Early Antibiotic Therapy and In-Hospital Mortality among Older Patients with SARS-CoV-2 Pneumonia.** J Gerontol A Biol Sci Med Sci 2021; Putot A, Bouiller K, Laborde C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272847>
12. **Background rates of hospital transfer and death in Australian aged care facilities: estimates to assist interpretation of rates after COVID-19 vaccination.** Med. J. Aust. 2021; Clothier HJ, Mesfin YM, Strange S, Buttery JP.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34268767>
13. **Treating elderly geriatric patients right - some special aspects regarding sequential acute medical treatment and rehabilitation, rehabilitation and the new IPReG and long-Covid- rehabilitation.** MMW-Fortschritte der Medizin 2021; 163:48-50Zeile T.
14. **COVID 19 meets changing traditional care systems for the elderly and a budding social work practice. Reflections for geriatric care in Ghana.** Qual Soc Work 2021; 20:501-506Deku CS, Forkuor JB, Agyemang E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34253991>
15. **Actual Frailty Conditions and Lifestyle Changes in Community-Dwelling Older Adults Affected by Coronavirus Disease 2019 Countermeasures in Japan: A Cross-Sectional Study.** SAGE Open Nurs 2021; 7:23779608211025117Shinohara T, Saida K, Tanaka S, Murayama A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263028>

Epidemiology (63 articles)

1. **Medical Challenges in hosting 2020 Tokyo Olympic and Paralympic Games to let us see brilliant blue sky over the clouds.** Anaesth Crit Care Pain Med 2021;100930Morimura N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252598>
2. **A multi-stage SEIR(D) model of the COVID-19 epidemic in Korea.** Ann. Med. 2021; 53:1159-1169Shin HY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269629>
3. **Transmission trend of the COVID-19 pandemic predicted by dendritic neural regression.** Appl Soft Comput 2021; 111:107683Dong M, Tang C, Ji J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248448>
4. **Covid-19 and the next outbreak: decreasing frailty by using mild stress?** Biogerontology 2021;1-5Le Bourg E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273015>
5. **Epidemiological characteristics and initial spatiotemporal visualisation of COVID-19 in a major city in the Middle East.** BMC Public Health 2021; 21:1373MohammadEbrahimi S, Mohammadi A, Bergquist R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247616>
6. **Mere rhetoric? Using solidarity as a moral guide for deliberations on border closures, border reopenings and travel restrictions in the age of COVID-19.** BMJ Glob Health 2021; 6Silva DS, Jackson C, Smith MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272273>
7. **National cross-sectional survey of 1.14 million NHS staff SARS-CoV-2 serology tests: a comparison of NHS staff with regional community seroconversion rates.** BMJ Open 2021; 11:e049703Coltart CEM, Wells D, Sutherland E, Fowler A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257096>
8. **Effectiveness of contact tracing apps for SARS-CoV-2: a rapid systematic review.** BMJ Open 2021; 11:e050519Jenniskens K, Bootsma MCJ, Damen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253676>
9. **Reducing COVID-19 quarantine with SARS-CoV-2 testing: a simulation study.** BMJ Open 2021; 11:e050473Peng B, Zhou W, Pettit RW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272225>
10. **Protecting olympic participants from COVID-19: the trialled and tested process.** Br. J. Sports Med. 2021; Pigozzi F, Wolfarth B, Cintron Rodriguez A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272272>
11. **A study on factors affecting privacy risk tolerance to prevent the spread of COVID-19 in South Korea.** Bus. Horiz. 2021; Kim M, Jung Y, Kim J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248157>
12. **The devil in the details: Herd immunity and pandemic response.** Cell Host Microbe 2021; 29:1048-1051Schaeffer B, Taylor B, Bushman M, Hanage WP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265244>
13. **Modelling and forecasting of growth rate of new COVID-19 cases in top nine affected countries: Considering conditional variance and asymmetric effect.** Chaos Solitons Fractals 2021; 151:111227Ekinci A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253942>
14. **Clustering of Countries for COVID-19 Cases based on Disease Prevalence, Health Systems and Environmental Indicators.** Chaos Solitons Fractals 2021:111240Rizvi SA, Umair M, Cheema MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253943>

15. **Impact of COVID-19 outbreak on Italian healthcare workers versus general population: results from an online survey.** Clin. Psychol. Psychother. 2021; Mansueto G, Lopes FL, Grassi L, Cosci F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255890>
16. **Bayesian inference of heterogeneous epidemic models: Application to COVID-19 spread accounting for long-term care facilities.** Comput Methods Appl Mech Eng 2021; 385:114020Chen P, Wu K, Ghattas O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248229>
17. **Impact of Nonpharmacological Public Health Interventions on Epidemiological Parameters of COVID-19 Pandemic in India.** Cureus 2021; 13:e15393Kharya P, Koparkar AR, Dixit AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249543>
18. **Epidemic, pandemic or endemic: When and how will we overcome the corona crisis?** Deutsche Apotheker Zeitung 2021; 161Grill E.
19. **Lockdown effect on COVID-19 incidence and death: Iran experience.** Disaster Med Public Health Prep 2021:1-10Delavari S, Jamali Z, Bayati M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247685>
20. **The impact of the COVID-19 pandemic on refugees and asylum seekers in Greece: A retrospective analysis of national surveillance data from 2020.** EClinicalMedicine 2021; 37:100958Kondilis E, Papamichail D, McCann S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258570>
21. **Lifting COVID-19 mitigation measures in Spain (May-June 2020).** Enferm. Infec. Microbiol. Clin. 2021; Monge S, Zamalloa PL, Moros MJS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274154>
22. **COVID-19 and emerging infectious diseases: The society is still unprepared for the next pandemic.** Environ. Res. 2021; 202:111676Frutos R, Gavotte L, Serra-Cobo J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252435>
23. **Transmission risks of respiratory infectious diseases in various confined spaces: A meta-analysis for future pandemics.** Environ. Res. 2021:111679Moon J, Ryu BH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265349>
24. **Passive Sampling of SARS-CoV-2 for Wastewater Surveillance.** Environ. Sci. Technol. 2021; Schang C, Crosbie ND, Nolan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264643>
25. **A Study of the Correlation between the Dates of the First Covid Case and the First Covid Death of 25 Selected Countries to Know the Virulence of the Covid-19 in Different Tropical Conditions.** Ethics Med Public Health 2021:100707Jamsheela O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254043>
26. **Trends in emergency department use by older people during the COVID-19 pandemic.** Eur. Geriatr. Med. 2021:1-9Howley F, Lavan A, Connolly E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273092>
27. **Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021.** Euro Surveill 2021; 26Alizon S, Haim-Boukobza S, Foulongne V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269174>
28. **Estimating the Prevalence of Asymptomatic COVID-19 Cases and Their Contribution in Transmission - Using Henan Province, China, as an Example.** Front Med (Lausanne) 2021; 8:591372Li C, Zhu Y, Qi C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249953>
29. **Epidemiology of SARS-CoV-2 Infection Evaluated by Immunochromatographic Rapid Testing for the Determination of IgM and IgG Against SARS-CoV-2 in a Cohort of Mask Wearing Workers in the Metal-Mechanical Sector in an Area**

- With a High Incidence of COVID-19.** *Front Public Health* 2021; 9:628098Esposito S, Neglia C, Affanni P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249830>
30. **No detection of SARS-CoV-2 in animals exposed to infected keepers: results of a COVID-19 surveillance program.** *Future Sci OA* 2021; 7:Fso711Cerino P, Buonerba C, Brambilla G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254029>
 31. **The profile of patients hospitalized with COVID-19 under the Quarantine Act in a designated hospital near an international airport in Japan.** *Glob Health Med* 2021; 3:180-183Hase R, Kubota Y, Niiyama Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250295>
 32. **School openings and the COVID-19 outbreak in Italy. A provincial-level analysis using the synthetic control method.** *Health Policy* 2021; Alfano V, Ercolano S, Cicatiello L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247845>
 33. **Pattern of COVID-19 infection and death across countries: A pilot study.** *Heliyon* 2021:e07504Asem N, Ramadan A, Hassany M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254048>
 34. **Impact of school reopening on pandemic spread: A case study using an agent-based model for COVID-19.** *Infect Dis Model* 2021; 6:839-847Tatapudi H, Das TK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258483>
 35. **High seroprevalence for SARS-CoV-2 infection in South America, but still not enough for heard immunity!** *Int J Infect Dis* 2021; Núñez-Zapata SF, Benites-Peralta B, Mayta-Tristan P, Rodríguez-Morales AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260956>
 36. **Reduction in COVID-19 prevalence in health care workers in a university hospital in southern Brazil after the start of vaccination.** *Int J Infect Dis* 2021; Toniassoa SCC, Fernandes FS, Jovelevithsb D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271203>
 37. **Validity of the Use of Wrist and Forehead Temperatures in Screening the General Population for COVID-19: A Prospective Real-World Study.** *Iran J. Public Health* 2020; 49:57-66Chen G, Xie J, Dai G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268206>
 38. **Exponentially Increasing Trend of Infected Patients with COVID-19 in Iran: A Comparison of Neural Network and ARIMA Forecasting Models.** *Iran J. Public Health* 2020; 49:92-100Mohtakhar L, Seif M, Safe MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268211>
 39. **Reflections on the Cluster Epidemic of COVID-19; Lessons Learned from Wuhan's Experience: A Brief Review.** *Iran J. Public Health* 2020; 49:12-17Zhou Q, Huang S, Xiao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268201>
 40. **A novel hybrid fuzzy time series model for prediction of COVID-19 infected cases and deaths in India.** *ISA Trans.* 2021; Kumar N, Kumar H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253340>
 41. **The forecast of COVID-19 spread risk at the county level.** *J Big Data* 2021; 8:99Hssayeni MD, Chala A, Dev R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249603>
 42. **#COVID#BACKTOSCHOOL: Qualitative study based on the voice of Portuguese adolescents.** *J. Community Psychol.* 2021; Branquinho C, Santos AC, Ramiro L, Gaspar de Matos M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252981>

43. **Hospitalisation and mortality from COVID-19 in Mexican indigenous people: a cross-sectional observational study.** J. Epidemiol. Community Health 2021; Serván-Mori E, Seiglie JA, Gómez-Dantés O, Wirtz VJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266980>
44. **Lessons Learnt and Pathways forward for National Civil Registration and Vital Statistics Systems after the COVID-19 Pandemic.** J Epidemiol Glob Health 2021; Kelly M, Mathenge G, Rao C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34270182>
45. **COVID-19 spread in a classroom equipped with partition - A CFD approach.** J. Hazard. Mater. 2021; 420:126587Mirzaie M, Lakzian E, Khan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273880>
46. **Viral infections amidst COVID-19 in Africa: Implications and recommendations.** J Med Virol 2021; Uwishema O, Adanur I, Babatunde AO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260094>
47. **Contact Tracing Apps: Lessons Learned on Privacy, Autonomy, and the Need for Detailed and Thoughtful Implementation.** JMIR Med Inform 2021; 9:e27449Hogan K, Macedo B, Macha V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254937>
48. **An epidemic model for COVID-19 transmission in Argentina: Exploration of the alternating quarantine and massive testing strategies.** Math. Biosci. 2021:108664Vassallo L, Perez IA, Alvarez-Zuzek LG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271015>
49. **COVID-19 Community Temporal Visualizer: a new methodology for the network-based analysis and visualization of COVID-19 data.** Netw Model Anal Health Inform Bioinform 2021; 10:46Milano M, Zucco C, Cannataro M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249598>
50. **Mathematical modelling of the second wave of COVID-19 infections using deterministic and stochastic SIRD models.** Nonlinear Dyn 2021:1-15Lobato FS, Libotte GB, Platt GM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248281>
51. **A stochastic SEIHR model for COVID-19 data fluctuations.** Nonlinear Dyn 2021:1-13Niu R, Chan YC, Wong EWM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248280>
52. **Different Trends in Excess Mortality in a Central European Country Compared to Main European Regions in the Year of the COVID-19 Pandemic (2020): a Hungarian Analysis.** Pathol. Oncol. Res. 2021; 27:1609774Bogos K, Kiss Z, Kerpel Fronius A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257618>
53. **Forecasting the COVID-19 transmission in Italy based on the minimum spanning tree of dynamic region network.** PeerJ 2021; 9:e11603Dong M, Zhang X, Yang K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249495>
54. **Novel Respiratory Viruses in the Context of Mass-Gathering Events: A Systematic Review to Inform Event Planning from a Health Perspective.** Prehosp. Disaster Med. 2021:1-12Ranse J, Beckwith D, Khan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261546>
55. **Predicting the SARS-CoV-2 effective reproduction number using bulk contact data from mobile phones.** Proc Natl Acad Sci U S A 2021; 118Rüdiger S, Konigorski S, Rakowski A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261775>
56. **Reflections on a pandemic and surveillance: Disruption, distractions, and discoveries in the United Arab Emirates.** Qual Soc Work 2021; 20:331-335Abu Sarhan TM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253976>

57. **Risk contagion of COVID-19 in Japanese firms: A network approach.** Res Int Bus Finance 2021; 58:101491 Kanno M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248246>
58. **Can Comorbidity Data Explain Cross-State and Cross-National Difference in COVID-19 Death Rates?** Risk Manag. Healthc. Policy 2021; 14:2877-2885 Cegan JC, Trump BD, Cibulsky SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267565>
59. **Spread of COVID-19 in Zambia: An assessment of environmental and socioeconomic factors using a classification tree approach.** Sci Afr 2021; 12:e00827 Phiri D, Salekin S, Nyirenda VR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250321>
60. **Monitoring of SARS-CoV-2 RNA in wastewater as an epidemiological surveillance tool in Mendoza, Argentina.** Sci Total Environ 2021; 796:148887 Giraud-Billoud M, Cuervo P, Altamirano JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274669>
61. **The existence, spread, and strategies for environmental monitoring and control of SARS-CoV-2 in environmental media.** Sci Total Environ 2021; 795:148949 Liu Z, Skowron K, Grudlewska-Buda K, Wiktorczyk-Kapischke N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252782>
62. **Performance Evaluation of Soft Computing Approaches for Forecasting COVID-19 Pandemic Cases.** SN Comput Sci 2021; 2:372 Shoaib M, Salahudin H, Hammad M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258586>
63. **One year of COVID-19 in Italy: are containment policies enough to shape the pandemic pattern?** Socioecon. Plann. Sci. 2021:101120 Panarello D, Tassinari G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248212>

Gastro-enterology (12 articles)

1. **Enteroclysis in gastrointestinal tuberculosis: an overview.** Adv Respir Med 2021; Muntean PE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269410>
2. **Acute Acalculous Cholecystitis Due to COVID-19, an Unusual Presentation.** Cureus 2021; 13:e15431 Abaleka FI, Nigussie B, Bedanie G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258107>
3. **Coronavirus Disease 2019 Pneumonia and Acute Pancreatitis in a Young Girl.** Cureus 2021; 13:e15374 Ehsan P, Haseeb M, Khan Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249527>
4. **Liver dysfunction in COVID-19: a useful prognostic marker of severe disease?** Frontline Gastroenterol. 2021; 12:293-298 Lok J, Gess M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249314>
5. **COVID-19: impetus to the adoption of capsule endoscopy as a primary diagnostic tool?** Frontline Gastroenterol. 2021; 12:263-264 McAlindon M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249309>
6. **COVID-19 in Gastroenterology Departments: The Impact of the First Wave.** GE Port J Gastroenterol 2021; 4:1-7 Leal T, Gonçalves M, Mocanu I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254041>
7. **Reply to: "COVID-19-associated liver injury (COVALI): role of hepatologists".** J. Gastroenterol. 2021:1-2 Li D, Ding X, Tian D, Xia L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251568>
8. **Unraveling the role of liver sinusoidal endothelial cells in COVID-19 liver injury.** J Hepatol 2021; Saviano A, Baumert TF.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34274367>

9. **A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma.** J. Oncol. Pharm. Pract. 2021;10781552211031304 Demir E, Sütçüoğlu O, Demir B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255596>
10. **Characteristics and outcomes of patients with COVID-19 and liver injury: a retrospective analysis and a multicenter experience.** Rom. J. Intern. Med. 2021; Voiosu A, Roman A, Pop R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253002>
11. **Impact of the COVID-19 pandemic on inflammatory bowel disease: the role of emotional stress and social isolation.** Stress Health 2021; Nass BY, Dibbets P, Markus CR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273129>
12. **High rate of percutaneous gastrostomy placement in COVID-19 patients with low overall complications.** Tech Innov Gastrointest Endosc 2021; Lipcsey M, Stein DJ, Yu RL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250514>

Guidelines (5 articles)

1. **The dynamics in applied COVID-19 pharmacotherapy and the influence of national guidance in The Netherlands: a quantitative and qualitative study.** Eur J Hosp Pharm 2021; Uitvlugt EB, Soeng DYF, van der Linden P, van de Garde EMW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272215>
2. **NOTTO COVID-19 Vaccine Guidelines for Transplant Recipients.** Indian J. Nephrol. 2021; 31:89-91 Kute VB, Agarwal SK, Prakash J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267426>
3. **Examining the role of government in shaping disability inclusiveness around COVID-19: a framework analysis of Australian guidelines.** Int J Equity Health 2021; 20:166 Colon-Cabrera D, Sharma S, Warren N, Sakellariou D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271933>
4. **Physician Experiences in Management of COVID-19-Associated Coagulopathy in Pregnancy: Communication from the ISTH SSC Subcommittee on Women's Health Issues in Thrombosis and Haemostasis.** J Thromb Haemost 2021; Jevtic SD, Malinowski AK, Othman M, Kadir RAA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260818>
5. **Validation of the French IVF guidelines during the COVID-19 pandemic.** Reprod. Biomed. Online 2021; Poulain M, Fossard C, Benammar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274240>

Imaging (31 articles)

1. **A human-computer collaboration for COVID-19 differentiation: combining a radiomics model with deep learning and human auditing.** Ann Palliat Med 2021; Xin X, Mo R, Shao M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263624>
2. **A new composite approach for COVID-19 detection in X-ray images using deep features.** Appl Soft Comput 2021; 111:107669 Özcan T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248447>
3. **FractalCovNet architecture for COVID-19 Chest X-ray image Classification and CT-scan image Segmentation.** Biocybern Biomed Eng 2021; 41:1025-

1038Munusamy H, Karthikeyan JM, Shriram G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34257471>

4. **Coronary artery calcium score may be a novel predictor of COVID-19 prognosis: a retrospective study.** *BMJ Open Respir Res* 2021; 8Takeshita Y, Terada J, Fujita R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272254>
5. **Intraoperative Ultrasonographic Assessment of Vocal Cord motion under sedation, following paediatric thyroidectomy in the Era of COVID-19: A double-blinded preliminary study.** *Clin. Otolaryngol.* 2021; Zavdy O, Schwarz M, Gilony D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255927>
6. **Diagnosis of COVID-19 Using Machine Learning and Deep Learning: A Review.** *Curr Med Imaging* 2021; Mondal MRH, Bharati S, Podder P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259149>
7. **Deep Learning-Based COVID-19 Pneumonia Classification Using Chest CT Images: Model Generalizability.** *Front Artif Intell* 2021; 4:694875Nguyen D, Kay F, Tan J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268489>
8. **Effects of COVID-19 vaccination on FDG-PET/CT imaging: A literature review.** *Glob Health Med* 2021; 3:129-133Minamimoto R, Kiyomatsu T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250287>
9. **SpecMEN-DL: spectral mask enhancement with deep learning models to predict COVID-19 from lung ultrasound videos.** *Health Inf Sci Syst* 2021; 9:28Sadik F, Dastider AG, Fattah SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257953>
10. **Dissociation between the clinical course and chest imaging in severe COVID-19 pneumonia: A series of five cases.** *Heart Lung* 2021; 50:818-824Basille D, Auquier MA, Andr  jak C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271253>
11. **Assessment of severity and mortality of COVID-19 with anti-A1 and B IgM isohemagglutinins, a reflection of the innate immune status.** *Int J Clin Pract* 2021:e14624Ozcelik F, Tanoglu A, Guven BB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251730>
12. **National and regional trends in MRI utilization in the face of the ongoing COVID-19 pandemic.** *Isr J Health Policy Res* 2021; 10:40Luxenburg O, Saban M, Myers V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266476>
13. **Brain Stress Mapping in COVID-19 Survivors Using MR Spectroscopy: New Avenue of Mental Health Status Monitoring.** *J. Alzheimers Dis.* 2021; Samkaria A, Punjabi K, Sharma S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250939>
14. **Development of cavitory lung disease as a long-term complication of coronavirus disease 2019 in a young previously healthy patient: a case report.** *J Med Case Rep* 2021; 15:377Egoryan G, Hyser E, Mushtaq AH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256831>
15. **Evolution of (18)F-FDG-PET/CT findings in patients following COVID-19 pneumonia: An Initial Investigation.** *J Nucl Med* 2021; Thornton A, Fraioli F, Wan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272318>
16. **Neuroimaging Findings in Patients with COVID-19: A Systematic Review and Meta-Analysis.** *Korean J Radiol* 2021; Kim PH, Kim M, Suh CH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269530>
17. **Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model.** *mBio* 2021:e0097421Dhakal S, Ruiz-Bedoya CA, Zhou R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253053>

18. **Radiography-based triage for COVID-19 in the Emergency Department in a Spanish cohort of patients.** *Med Clin (Barc)* 2021; Sempere-González A, Llaneras-Artigues J, Pinal-Fernández I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256936>
19. **Deep learning-based meta-classifier approach for COVID-19 classification using CT scan and chest X-ray images.** *Multimed Syst* 2021:1-15 Ravi V, Narasimhan H, Chakraborty C, Pham TD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248292>
20. **Improved manta ray foraging optimization for multi-level thresholding using COVID-19 CT images.** *Neural Comput Appl* 2021:1-21 Houssein EH, Emam MM, Ali AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248291>
21. **An optimized KELM approach for the diagnosis of COVID-19 from 2D-SSA reconstructed CXR Images.** *Optik (Stuttg)* 2021; 244:167572 Mohanty F, Dora C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248209>
22. **CME Sonography 98/Answers: Chest Ultrasound.** *Praxis* 2021; 110:508-509 Bürge T, Tuma J.
23. **Ultrasound in times of corona.** *Praxis* 2021; 110:419 Schwarzenbach HR, Tuma J.
24. **Prevalence of exercise-induced oxygen desaturation after recovery from SARS-CoV-2 pneumonia and use of lung ultrasound to predict need for pulmonary rehabilitation.** *Pulmonology* 2021; Carlucci A, Paneroni M, Carotenuto M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247995>
25. **Cross-sectional analysis of follow-up chest MRI and chest CT scans in patients previously affected by COVID-19.** *Radiol Med* 2021:1-9 Pecoraro M, Cipollari S, Marchitelli L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251585>
26. **COVID-19 pneumonia: relationship between initial chest X-rays and laboratory findings.** *Radiologia (Roma)* 2021; Nava-Muñoz Á, Gómez-Peña S, Fuentes-Ferrer ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253334>
27. **HOG + CNN Net: Diagnosing COVID-19 and Pneumonia by Deep Neural Network from Chest X-Ray Images.** *SN Comput Sci* 2021; 2:371 Rahman MM, Nooruddin S, Hasan KMA, Dey NK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254055>
28. **Thoracic imaging outcomes in COVID-19 survivors.** *World J Radiol* 2021; 13:149-156 Alqahtani JS, Alghamdi SM, Aldhahir AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249236>
29. **COVID-19 imaging: Diagnostic approaches, challenges, and evolving advances.** *World J Radiol* 2021; 13:171-191 Pezzutti DL, Wadhwa V, Makary MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249238>
30. **Imaging in the COVID-19 era: Lessons learned during a pandemic.** *World J Radiol* 2021; 13:192-222 Sideris GA, Nikolakea M, Karanikola AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249239>
31. **Imaging spectrum of abdominal manifestations of COVID-19.** *World J Radiol* 2021; 13:157-170 Vaidya T, Nanivadekar A, Patel R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=3424923>

Immune response (38 articles)

1. **Dye-Loaded Polymersome-Based Lateral Flow Assay: Rational Design of a COVID-19 Testing Platform by Repurposing SARS-CoV-2 Antibody Cocktail and Antigens Obtained from Positive Human Samples.** *ACS Sens* 2021;

- Ghorbanizamani F, Tok K, Moulahoum H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34270230>
2. **[Immune Response to Single-Dose Moderna Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2].** *Acta Med Port* 2021; Moreira-Pinto J, Gregório S, Camarinha J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256902>
 3. **Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report.** *Ann. Rheum. Dis.* 2021; Golding B, Lee Y, Golding H, Khurana S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34272252>
 4. **Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.** *Ann. Rheum. Dis.* 2021; Westhoff TH, Seibert FS, Anft M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34272253>
 5. **Titres and neutralising capacity of SARS-CoV-2-specific antibodies in human milk: a systematic review.** *Arch. Dis. Child. Fetal Neonatal Ed.* 2021; Low JM, Low YW, Zhong Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257103>
 6. **Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France.** *Arthritis Res. Ther.* 2021; 23:188 Felten R, Scherlinger M, Guffroy A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256812>
 7. **Dynamic changes of functional fitness, antibodies to SARS-CoV-2 and immunological indicators within 1 year after discharge in Chinese health care workers with severe COVID-19: a cohort study.** *BMC Med* 2021; 19:163 Xiong L, Li Q, Cao X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256745>
 8. **COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies.** *Br. J. Haematol.* 2021; Passamonti F, Romano A, Salvini M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272724>
 9. **An outline of SARS-CoV-2 pathogenesis and the complement cascade of immune system.** *Bull Natl Res Cent* 2021; 45:123 Hembram P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34257504>
 10. **Cardiac Implications of Multisystem Inflammatory Syndrome Associated with COVID-19 in Children under the age of Five Years.** *Cardiol. Young* 2021; 1-15 Rakha S, Sobh A, Hager AH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261560>
 11. **Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells.** *Cell Rep Med* 2021; 1:100354 Cohen KW, Linderman SL, Moodie Z *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34250512>
 12. **Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells.** *Cell Rep Med* 2021; 2:100354 Cohen KW, Linderman SL, Moodie Z *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34250512>
 13. **SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation.** *Clin Transl Immunology* 2021; 10:e1306 Sandberg JT, Varnaité R, Christ W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34257967>
 14. **The Meaning of SARS-CoV-2 Antibodies in a Patient with a Systemic Reaction to the mRNA-1273 SARS-CoV-2 Vaccine after Previous Natural Immunization.**

- [Eur J Case Rep Intern Med](#) 2021; 8:002617Sazgary L, Meienberg A, Berger CT, Mayr M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268264>
15. **Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C).** [Exp. Biol. Med. \(Maywood\)](#). 2021;15353702211028560Kuypers FA, Rostad CA, Anderson EJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255566>
 16. **Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy.** [Front. Immunol.](#) 2021; 12:680567Boudhabhay I, Rabant M, Roumenina LT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248962>
 17. **Differential Cytokine Responses in Hospitalized COVID-19 Patients Limit Efficacy of Remdesivir.** [Front. Immunol.](#) 2021; 12:680188Chan YH, Young BE, Fong SW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262564>
 18. **Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome.** [Front. Immunol.](#) 2021; 12:621440Illouz T, Biragyn A, Iulita MF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248930>
 19. **Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning.** [Front. Immunol.](#) 2021; 12:700782Patterson BK, Guevara-Coto J, Yogendra R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262570>
 20. **In vitro Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms.** [Front. Microbiol.](#) 2021; 12:698944Lassaunière R, Fonager J, Rasmussen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248922>
 21. **How and to What Extent Immunological Responses to SARS-CoV-2 Shape Pulmonary Function in COVID-19 Patients.** [Front. Physiol.](#) 2021; 12:628288Laveneziana P, Straus C, Meiners S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267671>
 22. **Epidemiology of SARS-CoV-2 Infection Evaluated by Immunochromatographic Rapid Testing for the Determination of IgM and IgG Against SARS-CoV-2 in a Cohort of Mask Wearing Workers in the Metal-Mechanical Sector in an Area With a High Incidence of COVID-19.** [Front Public Health](#) 2021; 9:628098Esposito S, Neglia C, Affanni P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249830>
 23. **COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge.** [Immunity](#) 2021; DiPiazza AT, Leist SR, Abiona OM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34270939>
 24. **Determinants of having severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egypt.** [Influenza Other Respir Viruses](#) 2021; El Rifay AS, Mahmoud SH, Marouf MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264010>
 25. **Analysis of SARS-CoV-2 RT-qPCR Ct values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region.** [Int J Infect Dis](#) 2021; Markewitz R, Torge A, Wandinger KP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273511>
 26. **SARS-CoV-2 infection in the immunodeficient host: necessary and dispensable immune pathways.** [J Allergy Clin Immunol Pract](#) 2021; Giardino G, Romano R, Coppola E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273582>

27. **Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study.** J. Clin. Immunol. 2021;1-12García-Abellán J, Padilla S, Fernández-González M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34273064>
28. **Surviving older patients show preserved cellular and humoral immunological memory several months after SARS-CoV-2 infection.** J Gerontol A Biol Sci Med Sci 2021; García-Torre A, Bueno-García E, López-Martínez R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34252180>
29. **Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors.** J Immunother Cancer 2021; 9Switzer B, Haanen J, Lorigan PC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34272309>
30. **SARS-CoV-2 B.1.617 mutations L452 and E484Q are not synergistic for antibody evasion.** J Infect Dis 2021; Ferreira I, Kemp S, Datir R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34260717>
31. **Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay.** JCI Insight 2021; Lopez E, Haycroft ER, Adair A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34251356>
32. **Systematic Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients with Chronic Kidney Disease.** Kidney Int Rep 2021; Carr EJ, Kronbichler A, Graham-Brown M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250319>
33. **Impact of Previous Coronavirus Disease 2019 on Immune Response After a Single Dose of BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.** Open Forum Infect Dis 2021; 8:ofab299Velasco M, Galán MI, Casas ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258322>
34. **Immunity and inflammatory biomarkers in COVID-19: A systematic review.** Rev Med Virol 2021; 31:e2199Iwamura APD, Tavares da Silva MR, Hümmelgen AL *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34260778>
35. **A systematic meta-analysis of immune signatures in patients with COVID-19.** Rev Med Virol 2021; 31:e2195Liu K, Yang T, Peng XF *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34260780>
36. **Short-term outcomes in children recovered from multisystem inflammatory syndrome associated with SARS-CoV-2 infection.** Rheumatol. Int. 2021;1-6Patnaik S, Jain MK, Ahmed S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259880>
37. **Comment on: Emerging Evidence on Multisystem Inflammatory Syndrome in Children Associated with SARS-CoV-2 Infection.** SN Compr Clin Med 2021;1-2Mantina NM, Madhivanan P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250445>
38. **The journey of SARS-CoV-2 in human hosts: a review of immune responses, immunosuppression, and their consequences.** Virulence 2021; 12:1771-1794Alshammary AF, Al-Sulaiman AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251989>

Management miscellaneous diseases (58 articles)

1. **ECONOMIC IMPACT OF COVID-19 ON BRAZILIAN ORTHOPEDISTS.** Acta Ortop Bras 2021; 29:61-66Stirma GA, Belangero PS, Pochini AC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34248402>

2. **Impact of COVID-19 pandemic on non-COVID patient's management in urology: a public hospital experience in Mumbai.** Afr J Urol 2021; 27:96Jibhakate NA, Patwardhan SK, Sawant AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248350>
3. **Patterns of Emergency Department visits for acute and chronic diseases during the two pandemic waves in Italy.** Am J Emerg Med 2021; 50:22-26Golinelli D, Campinoti F, Sanmarchi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271231>
4. **Kids are back in town: the return of high demand for paediatric emergency care.** Arch. Dis. Child. 2021; Jenner R, Walker A, Isba R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266875>
5. **Surveillance for Pressure Injuries upon admission to Inpatient Rehabilitation HOSPITALS during the COVID-19 Pandemic.** Arch. Phys. Med. Rehabil. 2021; Kendall JA, Haberl JK, Hartsgrove C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252395>
6. **Strategies to Offer Uninterrupted Neurosurgical Care at a Tertiary Center in Makka amid COVID-19 Pandemic.** Asian. J. Neurosurg. 2021; 16:271-275Azab MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268150>
7. **Getting Neurosurgery Services Back on Its Feet: "Learning to Live" with COVID-19.** Asian. J. Neurosurg. 2021; 16:340-348Goyal N, Gupta K, Chaturvedi J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268162>
8. **The impact of COVID-19 pandemic on the utilization of ambulatory care for patients with chronic neurological diseases in Japan: Evaluation of an administrative claims database.** Biosci Trends 2021; Sato K, Mano T, Niimi Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261836>
9. **Role of respiratory intermediate care units during the SARS-CoV-2 pandemic.** BMC Pulm. Med. 2021; 21:228Matute-Villacís M, Moisés J, Embid C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256747>
10. **Delayed diagnosis of ingested button battery leading to tracheoesophageal fistula in a child infected with SARS-CoV-2.** BMJ Case Rep. 2021; 14Goussard P, Janson J, Nel E, Schubert P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253535>
11. **The orthopaedic waiting list crisis : two sides of the story.** Bone Jt Open 2021; 2:530-534Hampton M, Riley E, Garneti N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261360>
12. **The personal limitations checklist: human factors insights from air accidents to reduce intraoperative harm.** Br. J. Oral Maxillofac. Surg. 2020; Hardie JA, Brennan PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274172>
13. **Characteristics of burn injury during COVID-19 pandemic in Tokyo: A descriptive study.** Burns Open 2021; Yamamoto R, Sato Y, Matsumura K, Sasaki J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254050>
14. **COVID-19 Pandemic Impact and Response in Canadian Pediatric Chronic Pain Care: A National Survey of Medical Directors and Pain Professionals.** Can J Pain 2021; 5:139-150Killackey T, Noel M, Birnie KA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263096>
15. **Pain Management Revisited.** Clin. J. Oncol. Nurs. 2021; 25:361-362Carr E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269344>
16. **Homecare Encounters: An Organizational Response to Innovative Care for Patients Undergoing Hematopoietic Stem Cell Transplantation During COVID-**

19. Clin. J. Oncol. Nurs. 2021; 25:457-464Liu J, Allen DH, Lassiter M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34269347>
17. **The impact of COVID-19 on obesity services across Europe: A physician survey.** Clin Obes 2021:e12474Nather K, Bolger F, DiModica L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34254445>
18. **Intraoperative Ultrasonographic Assessment of Vocal Cord motion under sedation, following pediatric thyroidectomy in the Era of COVID-19, a double-blinded preliminary study.** Clin. Otolaryngol. 2021; Zavdy O, Schwarz M, Gilony D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255927>
19. **COVID-19 Impact on Medical Practice in Sub-Saharan Africa; The Need to Guard Against Medical Negligence: A Case Report in a Health Care Facility in Kumasi, Ghana.** Clin Pathol 2021; 14:2632010x211025308Ossei PPS, Ayibor WG, Taylor J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263164>
20. **Impacts of the COVID-19 epidemic on the department of stomatology in a tertiary hospital: A case study in the General Hospital of the Central Theater Command, Wuhan, China.** Community Dent. Oral Epidemiol. 2021; Dong Q, Kuria A, Weng Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34270106>
21. **Sociodemographic changes in emergency department visits due to alcohol during COVID-19.** Drug Alcohol Depend. 2021; 226:108877Myran DT, Cantor N, Pugliese M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256266>
22. **SARS-CoV-2 infection and paediatric endocrine disorders: Risks and management considerations.** Endocrinol Diabetes Metab 2021; 4:e00262Miller R, Ashraf AP, Gourgari E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268455>
23. **Rethinking the management of immune checkpoint inhibitor-related adrenal insufficiency in cancer patients during the COVID-19 pandemic.** Endocrinol Diabetes Metab 2021; 4:e00246Yuen KCJ, Mortensen MJ, Azadi A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34268454>
24. **How Do Breast Cancer Patients Present Following COVID-19 Early Peak in a Breast Cancer Center in Turkey?** Eur J Breast Health 2021; 17:253-257Dauti Işıklar A, Deniz C, Soyder A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263153>
25. **Impact of the COVID-19 pandemic on the management of chronic non-infectious respiratory diseases.** Expert Rev. Respir. Med. 2021; Tiotiu A, Chong-Neto H, Bikov A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253132>
26. **How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center.** Front. Oncol. 2021; 11:669786Pasello G, Menis J, Pilotto S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34262861>
27. **COVID-19 and its impact on the control of Aedes (Stegomyia) aegypti mosquito and epidemiological surveillance of arbovirus infections.** Gac Med Mex 2021; 157:187-193Castañeda-Gómez J, González-Acosta C, Jaime-Rodríguez JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34270541>
28. **Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.** Hematol. Oncol. 2021; Cuneo A, Rigolin GM, Coscia M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34258787>
29. **Trends in urological emergencies in the Era of COVID-19.** Int Braz J Urol 2021; 47:997-1005Frumer M, Aharony SM, Shoshany O *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34260177>

30. **Acute and Late Toxicities of Patients Infected with SARS-CoV-2 and Treated for Cancer with Radiation Therapy During the COVID-19 Pandemic.** Int. J. Radiat. Biol. 2021;1-13Beddok A, Chevrier M, Calugaru V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34269644>
31. **The impact of COVID-19 on emergency surgical presentations in a university teaching hospital.** Ir. J. Med. Sci. 2021;1-7Kamil AM, Davey MG, Marzouk F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34254230>
32. **Reduction in the number of early melanomas diagnosed during the COVID-19 pandemic: a single-center cohort study.** J Eur Acad Dermatol Venereol 2021; Koch E, Villanueva F, Marchetti MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260770>
33. **Level of Knowledge, Understanding, and Impact of the COVID-19 Pandemic on Continuing Fixed Orthodontic Treatment in Adults: A Questionnaire Study.** J. Indian Orthod. Soc. 2021; 55:184-189Ram RR, Ranganayakulu I, Viswanadh KA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248253>
34. **The aftermath of COVID-19 pandemic on the diagnosis of TB at a tertiary care hospital in India.** J Infect Public Health 2021; 14:1095-1098Hazra D, Chawla K, Shenoy VP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274858>
35. **Challenges with the proposed approach in enhancing the accessibility of antimalarial activities during COVID 19 pandemic.** J Infect Public Health 2021; 14:1089-1094Kant R, Yadav P, Singh M, Meena MK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34252846>
36. **Resorting to alternate anesthesia techniques during Covid-19 crisis.** J. Maxillofac. Oral Surg. 2021;1-2Shadamarsan RA, Agrawal N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34257482>
37. **Viral Infections amidst COVID-19 in Africa: Implications and Recommendations.** J Med Virol 2021; Uwishema O, Adanur I, Babatunde AO *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34260094>
38. **Impact of COVID-19 on Aesthetic Plastic Surgery Practice in the United Kingdom.** J. Plast. Reconstr. Aesthet. Surg. 2021; Joji N, Nugent N, Vadodaria S, Sankar TK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257034>
39. **Room for Improvement: The Trephination Procedure for Pediatric Patients with Pilonidal Disease.** J. Surg. Res. 2021; 267:605-611Metzger GA, Apfeld JC, Nishimura L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271267>
40. **Increased risk of severe malaria in travellers during the COVID-19 pandemic.** J Travel Med 2021; de Laval F, Maugey N, de Bonet d'Oléon A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34254146>
41. **Emergency endovascular repair of aortoiliac aneurysms in COVID-19 times.** J Vasc Bras 2021; 20:e20200173Soares RA, Cury MVM, da Silva LM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34267788>
42. **What is the impact of COVID-19 on tissue viability services and pressure ulceration?** J. Wound Care 2021; 30:522-531Vowden K, Hill L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34256597>
43. **COVID-19 in chronic myeloid leukemia patients in Latin America.** Leuk. Lymphoma 2021;1-7Pagnano KB, Peralta EH, Navarro JR *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34254886>
44. **Endophthalmitis rate in immediately sequential vs delayed sequential bilateral cataract surgery within the IRIS® Registry data.** Ophthalmology 2021; Lacy M, Kung TH, Owen JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265315>

45. **Influence of COVID-19 Restrictions on Patients' Self-reported Oral Health Care Needs.** Oral Health Prev Dent 2021; 19:339-343 Sekundo C, Langowski E, Frese C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259426>
46. **Leukaemia and lockdown: The delayed infection model of childhood acute lymphoblastic leukaemia and the COVID-19 pandemic.** Pediatr Blood Cancer 2021:e29194 Lillie K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251092>
47. **COVID-19 in the Intensive Care Unit: Medical, Nursing, and Physical Therapy Challenges.** Praxis 2021; 110:512-516 Jakob SM, Michel K, Kindler A.
48. **[Outcomes following the triage of patients for urological cancer and non-cancer surgery during Covid-19 pandemic peak].** Prog Urol 2021; Durand M, Bentellis I, Barthe F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256992>
49. **[Effects of the COVID-19 pandemic on a cohort of patients with vein occlusion].** Rev Clin Esp 2021; García Palacios JD, Puente Ruiz N, Napal Lecumberri JJ, Hernández Hernández JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248175>
50. **[The waiting list in times of pandemic. A reflection about its indicators.].** Rev. Esp. Salud Publica 2021; 95:e1-e3 Núñez Díaz S, Espinilla Yagüe C, Mahtani Mahtani V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269335>
51. **Stick or twist: Everolimus for seizures in tuberous sclerosis complex during the COVID-19 pandemic.** Seizure 2021; 91:271-272 Moloney PB, Delanty N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252878>
52. **Impact of COVID-19 and lockdown regarding blood transfusion.** Transfusion 2021; Delabranche X, Kientz D, Tacquard C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255374>
53. **Is it safe to perform abdominal transplantation from SARS-CoV-2 polymerase chain reaction positive donors?** Transpl Infect Dis 2021; Frattaroli P, Anjan S, Coro A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258844>
54. **Blunt and penetrating chest trauma with concomitant COVID-19 infections: Two case reports.** Trauma Case Rep 2021; 34:100507 VanDruff RR, Lee JK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250219>
55. **Epidemic of plague amidst COVID-19 in Madagascar: efforts, challenges, and recommendations.** Trop Med Health 2021; 49:56 Aborode AT, Dos Santos Costa AC, Mohan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256858>
56. **Viral infections in urology.** Urologe 2021; Magistro G, Pilatz A, Schneede P *et al.*
57. **The negative effects of COVID-19 and national lockdown on emergency surgery morbidity due to delayed access.** World J Emerg Surg 2021; 16:37 Ciarleglio FA, Rigoni M, Mereu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256781>
58. **[COVID-19 pandemic-related burden and SARS-CoV-2 prevalence in care facilities].** Z Gerontol Geriatr 2021; 1-8 Perkhofer L, Grünke P, Gashi-Ymeri E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259902>

Management (52 articles)

1. **The Management of Pulmonary Fibrosis in COVID-19.** Acta Med Indones 2021; 53:233-241 Rumende CM, Susanto EC, Sitorus TP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251354>
2. Aktuelle Ernährungsmedizin 2021; 46:144.

3. **French Multicentre Observational Study on SARS-CoV-2 infections Intensive care initial management: the FRENCH CORONA Study.** Anaesth Crit Care Pain Med 2021;100931 Roger C, Collange O, Mezzarobba M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34256165>
4. **Management of a COVID-19-infected critically ill patient treated by extracorporeal membrane oxygenation: a case report.** Ann Palliat Med 2021; Fu Q, Li D, He W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263609>
5. **Practice of adjunctive treatments in critically ill COVID-19 patients-rational for the multicenter observational PROAcT-COVID study in The Netherlands.** Ann Transl Med 2021; 9:813 Valk CMA, Swart P, Boers LS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34268426>
6. **Nurses' pandemic lives: A mixed-methods study of experiences during COVID-19.** Appl. Nurs. Res. 2021; 60:151437 Gray K, Dorney P, Hoffman L, Crawford A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247785>
7. **Thromboprophylaxis strategies for COVID-19 patients.** Arch Med Res 2021; Porres-Aguilar M, Pérez-Nieto OR, Zamarrón-López É I, Ñamendys-Silva SA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34274156>
8. **Air leak with COVID-19 - A meta-summary.** Asian Cardiovasc. Thorac. Ann. 2021;2184923211031134 Nasa P, Juneja D, Jain R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34247490>
9. **Maintaining face-to-face contact during the COVID-19 pandemic: a longitudinal qualitative investigation in UK primary care.** BJGP Open 2021; Turner A, Scott A, Horwood J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257067>
10. **Role of respiratory intermediate care units during the SARS-CoV-2 pandemic.** BMC Pulm. Med. 2021; 21:228 Matute-Villacís M, Moisés J, Embid C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34256747>
11. **Health service experiences and preferences of frail home care clients and their family and friend caregivers during the COVID-19 pandemic.** BMC Res. Notes 2021; 14:271 Weeks LE, Nesto S, Hiebert B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34261523>
12. **Converting a British-era hospital into a state-of-the-art COVID-19 care centre.** BMJ Mil Health 2021; Dawra S, Patnaik S, Tevatia MS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34253641>
13. **Plausible Positive Effects of Statins in COVID-19 Patient.** Cardiovasc. Toxicol. 2021;1-9 Vitiello A, Ferrara F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255300>
14. **Longitudinal changes in compliance, oxygenation and ventilatory ratio in COVID-19 versus non-COVID-19 pulmonary acute respiratory distress syndrome.** Crit Care 2021; 25:248 Beloncle F, Studer A, Seegers V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34266454>
15. **Impact of Nonpharmacological Public Health Interventions on Epidemiological Parameters of COVID-19 Pandemic in India.** Cureus 2021; 13:e15393 Kharya P, Koparkar AR, Dixit AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249543>
16. **Lessons Learned From the COVID-19 Response in a Major New York City Hot Zone.** Curr. Probl. Diagn. Radiol. 2021; Yee J, Erdfarb A, Goldberg-Stein S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34274190>
17. **Outcome and death risk of diabetes patients with Covid-19 receiving pre-hospital and in-hospital metformin therapies.** Diabetol. Metab. Syndr. 2021; 13:76 Tamura RE, Said SM, de Freitas LM, Rubio IGS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34256824>

18. **Protection and Response of a Tertiary Hospital in Shenzhen, China to the COVID-19 Outbreak-the Practice of the Comprehensive Response Mode.** Disaster Med Public Health Prep 2021;1-17Hu B, Yang L, Wei C, Luo M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250888>
19. **Variations in Presentation and Management of COVID-19 Inpatients by Race and Ethnicity in a Large Texas Metroplex.** Disaster Med Public Health Prep 2021;1-23Liu A, Patel A, Pierce A, Fowler R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247684>
20. **Mortality in patients treated for COVID-19 in the emergency department of a tertiary care hospital during the first phase of the pandemic: Derivation of a risk model for emergency departments.** Emergencias 2021; 33:273-281García-Martínez A, López-Barbeito B, Coll-Vinent B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251140>
21. **Challenges faced by people with epilepsy on ketogenic diet therapy and their caregivers during the COVID-19 pandemic in Brazil.** Epilepsy Behav. 2021; 122:108193Alencastro Veiga Domingues Carneiro R, Dos Santos Lunardi M, Matheus Uberna Giacomini F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256342>
22. **Impact of non-pharmaceutical interventions against COVID-19 in Europe in 2020: a quasi-experimental non-equivalent group and time series design study.** Euro Surveill 2021; 26Hunter PR, Colón-González FJ, Brainard J, Rushton S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269173>
23. **Maintenance of Muscle Mass and Cardiorespiratory Fitness to Cancer Patients During COVID-19 Era and After SARS-CoV-2 Vaccine.** Front. Physiol. 2021; 12:655955Conceição MS, Derchain S, Vechin FC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248658>
24. **COVID-19 Preparedness and Response: Validation of a Rapid Assessment Tool to Evaluate Priorities of Health Workers at the Grassroots Level.** Front Public Health 2021; 9:562600Tran BX, Hoang CL, Nguyen NTT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268282>
25. **Standardization of Procedures to Contain Cost and Reduce Variability of Care After the Pandemic.** Front Surg 2021; 8:695341Raveglia F, Orlandi R, Rimessi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250010>
26. **Relevance of vitamin D(3) in COVID-19 infection.** Gene Rep 2021; 24:101270UI Afshan F, Nissar B, Chowdri NA, Ganai BA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250314>
27. **Changes in general practitioners' attitudes toward COVID-19 vaccination after first interim results: a longitudinal approach in France.** Hum Vaccin Immunother 2021;1-5Verger P, Scronias D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254880>
28. **The Efficacy of Tracheotomy for Covid-19 Pneumonia: Impacts on Survival and Prognostic Factors.** Indian J Otolaryngol Head Neck Surg 2021;1-6Tuna B, Birdane L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249667>
29. **Infection control professionals' and infectious diseases physicians' knowledge, preparedness, and experiences of managing COVID-19 in Australian healthcare settings.** Infect Dis Health 2021; Sotomayor-Castillo C, Nahidi S, Li C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266812>
30. **COVID-19: Zinc and Angiotensin-Converting Enzyme 2 (ACE2) Deficiencies as Determinants of Risk and Severity of Disease: A Narrative Review.** Infect Dis

- Ther 2021;1-11 Salgo MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251655>
31. **Impact of Non-pharmaceutical Interventions on the Control of COVID-19 in Iran: A Mathematical Modeling Study.** Int J Health Policy Manag 2021; Nakhaeizadeh M, Eybpoosh S, Jahani Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273920>
 32. **The effectiveness of Colchicine as an anti-inflammatory drug in the treatment of coronavirus disease 2019: Meta-analysis.** Int. J. Immunopathol. Pharmacol. 2021; 35:20587384211031763 Golpour M, Mousavi T, Alimohammadi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250834>
 33. **Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case.** Int J Infect Dis 2021; Connor BA, Couto-Rodriguez M, Barrows JE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271202>
 34. **Immunity against seasonal human coronavirus OC43 mitigates fatal deterioration of COVID-19.** Int J Infect Dis 2021; Yamaguchi T, Shinagawa T, Kobata H, Nakagawa H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273512>
 35. **The impact of COVID-19 on nursing workload and planning of nursing staff on the Intensive Care: A prospective descriptive multicenter study.** Int. J. Nurs. Stud. 2021; 121:104005 Hoogendoorn ME, Brinkman S, Bosman RJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273806>
 36. **Inhaled budesonide in the treatment of COVID-19.** Internist 2021; Kluge S, Nitschmann S, Scherer M.
 37. **Views on Discharge Criteria and Stratified Management of Admission for COVID-19: A Case Report.** Iran J. Public Health 2020; 49:101-108 Jiang L, Lin SH, Lin JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268212>
 38. **An Increase in Respiratory Protection Device Injuries Associated with the COVID-19 Pandemic.** J Am Acad Dermatol 2021; McGwin G, Jr., McGwin M, Griffin RL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274413>
 39. **Vitamin D supplementation and COVID-19 risk: a population-based, cohort study.** J. Endocrinol. Invest. 2021;1-13 Oristrell J, Oliva JC, Casado E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273098>
 40. **Association between Early Antibiotic Therapy and In-Hospital Mortality among Older Patients with SARS-CoV-2 Pneumonia.** J Gerontol A Biol Sci Med Sci 2021; Putot A, Bouiller K, Laborde C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272847>
 41. **Effective use of an advanced isolation unit during the COVID-19 pandemic: A retrospective cohort study.** J Microbiol Immunol Infect 2021; Park Y, Kwak SH, Chung K, Park MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261612>
 42. **"The office of disaster management" Nurse managers' experiences during COVID-19: A qualitative interview study using thematic analysis.** J. Nurs. Manag. 2021; Jackson J, Nowell L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34270140>
 43. **Symptoms, complications and management of long COVID: a review.** J R Soc Med 2021;1410768211032850 Aiyegbusi OL, Hughes SE, Turner G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265229>
 44. **Heparin -Messias or Verschlimmbesserung?** J Thromb Haemost 2021; Swan D, Carrier M, Lisman T, Thachil J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272818>

45. **Vitamin D in infectious complications in critically ill patients with or without COVID-19.** Metabol Open 2021;100106Vassiliou AG, Jahaj E, Orfanos SE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250458>
46. **SSRIs: Applications in inflammatory lung disease and implications for COVID-19.** Neuropsychopharmacol Rep 2021; Meikle CKS, Creedon JF, McCullumsmith C, Worth RG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254465>
47. **Workplace challenges and nurses recovered from COVID-19.** Nurs. Ethics 2021;9697330211020439Mohammadi F, Radfar M, Hemmati Maslak Pak M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254555>
48. **Innovative Strategies to Facilitate Safe Assessment and Intervention for Intimate Partner Violence During a Pandemic and Beyond.** Nurs. Womens Health 2021; Guarino JC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34270999>
49. **Lactoferrin: The Natural Protector of the Eye against Coronavirus-19.** Ocul Immunol Inflamm 2021;1-2Alpogan O, Karakucuk S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255583>
50. **Prior Statin Use and Risk of Mortality and Severe Disease From Coronavirus Disease 2019: A Systematic Review and Meta-analysis.** Open Forum Infect Dis 2021; 8:ofab284Yetmar ZA, Chesdachai S, Kashour T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258316>
51. **Outcomes of Continuous Positive Airway Pressure in the Management of Patients with Coronavirus (COVID-19) Pneumonia who are not Suitable for Invasive Ventilation.** Open Respir. Med. J. 2021; 15:23-27Aung H, Avraam E, Ashraf M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249179>
52. **SARS-CoV-2: What changes in the consultation.** Pharm. Ztg. 2020; 165:26-36Ude M, Ude C.
53. **COVID-19 in the Family Practice - Outpatient Treatment or Hospitalization?** Praxis 2021; 110:517-524Lehmann B, Baumgartner C, Brill AK *et al.*
54. **COVID 19 meets changing traditional care systems for the elderly and a budding social work practice. Reflections for geriatric care in Ghana.** Qual Soc Work 2021; 20:501-506Deku CS, Forkuor JB, Agyemang E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253991>
55. **Death, dying and bereavement care during COVID-19: Creativity in hospital social work practice.** Qual Soc Work 2021; 20:131-137Fox M, McIlveen J, Murphy E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253960>
56. **Interactive virtual medication counselling in outpatient pharmacy: An accessible and safe patient counselling method during the COVID-19 pandemic.** Res Social Adm Pharm 2021; Yong WY, Chang CT, Chew CC, Khoo TE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272201>
57. **Integrating Risk Assessment and Decision-Making Methods in Analyzing the Dynamics of COVID-19 Epidemics in Davao City, Mindanao Island, Philippines.** Risk Anal. 2021; Logrosa G, Mata MA, Lachica ZP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269475>
58. **COVID-19 in a rural health system in New York - case series and an approach to management.** Rural Remote Health 2021; 21:6464Kedar E, Scott R, Soule DM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253026>
59. **Warfarin anticoagulation in the Covid-19 pandemic: Telephone-based management at a regional hematology outpatient center in Joinville, Brazil.** Thromb Res 2021; 205:81-83Machado KLC, Rosa STD, Dobner S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265606>

60. **Identifying areas of potential critical healthcare shortages: A case study of spatial accessibility to ICU beds during the COVID-19 pandemic in Florida.** Transp Policy (Oxf) 2021; 110:478-486 Kim K, Ghorbanzadeh M, Horner MW, Ozguven EE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257481>
61. **A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial.** Trials 2021; 22:451 Sharma A, Sharma C, Raina S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266452>
62. **Contribution of phytotherapy to the management of COVID-19: Thinking instead of empty phrases.** Zeitschrift fur Phytotherapie 2021; 42:117-118.

Mental – public health (167 articles)

1. **Psychotherapy for Healthcare Provider During COVID-19 Pandemic: An Evidence Based Clinical Review.** Acta Med Indones 2021; 53:225-232 Shatri H, Putranto R, Faisal E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251353>
2. **[Internet Addiction During the Pandemic COVID-19: A New Paradigm?].** Acta Med Port 2021; 34:402 Nascimento S, Silva M, Oliveira J, Reis J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253283>
3. **[Reply to: Early Detection of COVID-19 in Portugal: Use of Clinical Records].** Acta Med Port 2021; 34:404 Valim AP, Franciscatto ME, Gomes E, Santos EM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253285>
4. **Dental Students' Discomfort and Anxiety During the First and the Second Lockdown Due to COVID-19 Pandemic at the School of Dental Medicine, University of Zagreb.** Acta Stomatol. Croat. 2021; 55:186-197 Adam M, Urbančić-Rak T, Crnić T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248152>
5. **COVID-19 Associated Suicidal Ideation in Older Adults: Two Case Reports With a Review of the Literature.** Am J Geriatr Psychiatry 2021; Asthana NK, Mehaffey E, Sewell DD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266752>
6. **Altered Mental Status: An Important but Overlooked Presenting Symptom of COVID-19 in Older Adults.** Am J Geriatr Psychiatry 2021; Oommen A, Thomas J, Parmar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257003>
7. **The impact of mental health on COVID 19 disease progression: Case report.** Ann Med Surg (Lond) 2021; 68:102543 Bouabdallaoui A, Taouihar S, El Aidouni G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249355>
8. **"It is the only constant in what feels like a completely upside down and scary world": Living with an eating disorder during COVID-19 and the importance of perceived control for recovery and relapse.** Appetite 2021; 167:105596 Branley-Bell D, Talbot CV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252493>
9. **Field observations and survey evidence to assess predictors of mask wearing across different outdoor activities in an Argentine city during the COVID-19 pandemic.** Appl Psychol Health Well Being 2021; Freidin E, Acera Martini L, Senci CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254447>
10. **Social media exposure during COVID-19 lockdowns could lead to emotional overeating via anxiety: The moderating role of neuroticism.** Appl Psychol Health Well Being 2021; Gao Y, Ao H, Hu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265167>

11. **The effect of type D personality on anxiety, depression and fear of COVID-19 disease in healthcare workers.** Arch. Environ. Occup. Health 2021;1-8Tuman TC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264179>
12. **Elevated risk for obsessive-compulsive symptoms in women pregnant during the COVID-19 pandemic.** Arch Womens Ment Health 2021; Mahaffey BL, Levinson A, Preis H, Lobel M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269873>
13. **Association between COVID-19 and catatonia manifestation in two adolescents in Central Asia: Incidental findings or cause for alarm?** Asian J Psychiatr 2021; 63:102761Kopishinskaia S, Cumming P, Karpukhina S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271538>
14. **The need for integrated primary and behavioral healthcare care in the post-pandemic era.** Asian J Psychiatr 2021; 63:102772Ulupinar D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274632>
15. **Impact of social media use (SMU) on mental health during COVID-19 pandemic.** Asian J Psychiatr 2021; 63:102767Verma K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274631>
16. **COVID-19 and loneliness: A rapid systematic review.** Aust. N. Z. J. Psychiatry 2021;48674211031489Pai N, Vella SL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256632>
17. **COVID-19 as a context in suicide: early insights from Victoria, Australia.** Aust. N. Z. J. Public Health 2021; Dwyer J, Dwyer J, Hiscock R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251732>
18. **Infectious disease activity during the COVID-19 epidemic in Japan: Lessons learned from prevention and control measures.** Biosci Trends 2021; Sawakami T, Karako K, Song P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261848>
19. **Risk perception and adherence to preventive behaviours related to the COVID-19 pandemic: a community-based study applying the health belief model.** BJPsych Open 2021; 7:e133Kamran A, Isazadehfar K, Heydari H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253277>
20. **Patient adherence with infection control measures on a novel 'COVID-19 triage' psychiatric in-patient ward.** BJPsych Open 2021; 7:e131Williams R, Tweed J, Rebolledo L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256887>
21. **Fatores associados ao óbito em casos confirmados de COVID-19 no estado do Rio de Janeiro.** BMC Infect. Dis. 2021; 21:687Cini Oliveira M, de Araujo Eleuterio T, de Andrade Corrêa AB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271868>
22. **Fear and depression during the COVID-19 outbreak in Cameroon: a nation-wide observational study.** BMC Psychiatry 2021; 21:356Siewe Fodjo JN, Ngarka L, Njamnshi WY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266400>
23. **How have people been coping during the COVID-19 pandemic? Patterns and predictors of coping strategies amongst 26,016 UK adults.** BMC Psychol 2021; 9:107Fluharty M, Fancourt D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266498>
24. **Moderating effect of people-oriented public health services on depression among people under mandatory social isolation during the COVID-19 pandemic: a cross-sectional study in China.** BMC Public Health 2021; 21:1374Cao B, Wang D, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247618>
25. **The impact of the COVID-19 pandemic on stress, mental health and coping behavior in German University students - a longitudinal study before and after**

- the onset of the pandemic. BMC Public Health 2021; 21:1385 Voltmer E, Köslich-Strumann S, Walther A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256717>
26. **Informal collectives and access to healthcare during India's COVID-19 second wave crisis.** BMJ Glob Health 2021; 6 Faruqui N, Raman VR, Shiv J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257140>
 27. **Mere rhetoric? Using solidarity as a moral guide for deliberations on border closures, border reopenings and travel restrictions in the age of COVID-19.** BMJ Glob Health 2021; 6 Silva DS, Jackson C, Smith MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272273>
 28. **A pilot study of the depression, anxiety and stress in Greek military personnel during the first year of the COVID-19 pandemic.** BMJ Mil Health 2021; Kotoulas AS, Karamanavis D, Lambrou G, Karanikas P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266974>
 29. **Development and validation of the Oxford Pandemic Attitude Scale-COVID-19 (OPAS-C): an internet-based cross-sectional study in the UK and USA.** BMJ Open 2021; 11:e043758 Kantor BN, Kantor J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261678>
 30. **COVID-19: a novel risk factor for perioperative neurocognitive disorders.** Br J Anaesth 2021; Wei P, Lyu W, Wan T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266660>
 31. **[Pandemic forced telework, a new psychosocial risk. Reflections on the health issues and the necessary support.].** Bull. Acad. Natl. Med. 2021; Chamoux A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248143>
 32. **A study on factors affecting privacy risk tolerance to prevent the spread of COVID-19 in South Korea.** Bus. Horiz. 2021; Kim M, Jung Y, Kim J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248157>
 33. **High perceived isolation and reduced social support affect headache impact levels in migraine after the Covid-19 outbreak: A cross sectional survey on chronic and episodic patients.** Cephalalgia 2021:3331024211027568 Cerami C, Crespi C, Bottiroli S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256651>
 34. **Mental health difficulties in students with suspected COVID-19 symptoms and students without suspected COVID-19 symptoms: A cross-sectional comparative study during the COVID-19 pandemic.** Child Youth Serv Rev 2021; 128:106137 Sultana MS, Khan AH, Hossain S, Hasan MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248237>
 35. **What Lessons Did I Learn From My Experience With Cancer and COVID-19 During the Pandemic?** Clin. J. Oncol. Nurs. 2021; 25:488 Stiver W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269340>
 36. **Risk and protective factors for psychological distress during COVID-19 in Israel.** Curr. Psychol. 2021:1-12 Oryan Z, Avinir A, Levy S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248314>
 37. **Mental health status and psychosocial issues during Nationwide COVID-19 quarantine in Iran in 2020: A cross-sectional study in Mazandaran Province.** Curr. Psychol. 2021:1-17 Reskati MH, Shafizad M, Aarabi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253946>
 38. **Moderation of Technology Use in the Association Between Self-Isolation During COVID-19 Pandemic and Adolescents' Romantic Relationship Quality.** Cyberpsychol Behav Soc Netw 2021; 24:493-498 Wright MF, Wachs S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264769>

39. **Impfung im EU-Ausland Digitale Zertifikate möglich.** Deutsche Apotheker Zeitung 2021; 161.
40. **Coping with COVID 19: Health Risk Communication and Vulnerable Groups.** Disaster Med Public Health Prep 2021;1-25 Bailey A, Harris MA, Bogle D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247692>
41. **Your call is important to us: COVID-19 and trends in Public Health Unit call service utilization.** Disaster Med Public Health Prep 2021;1-21 Horn ZB, Uren AM, Young MK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247688>
42. **The effects of the COVID-19 lockdown on adolescents with an eating disorder and identifying factors predicting disordered eating behaviour.** Early Interv Psychiatry 2021; Akgül S, Akdemir D, Nalbant K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263541>
43. **The linkage "Body Mass Index-Insomnia Levels-Eating Disorder Flexibility" in Italian nurses during the Covid-19 outbreak: a psychoendocrinological employment disease.** Endocr. Metab. Immune Disord. Drug Targets 2021; Vitale E, Galatola V, Mea R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269670>
44. **Lifting COVID-19 mitigation measures in Spain (May-June 2020).** Enferm. Infecc. Microbiol. Clin. 2021; Monge S, Zamalloa PL, Moros MJS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274154>
45. **A closer look to the high burden of the psychiatric disorders among health care workers (HCWs) in Egypt during COVID-19 outbreak: A meta-analysis of 3137 HCWs.** Epidemiol Health 2021:e2021045 El-Qushayri AE, Dahy A, Reda A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265893>
46. **Considering temporality in causal relationship between seizure worsening and psychological stress in patients with epilepsy during the COVID-19 pandemic: A systematic review.** Epilepsy Behav. 2021; 122:108184 Kuroda N, Fujimoto A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252833>
47. **Differential psychological response to the COVID-19 pandemic in psychiatric inpatients compared to a non-clinical population from Germany.** Eur. Arch. Psychiatry Clin. Neurosci. 2021; Rek SV, Freeman D, Reinhard MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268618>
48. **Mental health responses to COVID-19 around the world.** Eur J Psychotraumatol 2021; 12:1929754 Olff M, Primasari I, Qing Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262666>
49. **COVID-19 related difficulties and perceived coping among university and college students: the moderating role of media-related exposure and stress.** Eur J Psychotraumatol 2021; 12:1929029 Pat-Horenczyk R, Bergman YS, Schiff M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249243>
50. **COVID-19 unmasked: preschool children's negative thoughts and worries during the COVID-19 pandemic in Australia.** Eur J Psychotraumatol 2021; 12:1924442 Vasileva M, Alisic E, De Young A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249241>
51. **Sleep quality among undergraduate students of a medical college in Nepal during COVID-19 pandemic: an online survey.** F1000Res 2021; 10:505 Shrestha D, Adhikari SP, Rawal N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249344>
52. **The Association of Suicidal Ideation With Family Characteristics and Social Support of the First Batch of Students Returning to a College During the COVID-19 Epidemic Period: A Cross Sectional Study in China.** Front Psychiatry

- 2021; 12:653245Chen Y, Zhu LJ, Fang ZM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34262488>
53. **A Possible Next Covid-19 Pandemic: The Violence Against Women and Its Psychiatric Consequences.** *Front Psychiatry* 2021; 12:650671De Berardis D, Gianfelice G, Fornaro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248699>
 54. **Leveraging Technology for the Wellbeing of Individuals With Autism Spectrum Disorder and Their Families During Covid-19.** *Front Psychiatry* 2021; 12:566809Doeniyas C, Shohieb SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262486>
 55. **One Year Into the Pandemic: A Systematic Review of Perinatal Mental Health Outcomes During COVID-19.** *Front Psychiatry* 2021; 12:674194Iyengar U, Jaiprakash B, Haitsuka H, Kim S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248710>
 56. **Impact of SARS-CoV-2-Pandemic on Mental Disorders and Quality of Life in Patients With Pulmonary Arterial Hypertension.** *Front Psychiatry* 2021; 12:668647Park DH, Fuge J, Meltendorf T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34248706>
 57. **Inverse Correlation Between Distress and Performance in the Medical Rescuers Against COVID-19 in Wuhan.** *Front Psychiatry* 2021; 12:563533Xie F, Wang X, Zhao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248686>
 58. **High Prevalence of Post-stroke Anxiety in Elderly Patients Following COVID-19 Outbreak.** *Front Psychiatry* 2021; 12:699869Yao M, Li H, Luo Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34248720>
 59. **The Prevalence and Correlative Factors of Depression Among Chinese Teachers During the COVID-19 Outbreak.** *Front Psychiatry* 2021; 12:644276Zhou J, Yuan X, Huang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267681>
 60. **Explanatory Model of Perceived Stress in the General Population: A Cross-Sectional Study in Peru During the COVID-19 Context.** *Front. Psychol.* 2021; 12:673945Boluarte-Carbajal A, Navarro-Flores A, Villarreal-Zegarra D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34248770>
 61. **Social and Cognitive Interactions Through an Interactive School Service for RTT Patients at the COVID-19 Time.** *Front. Psychol.* 2021; 12:676238Dovigo L, Capri T, Iannizzotto G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248774>
 62. **Gender Differences in Psychological Impact of the Confinement During the COVID-19 Outbreak in Spain: A Longitudinal Study.** *Front. Psychol.* 2021; 12:682860Fenollar-Cortés J, Jiménez Ó, Ruiz-García A, Resurrección DM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34248784>
 63. **Dealing With the Pandemic of COVID-19 in Portugal: On the Important Role of Positivity, Experiential Avoidance, and Coping Strategies.** *Front. Psychol.* 2021; 12:647984Ferreira MJ, Sofia R, Carreno DF *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34248745>
 64. **Engagement in Music-Related Activities During the COVID-19 Pandemic as a Mirror of Individual Differences in Musical Reward and Coping Strategies.** *Front. Psychol.* 2021; 12:673772Ferreri L, Singer N, McPhee M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34262511>
 65. **What Should I Trust? Individual Differences in Attitudes to Conflicting Information and Misinformation on COVID-19.** *Front. Psychol.* 2021; 12:588478Filuková P, Ayton P, Rand K, Langguth J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34248728>

66. **Extra-Curricular Activities and Well-Being: Results From a Survey of Undergraduate University Students During COVID-19 Lockdown Restrictions.** *Front. Psychol.* 2021; 12:647402Finnerty R, Marshall SA, Imbault C, Trainor LJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262502>
67. **Perceptions of the Post First-Lockdown Era in the Current Covid-19 Pandemic: Quantitative and Qualitative Survey of the French Population.** *Front. Psychol.* 2021; 12:668961Fouques D, Castro D, Mouret M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262509>
68. **How Should Athletes Coping With COVID-19: Focus on Severity and Psychological Support.** *Front. Psychol.* 2021; 12:559125Han Q, Li X, Wang Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248725>
69. **A Crowd-Sourced Database of Coronamusic: Documenting Online Making and Sharing of Music During the COVID-19 Pandemic.** *Front. Psychol.* 2021; 12:684083Hansen NC, Treider JMG, Swarbrick D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248787>
70. **Fatalism in the Early Days of the COVID-19 Pandemic: Implications for Mitigation and Mental Health.** *Front. Psychol.* 2021; 12:560092Hayes J, Clerk L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262498>
71. **What Explains Natives and Sojourners Preventive Health Behavior in a Pandemic: Role of Media and Scientific Self-Efficacy.** *Front. Psychol.* 2021; 12:664399Keren F, Siddiquei AN, Anwar MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267704>
72. **The Mental Health Impacts of COVID-19 on Pediatric Patients Following Recovery.** *Front. Psychol.* 2021; 12:628707Liu D, Liu W, Rodriguez M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267693>
73. **An Innovative Approach for Online Neuroanatomy and Neurorehabilitation Teaching Based on 3D Virtual Anatomical Models Using Leap Motion Controller During COVID-19 Pandemic.** *Front. Psychol.* 2021; 12:590196Obrero-Gaitán E, Nieto-Escamez FA, Zagalaz-Anula N, Cortés-Pérez I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262499>
74. **Mindfully Reframing the Psychological Impact of the COVID-19 Outbreak Through a Social Media Community for Students: A Pragmatic Study.** *Front. Psychol.* 2021; 12:566778Pagnini F, Bonalda E, Montrasi E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248726>
75. **Teleworking in Times of COVID-19: Effects on the Acquisition of Personal Resources.** *Front. Psychol.* 2021; 12:685275Pulido-Martos M, Cortés-Denia D, Lopez-Zafra E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248789>
76. **A Game of Covid: Strategic Thoughts About a Ludified Pandemic.** *Front. Psychol.* 2021; 12:607309Raab MH, Döbler NA, Carbon CC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267692>
77. **Protect ya Grandma! The Effects of Students' Epistemic Beliefs and Prosocial Values on COVID-19 Vaccination Intentions.** *Front. Psychol.* 2021; 12:683987Rosman T, Adler K, Barbian L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248786>
78. **State Anhedonia in Young Healthy Adults: Psychometric Properties of the German Dimensional Anhedonia Rating Scale (DARS) and Effects of the COVID-19 Pandemic.** *Front. Psychol.* 2021; 12:682824Wellan SA, Daniels A, Walter H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248783>

79. **The Impact of General Self-Efficacy on Psychological Resilience During the COVID-19 Pandemic: The Mediating Role of Posttraumatic Growth and the Moderating Role of Deliberate Rumination.** Front. Psychol. 2021; 12:684354Zeng W, Wu X, Xu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248788>
80. **Latent Profiles and Influencing Factors of Posttraumatic Stress Symptoms Among Adults During the COVID-19 Pandemic.** Front Public Health 2021; 9:620521Duan W, Guan Q, Jin Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249828>
81. **Psychological and Demographic Determinants of Substance Use and Mental Health During the COVID-19 Pandemic.** Front Public Health 2021; 9:680028Mougharbel F, Sampasa-Kanyinga H, Heidinger B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249844>
82. **Knowledge, Attitude, and Practice of Healthcare Providers Toward Novel Coronavirus 19 During the First Months of the Pandemic: A Systematic Review.** Front Public Health 2021; 9:606666Tegegne GT, Kefale B, Engidaw MT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249826>
83. **Providing a Safe, In-Person, Residential College Experience During the COVID-19 Pandemic.** Front Public Health 2021; 9:672344Travis SA, Best AA, Bochniak KS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249839>
84. **Impact of COVID-19 on the Mental Health and Distress of Community-Dwelling Older Adults.** Geriatr. Nurs. 2021; 42:998-1005Scott JM, Yun SW, Qualls SH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256160>
85. **Behavioral changes adopted to constrain COVID-19 in Japan: What are the implications for seasonal influenza prevention and control?** Glob Health Med 2021; 3:125-128Sawakami T, Karako K, Song P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250286>
86. **Psychological response to the COVID-19 pandemic in Canada: main stressors and assets.** Glob Health Promot 2021:17579759211023671Généreux M, Roy M, David MD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269131>
87. **Lives saved during economic downturns: Evidence from Australia.** Health Econ. 2021; Atalay K, Edwards R, Schurer S, Ubilava D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268828>
88. **The effectiveness of mobility control, shortening of restaurants' opening hours, and working from home on control of COVID-19 spread in Japan.** Health Place 2021; 70:102622Chiba A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274896>
89. **The importance of investing in a public health system: evidence from COVID-19 mortality.** Indian Econ Rev 2021:1-22Balakrishnan P, Namboodhary SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248183>
90. **A Public Safety Compliance Model of Safety Behaviors in the Age of the COVID-19 Pandemic.** Inquiry 2021; 58:469580211031382Al-Bsheish M, Jarrar M, Scarbrough A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261334>
91. **Evaluation of dyspnea severity and sleep quality in patients with novel coronavirus.** Int J Clin Pract 2021:e14631Gungor S, Tosun B, Unal N, Dusak I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260144>
92. **Needs, gaps and opportunities for standard and e-mental health care among at-risk populations in the Asia Pacific in the context of COVID-19: a rapid scoping review.** Int J Equity Health 2021; 20:161Murphy JK, Khan A, Sun Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253198>

93. **Increments of gender-based violence amid COVID-19 in Bangladesh: A threat to global public health and women's health.** *Int. J. Health Plann. Manage.* 2021; Islam MR, Hossain MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254362>
94. **The Impact of COVID-19 Traumatic Stressors on Mental Health: Is COVID-19 a New Trauma Type.** *Int J Ment Health Addict* 2021:1-20 Kira IA, Shuwiekh HAM, Ashby JS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248442>
95. **Phobic COVID-19 Disorder Scale: Development, Dimensionality, and Item-Structure Test.** *Int J Ment Health Addict* 2021:1-13 Nasir M, Adil M, Kumar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254004>
96. **Global prevalence of mental health problems among healthcare workers during the Covid-19 pandemic: A systematic review and meta-analysis.** *Int. J. Nurs. Stud.* 2021; 121:104002 Saragih ID, Tonapa SI, Saragih IS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271460>
97. **Covid-19 fear, happiness and stress in adults: the mediating role of psychological resilience and coping with stress.** *Int. J. Psychiatry Clin. Pract.* 2021:1-9 Peker A, Cengiz S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253128>
98. **Perceived stress in different countries at the beginning of the coronavirus pandemic.** *Int. J. Psychiatry Med.* 2021:912174211033710 Gamonal-Limcaoco S, Montero-Mateos E, Lozano-López MT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266339>
99. **The effect of COVID-19 lockdowns on sleep time perception: Comparing actigraphy and sleep diary measures.** *Int. J. Psychophysiol.* 2021; 167:86-93 He L, Zhao W, Gao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252481>
100. **Prenatal Stress and Psychiatric Symptoms During Early Phases of the COVID-19 Pandemic in Italy.** *Int J Womens Health* 2021; 13:653-662 Colli C, Penengo C, Garzitto M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262355>
101. **Perceived and sources of occupational stress in intensive care nurses during the COVID-19 pandemic.** *Intensive Crit Care Nurs* 2021:103107 Şanlıtürk D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247941>
102. **COVID-19 with a Public Health Perspective: Measures Taken in Turkey and Public Compliance with the Measures.** *Iran J. Public Health* 2020; 49:67-75 Doğan M, Bayraktar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268207>
103. **The Impact of the COVID-19 Pandemic on the Number of Adolescents/Young Adults Seeking Eating Disorder-Related Care.** *J. Adolesc. Health* 2021; Lin JA, Hartman-Munick SM, Kells MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266715>
104. **Impact of the COVID-19 pandemic on adults with current and prior depression: initial findings from the longitudinal Texas RAD study.** *J. Affect. Disord.* 2021; 294:103-108 Czysz AH, Nandy K, Hughes JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274785>
105. **Psychometric properties of the Italian version of the Pandemic-Related Pregnancy Stress Scale (PREPS) and its correlation with anxiety and depression.** *J. Affect. Disord.* 2021; 294:48-53 Penengo C, Colli C, Garzitto M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271249>
106. **Social Isolation and Anxiety Disorder During the COVID-19 Pandemic and Lockdown in China.** *J. Affect. Disord.* 2021; 294:10-16 Wu S, Yao M, Deng C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256180>
107. **Brain Stress Mapping in COVID-19 Survivors Using MR Spectroscopy: New Avenue of Mental Health Status Monitoring.** *J. Alzheimers Dis.* 2021; Samkaria A,

- Punjabi K, Sharma S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250939>
108. **Resolving delayed sleep-wake phase disorder with a pandemic: two case reports.** J. Clin. Sleep Med. 2021; Epstein LJ, Cai A, Klerman EB, Czeisler CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254935>
 109. **The mediating role of psychological distress on the link between socio-ecological factors and quality of life of Filipino adults during COVID-19 crisis.** J. Community Psychol. 2021; Aruta J, Callueng C, Antazo BG, Ballada CJA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260751>
 110. **Anxiety symptoms and alcohol abuse during the COVID-19 pandemic: A cross-sectional study with Brazilian dental undergraduate students.** J. Dent. Educ. 2021; Fernandez MDS, Vieira IS, Silva N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268733>
 111. **Notifiable diseases interoperable framework toward improving Iran public health surveillance system: Lessons learned from COVID-19 pandemic.** J Educ Health Promot 2021; 10:179Shanbehzadeh M, Kazemi-Arpanahi H, Valipour AA, Zahedi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250113>
 112. **Bereavement from COVID-19, Gender, and Reports of Depression among Older Adults in Europe.** J. Gerontol. B Psychol. Sci. Soc. Sci. 2021; Wang H, Verdery AM, Margolis R, Smith-Greenaway E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252179>
 113. **Financial distress and suicidal behaviour during COVID-19: Family identification attenuates the negative relationship between COVID-related financial distress and mental ill-health.** J Health Psychol 2021:13591053211014597Stevenson C, Wakefield JRH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259082>
 114. **Identifying Patterns of Turnover Intention Among Alabama Frontline Nurses in Hospital Settings During the COVID-19 Pandemic.** J Multidiscip Healthc 2021; 14:1783-1794Cole A, Ali H, Ahmed A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267525>
 115. **Curbing Nurses' Burnout during COVID-19: the roles of Servant Leadership and Psychological Safety.** J. Nurs. Manag. 2021; Ma Y, Faraz NA, Ahmed F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259372>
 116. **Does time change the anxiety and depression scores for pregnant women on Covid-19 pandemic?** J. Obstet. Gynaecol. Res. 2021; Geren A, Birge Ö, Bakır MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254394>
 117. **Neural Responses to Social Reward Predict Depressive Symptoms in Adolescent Girls During the COVID-19 Pandemic.** J. Pediatr. Psychol. 2021; Sequeira SL, Silk JS, Hutchinson E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34270756>
 118. **Social distancing measures differentially affected rats in North America and Tokyo.** J Pest Sci (2004) 2021:1-8Kiyokawa Y, Tanikawa T, Ootaki M, Parsons MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248453>
 119. **Facing the "new normal": How adjusting to the easing of COVID-19 lockdown restrictions exposes mental health inequalities.** J. Psychiatr. Res. 2021; 141:276-286Fineberg NA, Pellegrini L, Wellsted D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271458>
 120. **Do Black Lives Matter in the American Public's Mitigation Responses to the COVID-19 Pandemic? An Analysis of Mask Wearing and Racial/Ethnic Disparities in Deaths from COVID-19.** J Racial Ethn Health Disparities 2021;

- Franz B, Milner A, Braddock I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269992>
121. **Further evidence for motivated helplessness in the context of the COVID-19 outbreak: the case of Argentina before and during the pandemic.** J. Soc. Psychol. 2021;1-14Lifshin U, Mikulincer M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259124>
 122. **What Predicts the Mood of Athletes Involved in Preparations for Tokyo 2020/2021 Olympic Games During the Covid - 19 Pandemic? The Role of Sense of Coherence, Hope for Success and Coping Strategies.** J. Sports Sci. Med. 2021; 20:421-430Szczypińska M, Samełko A, Guskowska M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267581>
 123. **Stress among nurses from countries variously affected by the COVID-19 pandemic - results collected in Poland and Iran.** Med. Pr. 2021; Piotrowski A, Nikkhah-Farkhani Z, Makarowski R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254588>
 124. **Did social isolation due to COVID-19 interfere with the quality of sleep and excessive daytime sleepiness in individuals with grade III obesity about to enter a surgical prehabilitation program? An observational study.** Metabol Open 2021; 11:100104de Medeiros G, Artismo RS, Coelho P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258573>
 125. **Dynamic analysis of emergency inter-organizational communication network under public health emergency: a case study of COVID-19 in Hubei Province of China.** Nat Hazards (Dordr) 2021;1-24Lu Y, Liu T, Wang T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248278>
 126. **The Impact of Quarantine on Sleep Quality and Psychological Distress During the COVID-19 Pandemic.** Nat Sci Sleep 2021; 13:1037-1048AlRasheed MM, Alkadir AM, Bin Shuqiran KI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262375>
 127. **Cancer, cognition, and COVID: delivering direct-to-home teleneuropsychology services to neuro-oncology patients.** Neurooncol Pract 2021; 8:485-496Gardner MM, Aslanzadeh FJ, Zarrella GV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267923>
 128. **Innovative Strategies to Facilitate Safe Assessment and Intervention for Intimate Partner Violence During a Pandemic and Beyond.** Nurs. Womens Health 2021; Guarino JC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34270999>
 129. **A National Public Health Workforce to Control COVID-19 and Address Health Disparities in the United States.** Open Forum Infect Dis 2021; 8:ofab304Kilmarx PH, Long T, Reid MJA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258323>
 130. **Reckoning with Our Trustworthiness, Leveraging Community Engagement.** Popul Health Manag 2021; Gray DM, 2nd, Nolan TS, Bignall ONR, 2nd *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271849>
 131. **Health Beliefs and Preventive Behaviors Among Adults During the Early COVID-19 Pandemic in the United States: a Latent Class Analysis.** Prev Sci 2021;1-10Smail E, Schneider KE, DeLong SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275054>
 132. **Telehealth Use for Mental Health Conditions Among Enrollees in Commercial Insurance.** Psychiatr. Serv. 2021:appips202000778Yu J, Casalino L, Pincus HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253038>

133. **The impact of the COVID-19 pandemic on suicide ideation and suicide attempts in a sample of psychiatric inpatients.** *Psychiatry Res* 2021; 303:114072 Berardelli I, Sarubbi S, Rogante E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256349>
134. **Longitudinal changes in the mental health of UK young male and female adults during the COVID-19 pandemic.** *Psychiatry Res* 2021; 303:114074 Stroud I, Gutman LM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271372>
135. **Parents' Perceived Impact of the Societal Lockdown of COVID-19 on Family Well-Being and on the Emotional and Behavioral State of Walloon Belgian Children Aged 4 to 13 Years: An Exploratory Study.** *Psychol. Belg.* 2021; 61:186-199 Stassart C, Wagener A, Etienne AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249370>
136. **Sleep quality and mental health status of healthcare professionals during the outbreak of coronavirus disease 2019 (COVID-19).** *Psychol Health Med* 2021:1-8 Jiang YF, Chen JQ, Wang YG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263682>
137. **The Impact of the COVID-19 Epidemic on Mental Health Among Residents of Assela Town.** *Psychol. Res. Behav. Manag.* 2021; 14:957-970 Disasa B, Teshome E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262366>
138. **Psychological Distress Among Ethiopian Pregnant Women During COVID-19: Negative Correlation with Self-Efficacy.** *Psychol. Res. Behav. Manag.* 2021; 14:1001-1010 Dule A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267564>
139. **Interpretive voices: coproducing creative enquiry in the time of COVID-19.** *Public Health* 2021; 196:201-203 Younie L, Elliott F, Buckland R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273606>
140. **Food insufficiency and mental health service utilization in the U.S. during the COVID-19 pandemic.** *Public Health Nutr.* 2021:1-15 Nagata JM, Ganson KT, Cattle CJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261566>
141. **Experiences of the coronavirus disease-19 (COVID-19) pandemic from the perspectives of young people: Rapid qualitative study.** *Public Health Pract (Oxf)* 2021; 2:100162 Fisher H, Lambert H, Hickman M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254057>
142. **A Descriptive Comparison of Substance Use Services in Recovery and Isolation Sites for People Experiencing Homelessness During the COVID-19 Pandemic, Boston and Toronto.** *Public Health Rep.* 2021:333549211032974 Harris MTH, Young S, Barocas J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269625>
143. **Exposing health inequities: Surreal snapshots from the Grand Canyon to global COVID-19 pandemic.** *Qual Soc Work* 2021; 20:90-96 Balestrery JE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253957>
144. **The dialogue between what we are living and what we are teaching and learning during Covid-19 pandemic: Reflections of two social work educators from Italy and Spain.** *Qual Soc Work* 2021; 20:273-283 Cabiati E, Gómez-Ciriano EJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253972>
145. **Demoralization in the wake of the COVID-19 pandemic: Whereto the future for young Australians?** *Qual Soc Work* 2021; 20:487-493 Fronek P, Briggs L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253989>
146. **The COVID-19 pandemic, emergency aid and social work in Brazil.** *Qual Soc Work* 2021; 20:356-365 Garcia MLT, Pandolfi AF, Leal FX *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253979>
147. **The impacts of the Covid-19 pandemic on surrogacy in India: The role of social work.** Qual Soc Work 2021; 20:472-478Goswami L, Larmar SA, Boddy J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253988>
 148. **COVID-19: Where are the Nigerian social workers?** Qual Soc Work 2021; 20:343-349Isangha SO, Choi WMA, Chiu MYL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253977>
 149. **Safeguarding health equality for the disadvantaged during the COVID-19 pandemic: Lessons learned for the social work profession.** Qual Soc Work 2021; 20:463-469Kwan CK, Ling HW, Cheung JC, Chui EW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253987>
 150. **Safe uncertainty: Reflecting on the pandemic responses of two Asian cities.** Qual Soc Work 2021; 20:305-311Sim T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253975>
 151. **Black women and COVID-19: The need for targeted mental health research and practice.** Qual Soc Work 2021; 20:247-255Walton QL, Campbell RD, Blakey JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253970>
 152. **Tales of precarity: A reflexive essay on experiencing the COVID pandemic as a social work educator on a precarious contract.** Qual Soc Work 2021; 20:579-586Whelan J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253997>
 153. **The limitations of polling data in understanding public support for COVID-19 lockdown policies.** R Soc Open Sci 2021; 8:210678Foad CMG, Whitmarsh L, Hanel PHP, Haddock G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258021>
 154. **Knowledge, Attitude, and Perceived Risks Towards COVID-19 Pandemic and the Impact of Risk Communication Messages on Healthcare Workers in Saudi Arabia.** Risk Manag. Healthc. Policy 2021; 14:2811-2824Mushi A, Yassin Y, Khan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262368>
 155. **Care for the Carers: An Evaluation of Job Satisfaction of Community Healthcare Workers in Charge of Infectious Disease Prevention and Control in Vietnam.** Risk Manag. Healthc. Policy 2021; 14:2831-2839Thai TT, Le TAT, Truong LTT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262370>
 156. **US trends in mask wearing during the COVID-19 pandemic depend on rurality.** Rural Remote Health 2021; 21:6596Pro G, Schumacher K, Hubach R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252284>
 157. **Weathering the storm: A qualitative study of social prescribing in urban and rural Scotland during the COVID-19 pandemic.** SAGE Open Med 2021; 9:20503121211029187Fixsen A, Barrett S, Shimonovich M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262766>
 158. **How the Norwegian population was affected by non-pharmaceutical interventions during the first six weeks of the COVID-19 lockdown.** Scand J Public Health 2021;14034948211027817Mæland S, Bjørknes R, Lehmann S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250865>
 159. **The COVID-19 Pandemic Introduces Diagnostic and Treatment Planning Complexity for Individuals at Clinical High Risk for Psychosis.** Schizophr. Bull. 2021; Mittal VA, Walker EF, Strauss GP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259874>
 160. **Perception towards E-learning and COVID-19 on the mental health status of university students in Malaysia.** Sci. Prog. 2021; 104:368504211029812Moy FM, Ng YH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260295>

161. **How the COVID-19 Pandemic Affects Sexual Behavior of Hetero-, Homo-, and Bisexual Males in Germany.** Sex Med 2021; 9:100380Mumm JN, Vilsmaier T, Schuetz JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273787>
162. **Sufficient sleep attenuates COVID-19 pandemic-related executive dysfunction in late adolescents and young adults.** Sleep Med. 2021; 85:21-24Ji X, Saylor J, Earle FS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271179>
163. **Validation of the Japanese version of Stress and Anxiety to Viral Epidemics-9 (SAVE-9) and relationship among stress, insomnia, anxiety, and depression in healthcare workers exposed to coronavirus disease 2019.** Sleep Med. 2021; 84:397-402Okajima I, Chung S, Suh S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265636>
164. **The psychological distress and mental health disorders from COVID-19 stigmatization in Ghana.** Soc Sci Humanit Open 2021; 4:100186Adom D, Mensah JA, Osei M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250461>
165. **One year of COVID-19 in Italy: are containment policies enough to shape the pandemic pattern?** Socioecon. Plann. Sci. 2021;101120Panarello D, Tassinari G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248212>
166. **[Development of a psychiatric care facility into a Covid unit].** Soins Psychiatr. 2021; 42:43-47Kimmel É, Satori N, Ménage G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266550>
167. **Impact of the COVID-19 pandemic on inflammatory bowel disease: the role of emotional stress and social isolation.** Stress Health 2021; Nass BY, Dibbets P, Markus CR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273129>

Meta-analyses - systematic reviews (21 articles)

1. **Neurological Manifestations in COVID-19 Patients: A Meta-Analysis.** ACS Chem Neurosci 2021; D V, Sharma A, Kumar A, Flora SJS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260855>
2. **Serum CK-MB, COVID-19 severity and mortality: An updated systematic review and meta-analysis with meta-regression.** Adv. Med. Sci. 2021; 66:304-314Zinellu A, Sotgia S, Fois AG, Mangoni AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256241>
3. **Insulin therapy and outcome from coronavirus disease 2019 (COVID-19): A Systematic Review, Meta-Analysis, and Meta-Regression.** Endocr. Metab. Immune Disord. Drug Targets 2021; Hariyanto TI, Lugito NPH, Yanto TA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250875>
4. **Transmission risks of respiratory infectious diseases in various confined spaces: A meta-analysis for future pandemics.** Environ. Res. 2021;111679Moon J, Ryu BH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265349>
5. **B-Type Natriuretic Peptide Concentrations, COVID-19 Severity, and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression.** Front Cardiovasc Med 2021; 8:690790Zinellu A, Sotgia S, Carru C, Mangoni AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250044>
6. **COVID-19 and Influenza Co-infection: A Systematic Review and Meta-Analysis.** Front Med (Lausanne) 2021; 8:681469Dadashi M, Khaleghnejad S, Abedi Elkhichi P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249971>
7. **Association of Preexisting Asthma and Other Allergic Diseases With Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis.** Front Med

- (Lausanne) 2021; 8:670744Wu X, Xu Y, Jin L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34249969>
8. **Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2.** *Front. Microbiol.* 2021; 12:676314Castonguay N, Zhang W, Langlois MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267735>
 9. **Mortality rate and biomarker expression within COVID-19 patients who develop acute ischemic stroke: a systematic review and meta-analysis.** *Future Sci OA* 2021; 7:Fso713Yassin A, Ghzawi A, Al-Mistarehi AH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34254031>
 10. **Frailty as a mortality predictor in older adults with COVID-19: A systematic review and meta-analysis of cohort studies.** *Geriatr. Nurs.* 2021; 42:983-992Saragih ID, Advani S, Saragih IS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256158>
 11. **Tocilizumab and Systemic Corticosteroids in the Management of COVID-19 Patients:A Systematic Review and Meta-Analysis.** *Int J Infect Dis* 2021; Alkofide H, Almohaizeie A, Almuahini S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273515>
 12. **Global prevalence of mental health problems among healthcare workers during the Covid-19 pandemic: A systematic review and meta-analysis.** *Int. J. Nurs. Stud.* 2021; 121:104002Saragih ID, Tonapa SI, Saragih IS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34271460>
 13. **Impact of cardiovascular disease on clinical outcomes in hospitalized patients with Covid-19: a systematic review and meta-analysis.** *Intern Emerg Med* 2021:1-11Maddaloni E, D'Onofrio L, Siena A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34273056>
 14. **Clinical Trials in COVID-19 Management & Prevention: A Meta-epidemiological Study examining.** *J. Clin. Epidemiol.* 2021; Honarmand K, Penn J, Agarwal A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34274489>
 15. **Bereavement from COVID-19, Gender, and Reports of Depression among Older Adults in Europe.** *J. Gerontol. B Psychol. Sci. Soc. Sci.* 2021; Wang H, Verdery AM, Margolis R, Smith-Greenaway E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34252179>
 16. **Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis.** *Microvasc. Res.* 2021:104224Andrianto, Al-Farabi MJ, Nugraha RA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34273359>
 17. **Prior Statin Use and Risk of Mortality and Severe Disease From Coronavirus Disease 2019: A Systematic Review and Meta-analysis.** *Open Forum Infect Dis* 2021; 8:ofab284Yetmar ZA, Chesdachai S, Kashour T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34258316>
 18. **Contribution of traditional Chinese medicine combined with conventional western medicine treatment for the novel coronavirus disease (COVID-19), current evidence with systematic review and meta-analysis.** *Phytother. Res.* 2021; Jiang F, Xu N, Zhou Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256418>
 19. **The impact of Parkinson's disease on manifestations and outcomes of Covid-19 patients: A systematic review and meta-analysis.** *Rev Med Virol* 2021:e2278El-Qushayri AE, Ghozy S, Reda A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34260773>

20. **A systematic meta-analysis of immune signatures in patients with COVID-19.** Rev Med Virol 2021; 31:e2195Liu K, Yang T, Peng XF *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34260780>
21. **Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: A meta-review of systematic reviews and an updated meta-analysis.** Travel Med Infect Dis 2021; 43:102135Chivese T, Musa OAH, Hindy G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34265436>

Mortality (46 articles)

1. **Serum CK-MB, COVID-19 severity and mortality: An updated systematic review and meta-analysis with meta-regression.** Adv. Med. Sci. 2021; 66:304-314Zinellu A, Sotgia S, Fois AG, Mangoni AA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34256241>
2. **Myeloid phenotypes in severe COVID-19 predict secondary infection and mortality: a pilot study.** Ann Intensive Care 2021; 11:111Marais C, Claude C, Semaan N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259942>
3. **Clinical features and survival analysis of 97 coronavirus disease 2019 (COVID-19) patients.** Ann Palliat Med 2021; Li A, Chen F, Gao Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34263633>
4. **Absolute mortality risk assessment of COVID-19 patients: the Khorshid COVID Cohort (KCC) study.** BMC Med. Res. Methodol. 2021; 21:146Marateb HR, von Cube M, Sami R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261439>
5. **Fatal Case of COVID-19 Pneumonia Associated with Acute Myelopathy.** Case Rep. Neurol. 2021; 13:398-404Hassoun HK, Radeef MR, Aljid Z, Allebban Z.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34248577>
6. **Biomarkers Predictive of Extubation and Survival of COVID-19 Patients.** Cureus 2021; 13:e15462Topp G, Bouyea M, Cochran-Caggiano N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34258124>
7. **Higher admission activated partial thromboplastin time, neutrophil-lymphocyte ratio, serum sodium, and anticoagulant use predict in-hospital COVID-19 mortality in people with Diabetes: Findings from Two University Hospitals in the U.K.** Diabetes Res Clin Pract 2021; 178:108955Iqbal A, Greig M, Arshad MF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273452>
8. **Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States.** Diabetes Ther. 2021:1-17Boye KS, Tokar Erdemir E, Zimmerman N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275115>
9. **The association between disability and risk of exposure to peer cyber victimisation is moderated by gender: Cross-sectional survey.** Disabil Health J 2021:101170Emerson E, Aitken Z, King T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34253505>
10. **Lockdown effect on COVID-19 incidence and death: Iran experience.** Disaster Med Public Health Prep 2021:1-10Delavari S, Jamali Z, Bayati M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34247685>
11. **Mortality in patients treated for COVID-19 in the emergency department of a tertiary care hospital during the first phase of the pandemic: Derivation of a risk model for emergency departments.** Emergencias 2021; 33:273-281García-

- Martínez A, López-Barbeito B, Coll-Vinent B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34251140>
12. **Risk models for predicting in-hospital mortality from COVID-19 pneumonia in the elderly.** *Emergencias* 2021; 33:282-291López-Izquierdo R, Ruiz Albi T, Bermejo-Martín JF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251141>
 13. **Mortality risk model for patients with suspected COVID-19 based on information available from an emergency dispatch center.** *Emergencias* 2021; 33:265-272Martín-Rodríguez F, Sanz-García A, Alberdi Iglesias A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34251139>
 14. **A Study of the Correlation between the Dates of the First Covid Case and the First Covid Death of 25 Selected Countries to Know the Virulence of the Covid-19 in Different Tropical Conditions.** *Ethics Med Public Health* 2021;100707Jamsheela O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254043>
 15. **Symptom Prediction and Mortality Risk Calculation for COVID-19 Using Machine Learning.** *Front Artif Intell* 2021; 4:673527Jamshidi E, Asgary A, Tavakoli N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250465>
 16. **B-Type Natriuretic Peptide Concentrations, COVID-19 Severity, and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression.** *Front Cardiovasc Med* 2021; 8:690790Zinellu A, Sotgia S, Carru C, Mangoni AA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34250044>
 17. **Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome.** *Front. Immunol.* 2021; 12:621440Illouz T, Biragyn A, Iulita MF *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34248930>
 18. **EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients.** *Front. Immunol.* 2021; 12:634416Luft T, Wendtner CM, Kosely F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34248931>
 19. **Comorbidities predict 30-day hospital mortality of older adults with COVID-19.** *Geriatr. Nurs.* 2021; 42:1024-1028Pott Junior H, Cominetti MR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34256151>
 20. **The "Great Lockdown": Inactive workers and mortality by Covid-19.** *Health Econ.* 2021; Borri N, Drago F, Santantonio C, Sobbrío F.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34250694>
 21. **Pattern of COVID-19 infection and death across countries: A pilot study.** *Heliyon* 2021:e07504Asem N, Ramadan A, Hassany M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34254048>
 22. **Pattern and determinants of COVID-19 infection and mortality across countries: An ecological study.** *Heliyon* 2021; 7:e07504Asem N, Ramadan A, Hassany M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254048>
 23. **The importance of investing in a public health system: evidence from COVID-19 mortality.** *Indian Econ Rev* 2021:1-22Balakrishnan P, Namboodhary SK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34248183>
 24. **Assessment of severity and mortality of COVID-19 with anti-A1 and B IgM isohemagglutinins, a reflection of the innate immune status.** *Int J Clin Pract* 2021:e14624Ozcelik F, Tanoglu A, Guven BB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34251730>
 25. **CareFiji app to track people during COVID-19 pandemic: "Digital gap and challenges triggered in Fiji": Correspondence.** *Int J Surg* 2021:106023Chand SS, Chand AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252596>

26. **Deaths of people with intellectual disabilities: Analysis of deaths in England from COVID-19 and other causes.** J Appl Res Intellect Disabil 2021; Heslop P, Byrne V, Calkin R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272793>
27. **Mortality associated with early changes in ARDS severity in COVID-19 patients - Insights from the PRoVENT-COVID study.** J Crit Care 2021; 65:237-245Schuijt MTU, Martin-Loeches I, Schultz MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271294>
28. **Age-standardized mortality rate and predictors of mortality among COVID-19 patients in Iran.** J Educ Health Promot 2021; 10:169Moradzadeh R, Jamalian SM, Nazari J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250103>
29. **Hospitalisation and mortality from COVID-19 in Mexican indigenous people: a cross-sectional observational study.** J. Epidemiol. Community Health 2021; Serván-Mori E, Seiglie JA, Gómez-Dantés O, Wirtz VJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266980>
30. **Association between Early Antibiotic Therapy and In-Hospital Mortality among Older Patients with SARS-CoV-2 Pneumonia.** J Gerontol A Biol Sci Med Sci 2021; Putot A, Bouiller K, Laborde C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272847>
31. **The Impact of Corticosteroids on Secondary Infection and Mortality in Critically Ill COVID-19 Patients.** J. Intensive Care Med. 2021:8850666211032175Ritter LA, Britton N, Heil EL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247526>
32. **Maternal deaths due to COVID-19 disease: The cases in a single center pandemic hospital in the south east of Turkey.** J. Obstet. Gynaecol. Res. 2021; Bağlı İ, Öcal E, Yavuz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254718>
33. **Clinical utility of biochemical markers for the prediction of COVID-19-related mortality in kidney transplant recipients.** Kidney Int Rep 2021; Caillard S, Chavarot N, Francois H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254049>
34. **Reduction of hospitalisations and increased mortality for acute coronary syndromes during covid-19 era: Not all countries are equal.** Lancet Reg Health West Pac 2021; 12:100155Spaccarotella C, Sorrentino S, Indolfi C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250516>
35. **Background rates of hospital transfer and death in Australian aged care facilities: estimates to assist interpretation of rates after COVID-19 vaccination.** Med. J. Aust. 2021; Clothier HJ, Mesfin YM, Strange S, BATTERY JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268767>
36. **Comparison of the effects of etomidate, ketamine, sodium thiopental, and midazolam on the mortality of patients with COVID-19 requiring intubation.** Med. J. Islam. Repub. Iran 2021; 35:49Edalatkhah A, Kazemi MR, Samadi Khorshidi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268237>
37. **Palliative medicine in times of COVID-19 pandemia.** Nieren- und Hochdruckkrankheiten 2021; 50:216-219Pommer W, Hoffmann U.
38. **Parkinson's disease patients may have higher rates of Covid-19 mortality in Iran.** Parkinsonism Relat. Disord. 2021; 89:90-92Salari M, Etemadifar M, Ashrafi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256334>
39. **Different Trends in Excess Mortality in a Central European Country Compared to Main European Regions in the Year of the COVID-19 Pandemic (2020): a Hungarian Analysis.** Pathol. Oncol. Res. 2021; 27:1609774Bogos K, Kiss Z, Kerpel Fronius A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257618>

40. **COVID-19: Increased mortality among pregnant women.** Pharm. Ztg. 2021; 166:52-53Dingermann T.
41. **Longitudinal changes in the mental health of UK young male and female adults during the COVID-19 pandemic.** Psychiatry Res 2021; 303:114074Stroud I, Gutman LM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271372>
42. **Death, dying and bereavement care during COVID-19: Creativity in hospital social work practice.** Qual Soc Work 2021; 20:131-137Fox M, McIlveen J, Murphy E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253960>
43. **Can Comorbidity Data Explain Cross-State and Cross-National Difference in COVID-19 Death Rates?** Risk Manag. Healthc. Policy 2021; 14:2877-2885Cegan JC, Trump BD, Cibulsky SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267565>
44. **The COVID-19 pandemic and cause of death.** Sociol. Health Illn. 2021; Armstrong D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255866>
45. **Spatial-temporal generalized additive model for modeling COVID-19 mortality risk in Toronto, Canada.** Spat Stat 2021; 100526Feng C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249608>
46. **Deaths due to COVID-19 in a state of northeastern Brazil: spatiotemporal distribution, sociodemographic and clinical and operational characteristics.** Trans. R. Soc. Trop. Med. Hyg. 2021; da Silva WM, Brito PDS, de Sousa G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252184>

Online – IT – Apps (51 articles)

1. **[Internet Addiction During the Pandemic COVID-19: A New Paradigm?].** Acta Med Port 2021; 34:402Nascimento S, Silva M, Oliveira J, Reis J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253283>
2. **Is remote near-peer anatomy teaching an effective teaching strategy? Lessons learned from the transition to online learning during the Covid-19 pandemic.** Anat Sci Educ 2021; Thom ML, Kimble BA, Qua K, Wish-Baratz S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268899>
3. **Social media exposure during COVID-19 lockdowns could lead to emotional overeating via anxiety: The moderating role of neuroticism.** Appl Psychol Health Well Being 2021; Gao Y, Ao H, Hu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265167>
4. **Impact of social media use (SMU) on mental health during COVID-19 pandemic.** Asian J Psychiatr 2021; 63:102767Verma K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274631>
5. **Acceptability and Feasibility of Virtual Behavior Analysis Supervision.** Behav Anal Pract 2021; 1-17Simmons CA, Ford KR, Salvatore GL, Moretti AE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257834>
6. **Effectiveness of contact tracing apps for SARS-CoV-2: a rapid systematic review.** BMJ Open 2021; 11:e050519Jenniskens K, Bootsma MCJ, Damen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253676>
7. **Are the rights of people with disabilities included in international guidance on WASH during the COVID-19 pandemic? Content analysis using EquiFrame.** BMJ Open 2021; 11:e046112Scherer N, Mactaggart I, Huggett C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257092>

8. **Telemedicine in primary healthcare for the quality of care in times of COVID-19: a scoping review protocol.** BMJ Open 2021; 11:e046227Silva C, Lopes RH, Júnior OGB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253666>
9. **Pulmonary Telerehabilitation and Efficacy among Discharged COVID-19 Patients: Rational and Design of a Prospective Real-world Study.** Clin. Respir. J. 2021; Lei J, Yang L, Wen G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260823>
10. **Media use before, during and after COVID-19 lockdown according to parents in a clinically referred sample in child and adolescent psychiatry: Results of an online survey in Switzerland.** Compr. Psychiatry 2021; 109:152260Werling AM, Walitza S, Grünblatt E, Drechsler R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265597>
11. **The COVID-19 Outpatient Pragmatic Platform Study (COPPS): Study design of a multi-center pragmatic platform trial.** Contemp Clin Trials 2021:106509Bunning B, Hedlin H, Purington N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274494>
12. **Content and Functionality of United States Medical School Websites.** Cureus 2021; 13:e15534Pollock JR, Moore ML, Smith JF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268052>
13. **Promise and Perils of Telehealth in the Current Era.** Curr Cardiol Rep 2021; 23:115Mahtta D, Daher M, Lee MT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269884>
14. **The Role and Impact of Social Media in Cardio-oncology During the COVID-19 Pandemic.** Curr. Oncol. Rep. 2021; 23:99Kwan JM, Henry ML, Christophers B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259950>
15. **Developing a digital health strategy for people who use drugs: Lessons from COVID-19.** Digit Health 2021; 7:20552076211028404Perri M, Guta A, Gagnon M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262782>
16. **General Public Perception of Social Media, Impact of Covid-19 Pandemic, and Related Misconceptions.** Disaster Med Public Health Prep 2021:1-22Ali R, Jawed S, Baig M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261567>
17. **NOTA: a novel online teaching and assessment scheme using Blockchain for emergency cases.** Educ Inf Technol (Dordr) 2021:1-18Cheriguene A, Kabache T, Kerrache CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248386>
18. **Flow of online misinformation during the peak of the COVID-19 pandemic in Italy.** EPJ Data Sci 2021; 10:34Caldarelli G, De Nicola R, Petrocchi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249599>
19. **COVID-19 related difficulties and perceived coping among university and college students: the moderating role of media-related exposure and stress.** Eur J Psychotraumatol 2021; 12:1929029Pat-Horenczyk R, Bergman YS, Schiff M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249243>
20. **A COVID-19 Emergency Response for Remote Control of a Dialysis Machine with Mobile HRI.** Front Robot AI 2021; 8:612855Wazir HK, Lourido C, Chacko SM, Kapila V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262944>
21. **A machine learning PROGRAM to identify COVID-19 and other diseases from hematology data.** Future Sci OA 2021; 7:Fso733Gladding PA, Ayar Z, Smith K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254032>
22. **Social media affordances and information abundance: Enabling fake news sharing during the COVID-19 health crisis.** Health Informatics J 2021;

- 27:14604582211021470Apuke OD, Omar B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250868>
23. **Telemedicine as a component of forward triage in a pandemic.** Healthc (Amst). 2021; 9:100567Gupta VS, Popp EC, Garcia EI *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34274883>
 24. **Impact of online education on fear of academic delay and psychological distress among university students following one year of COVID-19 outbreak in Bangladesh.** Heliyon 2021; 7:e07388Hossain MJ, Ahmmed F, Rahman SMA *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258456>
 25. **Needs, gaps and opportunities for standard and e-mental health care among at-risk populations in the Asia Pacific in the context of COVID-19: a rapid scoping review.** Int J Equity Health 2021; 20:161Murphy JK, Khan A, Sun Q *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34253198>
 26. **Oncophone20 study: Patients' perception of telemedicine in the COVID-19 pandemic during follow-up visits for gynecological and breast cancers.** Int J Gynaecol Obstet 2021; Picardo E, Baù MG, Anatrone C *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34258764>
 27. **High variability in model performance of Google relative search volume in spatially clustered COVID-19 areas of the United States.** Int J Infect Dis 2021; Husnayain A, Chuang TW, Fuad A, Su EC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273513>
 28. **Remote learning and online teaching in Fiji during COVID-19: The challenges and opportunities: Correspondence.** Int J Surg 2021:106019Chand AA, Lal PP.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34252594>
 29. **Remote learning and online teaching in Fiji during COVID-19: The challenges and opportunities.** Int J Surg 2021:106019Chand AA, Lal PP, Chand KK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34252594>
 30. **Health technology assessment applied to emergency preparedness: a new perspective.** Int. J. Technol. Assess. Health Care 2021; 37:e77Miglietta A, de Waure C, Chronaki C *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269171>
 31. **Effectiveness of video modules in infection control trainings during COVID-19 pandemic: A quasi-experimental study in tertiary care institute.** J Educ Health Promot 2021; 10:183Singh V, Supehia S, Gupta PK *et al*.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34250117>
 32. **Transitioning to telegenetics in the COVID-19 era: Patient satisfaction with remote genetic counseling in adult neurology.** J Genet Couns 2021; Dratch L, Paul RA, Baldwin A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265143>
 33. **Investigating Public Discourses Around Gender and COVID-19: a Social Media Analysis of Twitter Data.** J Healthc Inform Res 2021:1-21Al-Rawi A, Grepin K, Li X *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258510>
 34. **Remote Reporting During a Pandemic Using Digital Pathology Solution: Experience from a Tertiary Care Cancer Center.** J. Pathol. Inform. 2021; 12:20Ramaswamy V, Tejaswini BN, Uthaiiah SB.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34267985>
 35. **YouTube as a source of information about COVID-19 for children: Content quality, reliability, and audience participation analysis.** J. Pediatr. Nurs. 2021; Azak M, Şahin K, Korkmaz N, Yıldız S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247879>

36. **In-person vs. home schooling during the COVID-19 pandemic: Differences in sleep, circadian timing, and mood in early adolescence.** J. Pineal Res. 2021:e12757Stone JE, Phillips AJK, Chachos E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273194>
37. **Analysis of COVID-19 Resulting Cough Using Formants and Automatic Speech Recognition System.** J. Voice 2021; Zealouk O, Satori H, Hamidi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256982>
38. **Strategies for the Identification and Prevention of Survey Fraud: Data Analysis of a Web-Based Survey.** JMIR Cancer 2021; 7:e30730Pratt-Chapman M, Moses J, Arem H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269685>
39. **Contact Tracing Apps: Lessons Learned on Privacy, Autonomy, and the Need for Detailed and Thoughtful Implementation.** JMIR Med Inform 2021; 9:e27449Hogan K, Macedo B, Macha V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254937>
40. **eHealth solutions to fight against COVID-19: A scoping review of applications.** Med. J. Islam. Repub. Iran 2021; 35:43Eslami P, Niakan Kalhori SR, Taheriyani M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268231>
41. **Cancer, cognition, and COVID: delivering direct-to-home teleneuropsychology services to neuro-oncology patients.** Neurooncol Pract 2021; 8:485-496Gardner MM, Aslanzadeh FJ, Zarrella GV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267923>
42. **Associations between individual and environmental determinants and physical activity levels of an active population during the Spanish lockdown.** Prev. Med. 2021:106719Gonzalo-Encabo P, Cereijo L, Remón Á LC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256066>
43. **COVID-19 pandemic lockdown in young people with type 1 diabetes: Positive results of an unprecedented challenge for patients through telemedicine and change in use of continuous glucose monitoring.** Prim. Care Diabetes 2021; Salabelle C, Ly Sall K, Eroukmanoff J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257050>
44. **Predicting the SARS-CoV-2 effective reproduction number using bulk contact data from mobile phones.** Proc Natl Acad Sci U S A 2021; 118Rüdiger S, Konigorski S, Rakowski A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261775>
45. **Telehealth Use for Mental Health Conditions Among Enrollees in Commercial Insurance.** Psychiatr. Serv. 2021:appips202000778Yu J, Casalino L, Pincus HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253038>
46. **#SupportLocal: how online food delivery services leveraged the COVID-19 pandemic to promote food and beverages on Instagram.** Public Health Nutr. 2021:1-11Jia SS, Raeside R, Redfern J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247686>
47. **Chronic disease management in heart failure: focus on telemedicine and remote monitoring.** Rev Cardiovasc Med 2021; 22:403-413Alvarez P, Sianis A, Brown J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258907>
48. **Perception towards E-learning and COVID-19 on the mental health status of university students in Malaysia.** Sci. Prog. 2021; 104:368504211029812Moy FM, Ng YH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260295>
49. **Performance Evaluation of Soft Computing Approaches for Forecasting COVID-19 Pandemic Cases.** SN Comput Sci 2021; 2:372Shoaib M, Salahudin H,

- Hammad M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258586>
50. **Telestroke: Maintaining Quality Acute Stroke Care During the COVID-19 Pandemic.** Telemed J E Health 2021; Sevilis T, McDonald M, Avila A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265222>
51. **Pandemic Telemedicine Technology Response Plan and Technology Assessment Phase 2: Pandemic Action Plan Key Issues and Technology Solutions for Health Care Delivery Organizations in a Pandemic.** Telemed J E Health 2021; VanderWerf M, Bernard J, Barta DT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265217>

Other – Miscellaneous (79 articles)

1. **Impact of COVID-19 on Radiology Faculty - An Exacerbation of Gender Differences in Unpaid Home Duties and Professional Productivity.** Acad Radiol 2021; Plaunova A, Heller SL, Babb JS, Heffernan CC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266739>
2. **Fluid Dynamics of Respiratory Infectious Diseases.** Annu. Rev. Biomed. Eng. 2021; 23:547-577 Bourouiba L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255991>
3. **COVID-19 & culinary behaviours of Australian household food gatekeepers: A qualitative study.** Appetite 2021:105598 Ronto R, Nanayakkara J, Worsley A, Rathin N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271079>
4. **Equity without human rights: a false COVID-19 narrative?** BMJ Glob Health 2021; 6Khosla R, Gruskin S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266850>
5. **Impact of severe SARS-CoV-2 infection on nutritional status and subjective functional loss in a prospective cohort of COVID-19 survivors.** BMJ Open 2021; 11:e048948 Quilliot D, Gérard M, Bonsack O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261689>
6. **COVID-19-related attitudes, risk perceptions, preventive behaviours and economic impact in sub-Saharan African countries: implementing a longitudinal phone-based survey protocol in rural Senegalese households.** BMJ Open 2021; 11:e050090 Seror V, Maradan G, Ba EH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272224>
7. **Social isolation and its psychosocial factors in mild lockdown for the COVID-19 pandemic: a cross-sectional survey of the Japanese population.** BMJ Open 2021; 11:e048380 Sugaya N, Yamamoto T, Suzuki N, Uchiumi C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261687>
8. **["From Crisis to Health in All Policies." Conference report from the Poverty and Health 2021 Congress].** Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2021:1-6 Amler M, Bollmann J, Waldhauer J, Janella M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251465>
9. **Who are the essential and frontline workers?** Bus Econ 2021:1-11 Blau FD, Koebe J, Meyerhofer PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253931>
10. **Investigating similarities and differences in individual reactions to the COVID-19 pandemic and the climate crisis.** Clim Change 2021; 167:1 Geiger N, Gore A, Squire CV, Attari SZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248235>
11. **The World Against Versatile SARS-Cov-2 Nanomachines; Mythological or Reality?** Curr. Stem Cell Res. Ther. 2021; Tavakol S, Tavakol H, Alavijeh MS, Seifalian A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254928>

12. **Training bonuses doubled: Federal program aims to mitigate corona consequences.** Deutsche Apotheker Zeitung 2021; 161.
13. **Risk management required: Pension funds hold their ground in the corona pandemic.** Deutsche Apotheker Zeitung 2021; 161 Ulbrich H.
14. **Food insecurity of people with disabilities who were Medicare Beneficiaries during the COVID-19 pandemic.** Disabil Health J 2021:101166Friedman C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34272190>
15. **Local Perceptions of COVID-19 in Pakistan's Sindh Province: "Political Game", Supernatural Test, or Western Conspiracy?** Disaster Med Public Health Prep 2021:1-19Ali I, Saddique S, Ali S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247693>
16. **COVID-19 and the Demand for Online Grocery Shopping: Empirical Evidence from the Netherlands.** Economist (Leiden) 2021:1-14Baarsma B, Groenewegen J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34253932>
17. **A post-pandemic sustainable scenario: What actions can be pursued to increase the raw materials availability?** Environ. Res. 2021:111681Zanoletti A, Cornelio A, Bontempi E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273363>
18. **The contribution of bovines to human health against viral infections.** Environ. Sci. Pollut. Res. Int. 2021:1-25Saied AA, Metwally AA, Mohamed HMA, Haridy MAM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272669>
19. **The impact of artificial intelligence and digital style on industry and energy post-COVID-19 pandemic.** Environ. Sci. Pollut. Res. Int. 2021; Sharifi A, Ahmadi M, Ala A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269979>
20. **Contextualizing the COVID-19 pandemic's impact on food security in two small cities in Bangladesh.** Environ. Urban. 2021; 33:239-254Ruszczczyk HA, Rahman MF, Bracken LJ, Sudha S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253941>
21. **Challenges faced by people with epilepsy on ketogenic diet therapy and their caregivers during the COVID-19 pandemic in Brazil.** Epilepsy Behav. 2021; 122:108193Alencastro Veiga Domingues Carneiro R, Dos Santos Lunardi M, Matheus Uberna Giacomini F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256342>
22. **How the COVID-19 pandemic can distort risk adjustment of health plan payment.** Eur J Health Econ 2021; van Kleef RC, Reuser M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34264411>
23. **Changes in patterns of take-away food ordering among youths before and after COVID-19 lockdown in China: the COVID-19 Impact on Lifestyle Change Survey (COINLICS).** Eur. J. Nutr. 2021:1-11Luo M, Wang Q, Yang S, Jia P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34254188>
24. **Food insecurity during the COVID-19 pandemic: evidence from a survey of low-income Americans.** Food Secur 2021:1-19Fang D, Thomsen MR, Nayga RM, Jr., Yang W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254010>
25. **Association Between Air Pollution and Acute Coronary Syndromes During Lockdown for COVID-19: Results From the Terni Hub Center.** Front Public Health 2021; 9:683683Arrivi A, Dominici M, Bier N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34249847>
26. **Social Class and Changes in Australian Women's Affect and Alcohol Consumption During COVID-19.** Front Public Health 2021; 9:645376Lunnay B, Toson B, Wilson C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268284>

27. **Covid-19 Impact on the Music Sector in Belo Horizonte (Minas Gerais, Brazil).** *Front Sociol* 2021; 6:643344Teixeira N, Mello Vianna G, Lima R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34268350>
28. **The Impact of the Covid-19 Pandemic on Food Consumers' Awareness of Antimicrobial Resistance, OneHealth, and Animal Welfare Information on Food Labels.** *Front Vet Sci* 2021; 8:678509Regan Á, Sweeney S, McKernan C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34268348>
29. **Health economy. Foreign Trade Day 2021: Corona crisis must not become a protectionism crisis.** *Gesundheitsökonomie und Qualitätsmanagement* 2021; 26:132-133.
30. **A Gulf in Lockdown: how an enforced ban on recreational vessels increased dolphin and fish communication ranges.** *Glob. Chang. Biol.* 2021; Pine MK, Wilson L, Jeffs AG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254409>
31. **Care Ethics versus the CARES Act.** *Hastings Cent Rep* 2021; 51:7-8Sontan O.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34255366>
32. **The Impact of Embarrassment to Product Purchase and Brand Influence on the Perceived Benefits and Availability of Ayurveda Products in the COVID-19 Era: an Investigation by SEM Approach.** *Hosp. Top.* 2021:1-8Mhatre K, Singh A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34251990>
33. **Immunity against seasonal human coronavirus OC43 mitigates fatal deterioration of COVID-19.** *Int J Infect Dis* 2021; Yamaguchi T, Shinagawa T, Kobata H, Nakagawa H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273512>
34. **Comparing Food Security Before and During the COVID-19 Pandemic: Considerations When Choosing Measures.** *J. Acad. Nutr. Diet.* 2021; Poblacion A, Ettinger de Cuba S, Cook JT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247979>
35. **Stock price reaction to appointment of a chief health officer during COVID-19.** *J Behav Exp Finance* 2021; 31:100541Ichev R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34249615>
36. **Food Safety and Employee Health Implications of COVID-19.** *J. Food Prot.* 2021; Trmcic A, Demmings E, Kniel K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265068>
37. **Effect of COVID-19 on the Generation of Waste in Marrakech, Morocco.** *J Health Pollut* 2021; 11:210606Ouigmane A, Boudouch O, Hasib A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34267993>
38. **COVID-19 Leads to Dramatic Changes in the Food Retail Environment in New York City: May-July 2020.** *J Immigr Minor Health* 2021:1-7Yi SS, Ali SH, Russo RG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258716>
39. **Letter to the Editor in Response to Zhou et al.** *J Infect Dis* 2021; Troth S, Butters J, DeAnda CS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251432>
40. **Lord Sumption and the values of life, liberty and security: before and since the COVID-19 outbreak.** *J. Med. Ethics* 2021; Coggon J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34253623>
41. **Age and Social Disparities in the Use of Telemedicine During the COVID-19 Pandemic in Japan: Cross-sectional Study.** *J Med Internet Res* 2021; 23:e27982Miyawaki A, Tabuchi T, Ong MK, Tsugawa Y.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34259641>
42. **Unamuno on suffering and Frankl's 'will to meaning': a philo-logotherapeutic advice to humankind here and beyond and the role of social relations towards**

- mental fitness.** J Public Health (Oxf) 2021; Pacaol NF.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34252976>
43. **Young African Americans' Communication with Family Members About COVID-19: Impact on Vaccination Intention and Implications for Health Communication Interventions.** J Racial Ethn Health Disparities 2021:1-7 Francis DB, Mason N, Occa A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272682>
 44. **An Ethical Roadmap for Prioritizing Medical Resources Within Muslim Societies During the COVID-19 Pandemic.** J Relig Health 2021:1-7 Al-Balas QAE, Al-Delaimy WK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275033>
 45. **Spiritual Health and the COVID-19 Pandemic: Impacts on Orthodox Christianity Devotion Practices, Rituals, and Religious Pilgrimages.** J Relig Health 2021; Papazoglou AS, Moysidis DV, Tsagkaris C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34263390>
 46. **Islam and the COVID-19 Pandemic: Between Religious Practice and Health Protection.** J Relig Health 2021; Piwko AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268671>
 47. **The Orthodox Church and the Mental Health Burden of a Pandemic: A Narrative Mini-Review.** J Relig Health 2021; Schieffler DA, Jr., Genig J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34263389>
 48. **The onset of COVID-19, common identity, and intergroup prejudice.** J. Soc. Psychol. 2021:1-17 Toprakiran S, Gordils J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251994>
 49. **Measuring business-level expectations and uncertainty: survey evidence and the COVID-19 pandemic.** Jpn Econ Rev (Oxf) 2021:1-24 Chen C, Senga T, Zhang H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248384>
 50. **#workfromhome: how multi-level marketers enact and subvert federal language policy for profit.** Lang Policy 2021:1-34 Fluegel S, King K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34248446>
 51. **Provision and utilisation of health and nutrition services during COVID-19 pandemic in urban Bangladesh.** Matern. Child Nutr. 2021:e13218 Nguyen PH, Sununtnasuk C, Pant A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264002>
 52. **Declaration of COVID-19 as an occupational disease in healthcare workers: challenges and reality.** Med Clin (Engl Ed) 2021; Gil-Blanco L, Martínez-Jarreta B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34250245>
 53. **A mirror in fiction: drawing parallelisms between Camus's La Peste and COVID-19.** Med. Humanit. 2021; Pérez Romero C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34253585>
 54. **Clinical pharmacy goes Hollywood - Depiction of medication in movies.** Med. Monatsschr. Pharm. 2020; 43:489-495 Pudritz YM, Albien AL, Barth M *et al.*
 55. **[Change in dietary consciousness and its related factors among Japanese adults under the COVID-19 pandemic: Analysis using Dietary Consciousness Scale].** Nihon Koshu Eisei Zasshi 2021; Hayashi F, Takemi Y, Akaiwa Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34261842>
 56. **Ethical dilemmas faced by frontline support nurses fighting COVID-19.** Nurs. Ethics 2021:9697330211015284 Liu X, Xu Y, Chen Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34254552>
 57. **Understanding the disproportionate effects of COVID-19 on nurses from ethnic minority backgrounds.** Nurs. Stand. 2021; Qureshi I, Garcia R, Ali N, Randhawa G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250768>

58. **Clinical significance of prognostic nutrition index in hospitalized patients with COVID-19: Results from single-center experience with systematic review and meta-analysis.** Nutr. Clin. Pract. 2021; Rashedi S, Keykhaei M, Pazoki M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34270114>
59. **The Effect of the COVID-19 on Corrosive Ingestion in Thailand.** Open Access Emerg. Med. 2021; 13:299-304Thongchuam C, Mahawongkajit P, Kanlerd A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267561>
60. **Customized bus passenger boarding and debording planning optimization model with the least number of contacts between passengers during COVID-19.** Physica A 2021; 582:126244Chen F, Peng H, Ding W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257475>
61. **COVID-19: High prevalence of malnutrition.** Pneumologie 2021; 75:412Simon A.
62. **Associations between individual and environmental determinants and physical activity levels of an active population during the Spanish lockdown.** Prev. Med. 2021; 153:106719Gonzalo-Encabo P, Cereijo L, Remón Á LC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256066>
63. **From Shelters to Hotels: An Enduring Solution to Ending Homelessness for Thousands of Americans.** Psychiatr. Serv. 2021:appips202100170Padgett DK, Herman D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253037>
64. **An exploration of the impact of SARS-CoV-2 (COVID-19) restrictions on marginalised groups in the UK.** Public Health 2021; 197:6-10Eshareturi C, Wareham A, Rattray M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256281>
65. **The lie of pandemic pivot and essential work.** Qual Soc Work 2021; 20:193-199Crampton A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253964>
66. **Migrants in Chile: Social crisis and the pandemic (or sailing over troubled water...).** Qual Soc Work 2021; 20:284-288Jara-Labarthé V, Cisneros Puebla CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253973>
67. **Resisting the politics of the pandemic and racism to foster humanity.** Qual Soc Work 2021; 20:225-232Lee E, Johnstone M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253968>
68. **Global collaboration and social practices to mitigate impacts of COVID-19 in the world: a lived experience of infecting.** Qual Soc Work 2021; 20:366-374Moshtagh M, Mirlashari J, Amiri R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253980>
69. **The revitalization of "Osekkai": How the COVID-19 pandemic has emphasized the importance of Japanese voluntary social work.** Qual Soc Work 2021; 20:423-432Ohta R, Yata A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253984>
70. **Interactive virtual medication counselling in outpatient pharmacy: An accessible and safe patient counselling method during the COVID-19 pandemic.** Res Social Adm Pharm 2021; Yong WY, Chang CT, Chew CC, Khoo TE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272201>
71. **Plastic waste footprint in the context of COVID-19: Reduction challenges and policy recommendations towards sustainable development goals.** Sci Total Environ 2021; 796:148951Mallick SK, Pramanik M, Maity B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271381>
72. **Sandstorm and its effect on particulate matter PM 2.5, carbon monoxide, nitrogen dioxide, ozone pollutants and SARS-CoV-2 cases and deaths.** Sci Total Environ 2021; 795:148764Meo SA, Almutairi FJ, Abukhalaf AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252765>

73. **Unveiling the changes in urban atmospheric CO₂ in the time of COVID-19 pandemic: A case study of Florence (Italy).** Sci Total Environ 2021; 795:148877Venturi S, Randazzo A, Tassi F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34252774>
74. **Thoughts of social distancing experiences affect food intake and hypothetical binge eating: Implications for people in home quarantine during COVID-19.** Soc. Sci. Med. 2021; 284:114218Yi-Chi Chang Y, Wu PL, Chiou WB.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34265658>
75. **6 Feet Apart: Spaces and Cultures of Quarantine.** Space Cult 2020; 23:216-220Shields R, Schillmeier M, Lloyd J, Van Loon J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34253950>
76. **Urogynecological survey in a group of Italian women treated for overactive bladder: Symptoms and quality of life analysis during the Covid-19 period.** Taiwan. J. Obstet. Gynecol. 2021; 60:674-678Schiavi MC, Zullo MA, Luffarelli P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247805>
77. **Impact of biomass induced black carbon particles in cascading COVID-19.** Urban Clim 2021; 38:100913Rathod A, Beig G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34258181>
78. **Paying the Price for a Broken Healthcare System: Rethinking Employment, Labor, and Work in a Post-Pandemic World.** Work Occup 2020; 47:267-279Avar AC, Eaton AE, Givan RK, Litwin AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253939>
79. **Impact of COVID-19 on the exercise habits of Pennsylvania residents and their families.** Z Gesundh Wiss 2021:1-8Wallace LN.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34258148>

Pathology (8 articles)

1. **Laboratory Medicine and Pathology Education During the COVID-19 Pandemic-Lessons Learned.** Acad Pathol 2021; 8:23742895211020487Patel R, Hoppman NL, Gosse CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263023>
2. **Probe-based confocal laser endomicroscopy in COVID-19.** Adv Respir Med 2021; Vasilev IV, Mamenko IS, Makarova AV *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34269405>
3. **Rethinking the management of immune checkpoint inhibitor-related adrenal insufficiency in cancer patients during the COVID-19 pandemic.** Endocrinol Diabetes Metab 2021; 4:e00246Yuen KCJ, Mortensen MJ, Azadi A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34268454>
4. **Distinctive Pseudopalisaded Histiocytic Hyperplasia Characterizes the Transition of Exudative to Proliferative Phase of Diffuse Alveolar Damage in Patients Dying of COVID-19.** Hum. Pathol. 2021; Kritselis M, Yambayev I, Prilutskiy A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273395>
5. **A clinico-pathological description of COVID-19-induced chilblains (COVID toes) correlated with a published literature review.** J. Cutan. Pathol. 2021; Kolivras A, Thompson C, Pastushenko I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272741>
6. **Historical Evolution and Filtering Characteristics of Masks and Respirators in Dentistry in the Context of COVID-19: A Literature Review.** J Int Soc Prev

- Community Dent 2021; 11:248-255Ramírez A, Ochoa D, Llanque G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34268186>
7. **Remote Reporting During a Pandemic Using Digital Pathology Solution: Experience from a Tertiary Care Cancer Center.** J. Pathol. Inform. 2021; 12:20Ramaswamy V, Tejaswini BN, Uthaiiah SB.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34267985>
 8. **Demystifying COVID-19 lung pathology: A clinicopathological study of postmortem core needle biopsy.** Lung India 2021; 38:343-349Bhandari S, Solanki R, Jindal A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259173>

Protection (28 articles)

1. **Wearing masks to reduce the spread of respiratory viruses: a systematic evidence mapping.** Ann Transl Med 2021; 9:811Li Y, Wei Z, Zhang J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34268424>
2. **Field observations and survey evidence to assess predictors of mask wearing across different outdoor activities in an Argentine city during the COVID-19 pandemic.** Appl Psychol Health Well Being 2021; Freidin E, Acera Martini L, Senci CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254447>
3. **Paediatric headbox as aerosol and droplet barrier.** Arch. Dis. Child. 2021; Sahih M, Schultz A, Wilson A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266877>
4. **Efficacy of frontline chemical biocides and disinfection approaches for inactivating SARS-CoV-2 variants of concern that cause coronavirus disease (COVID-19) with emergence of opportunities for green eco-solutions.** Curr Opin Environ Sci Health 2021:100290Rowan NJ, Meade E, Garvey M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34250323>
5. **An in vitro visual study of fugitive aerosols released during aerosol therapy to an invasively ventilated simulated patient.** Drug Deliv 2021; 28:1496-1500Mac Giolla Eain M, Joyce M, MacLoughlin R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259091>
6. **Face masks as a source of nanoplastics and microplastics in the environment: Quantification, characterization, and potential for bioaccumulation.** Environ Pollut 2021; 288:117748Ma J, Chen F, Xu H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34265560>
7. **Changes in handwashing and hygiene product usage patterns in Korea before and after the outbreak of COVID-19.** Environ Sci Eur 2021; 33:79Choi K, Sim S, Choi J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249592>
8. **Time patterns of precautionary health behaviours during an easing phase of the COVID-19 pandemic in Europe.** Eur J Ageing 2021:1-12Bíró A, Branyiczki R, Elek P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248455>
9. **The Significance of Duration of Exposure and Circulation of Fresh Air in SARS-CoV-2 Transmission Among Healthcare Workers.** Front Med (Lausanne) 2021; 8:664297Vlacha V, Feketea G, Petropoulou A, Trancá SD.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34249965>
10. **Face Masks in Young Children During the COVID-19 Pandemic: Parents' and Pediatricians' Point of View.** Front Pediatr 2021; 9:676718Assathiany R, Salinier C, Béchet S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249814>
11. **COVID-19 Incidence After Exposures in Shared Patient Rooms, Tertiary Care Center, Iowa, July 2020-May 2021.** Infect Control Hosp Epidemiol 2021:1-

- 13Trannel A, Kobayashi T, Dains A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250882>
12. **Detection of SARS-CoV-2 RNA on contact surfaces within shared sanitation facilities.** *Int J Hyg Environ Health* 2021; 236:113807Amoah ID, Pillay L, Deepnarian N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265632>
 13. **Effects of Masks Worn to Protect Against COVID-19 on the Perception of Facial Attractiveness.** *lperception* 2021; 12:20416695211027920Kamatani M, Ito M, Miyazaki Y, Kawahara JI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262683>
 14. **Discussion on the Management Method of COVID-19 Infection Prevention in Medical Residents.** *Iran J. Public Health* 2020; 49:87-91Zhou Y, Fang JJ, Wang SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268210>
 15. **COVID-19 spread in a classroom equipped with partition - A CFD approach.** *J. Hazard. Mater.* 2021; 420:126587Mirzaie M, Lakzian E, Khan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273880>
 16. **Presentation of a participatory approach to develop preventive measures to reduce COVID-19 transmission in child care.** *J. Occup. Med. Toxicol.* 2021; 16:26Diebig M, Gritzka S, Dragano N, Angerer P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261512>
 17. **Do Black Lives Matter in the American Public's Mitigation Responses to the COVID-19 Pandemic? An Analysis of Mask Wearing and Racial/Ethnic Disparities in Deaths from COVID-19.** *J Racial Ethn Health Disparities* 2021; Franz B, Milner A, Braddock I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269992>
 18. **COVID-19: Acoustic Measures of Voice in Individuals Wearing Different Facemasks.** *J. Voice* 2021; Joshi A, Procter T, Kulesz PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261582>
 19. **Operating-Room Procedures Do Not Increase Risk of COVID-19 Infection.** *JSLIS* 2021; 25Manuia EP, Ostapenko A, Liechty ST, Kleiner DE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248337>
 20. **Effect of sanitizer on obliteration of SARS -CoV2/COVID 19: A mini review.** *Mater Today Proc* 2021; Andal V, Lakshmpathy R, Jose D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249617>
 21. **Effects of surgical and cloth facemasks during a submaximal exercise test in healthy adults.** *Respir. Med.* 2021; 186:106530Reychler G, Straeten CV, Schalkwijk A, Poncin W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273733>
 22. **US trends in mask wearing during the COVID-19 pandemic depend on rurality.** *Rural Remote Health* 2021; 21:6596Pro G, Schumacher K, Hubach R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252284>
 23. **Hand Hygiene Practices and the Risk of Human Coronavirus Infections in a UK Community Cohort.** *Wellcome Open Res* 2020; 5:98Beale S, Johnson AM, Zambon M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250260>

Pulmonary disease (29 articles)

1. **Pulmonary Fibrosis Caused by Severe COVID-19 Infection: Discharge May Not Be The End of Treatment.** *Acta Med Indones* 2021; 53:141-142Rumende CM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251340>
2. **The Management of Pulmonary Fibrosis in COVID-19.** *Acta Med Indones* 2021; 53:233-241Rumende CM, Susanto EC, Sitorus TP.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251354>
3. **Management of non-COVID respiratory illnesses during the COVID-19 pandemic - a pulmonologist's perspective.** *Adv Respir Med* 2021; Shadrach BJ, Jain A, Goel R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269413>
 4. **Probe-based confocal laser endomicroscopy in COVID-19.** *Adv Respir Med* 2021; Vasilev IV, Mamenko IS, Makarova AV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269405>
 5. **The Impact of the COVID-19 Pandemic on Exacerbations and Symptoms in Bronchiectasis: A Prospective Study.** *Am J Respir Crit Care Med* 2021; Crichton ML, Shoemark A, Chalmers JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265234>
 6. **High risk of patient self-inflicted lung injury in COVID-19 with frequently encountered spontaneous breathing patterns: a computational modelling study.** *Ann Intensive Care* 2021; 11:109Weaver L, Das A, Saffaran S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255207>
 7. **Asthma and COVID-19: a dangerous liaison?** *Asthma Res Pract* 2021; 7:9Lombardi C, Gani F, Berti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261543>
 8. **Longitudinal trajectories of pneumonia lesions and lymphocyte counts associated with disease severity among convalescent COVID-19 patients: a group-based multi-trajectory analysis.** *BMC Pulm. Med.* 2021; 21:233Shi N, Huang C, Zhang Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256743>
 9. **Pulmonary Telerehabilitation and Efficacy among Discharged COVID-19 Patients: Rational and Design of a Prospective Real-world Study.** *Clin. Respir. J.* 2021; Lei J, Yang L, Wen G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260823>
 10. **Acute bronchiolitis during the COVID-19 pandemic.** *Enferm. Infecc. Microbiol. Clin.* 2021; Flores-Pérez P, Gerig N, Cabrera-López MI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256973>
 11. **Development of a Large Pneumatocele in a Patient Recovering from COVID-19 Pneumonitis.** *Eur J Case Rep Intern Med* 2021; 8:002605Hampson F, Salih W, Helm J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268263>
 12. **Impact of the COVID-19 pandemic on the management of chronic noninfectious respiratory diseases.** *Expert Rev. Respir. Med.* 2021:1-14Tiotiu A, Chong Neto H, Bikov A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253132>
 13. **Impact of the COVID-19 pandemic on the management of chronic non-infectious respiratory diseases.** *Expert Rev. Respir. Med.* 2021; Tiotiu A, Chong-Neto H, Bikov A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253132>
 14. **Association of Preexisting Asthma and Other Allergic Diseases With Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis.** *Front Med (Lausanne)* 2021; 8:670744Wu X, Xu Y, Jin L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249969>
 15. **Comparison of Residual Pulmonary Abnormalities 3 Months After Discharge in Patients Who Recovered From COVID-19 of Different Severity.** *Front Med (Lausanne)* 2021; 8:682087Zhou M, Xu J, Liao T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249973>
 16. **How and to What Extent Immunological Responses to SARS-CoV-2 Shape Pulmonary Function in COVID-19 Patients.** *Front. Physiol.* 2021;

- 12:628288Laveneziana P, Straus C, Meiners S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34267671>
17. **Distinctive Pseudopalisaded Histiocytic Hyperplasia Characterizes the Transition of Exudative to Proliferative Phase of Diffuse Alveolar Damage in Patients Dying of COVID-19.** Hum. Pathol. 2021; Kritselis M, Yambayev I, Prilutskiy A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273395>
 18. **The Long-Term Impact of COVID-19 Pneumonia on the Pulmonary Function of Survivors.** Int. J. Gen. Med. 2021; 14:3271-3280Salem AM, Al Khathlan N, Alharbi AF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267545>
 19. **Pulmonary Covid Fibrosis a New Pharmaceutic Approach.** Int. J. Prev. Med. 2021; 12:35Menicagli R, Limodio M, Limodio M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34249284>
 20. **Association Between Pediatric Asthma and Positive Tests for SARS-CoV-2 in the District of Columbia.** J Allergy Clin Immunol Pract 2021; Margolis RHF, Patel SJ, Sheehan WJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265448>
 21. **Development of cavitory lung disease as a long-term complication of coronavirus disease 2019 in a young previously healthy patient: a case report.** J Med Case Rep 2021; 15:377Egoryan G, Hyser E, Mushtaq AH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34256831>
 22. **Impact of nonpharmacological COVID-19 interventions in hospitalizations for childhood pneumonia in Brazil.** Pediatr Pulmonol 2021; Friedrich F, LC EG, Petry LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265188>
 23. **Change in CF care during COVID-19 pandemic: Single-center experience in a middle-income setting.** Pediatr Pulmonol 2021; Hatziagorou E, Toulia I, Avramidou V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265187>
 24. **Impact of COVID-19 on pediatric pulmonology healthcare practice.** Pediatr Pulmonol 2021; Nayir Buyuksahin H, Emiralioglu N, Ademhan Tural D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34265185>
 25. **Unaffected asthma control in children with mild asthma after COVID-19.** Pediatr Pulmonol 2021; Tosca MA, Crocco M, Gironi D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34265183>
 26. **Monitoring lung injury with particle flow rate in LPS- and COVID-19-induced ARDS.** Physiol Rep 2021; 9:e14802Stenlo M, Silva IAN, Hyllén S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34250766>
 27. **COVID-19 and acute exacerbation of interstitial lung disease.** Respir Investig 2021; Kondoh Y, Kataoka K, Ando M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272158>
 28. **Secondary spontaneous pneumothorax: a time to re-evaluate management.** Respir Case Rep 2021; 9:e00749Cortes-Telles A, Ortiz-Farias DL, Perez-Hernandez F, Rodriguez-Morejon D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262774>
 29. **A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial.** Trials 2021; 22:451Sharma A, Sharma C, Raina S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266452>

Renal disease (10 articles)

1. **SARS-CoV-2 assessment in an outpatient dialysis facility of a single center in Brazil.** Braz. J. Infect. Dis. 2021; 25:101595Gorayeb-Polacchini FS, Caldas HC, Bottazzo AC, Abbud-Filho M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273270>
2. **Two episodes of acute dyspnea that were induced by COVID-19 in a peritoneal dialysis patient.** CEN Case Rep 2021; Toda N, Takeoka J, Tanigaki K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269997>
3. **Complement activation and increased expression of Syk, mucin-1 and CaMK4 in kidneys of patients with COVID-19.** Clin Immunol 2021; 229:108795Jamaly S, Tsokos MG, Bhargava R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252574>
4. **A Retrospective Multi-Center Experience of Renal Transplants from India During COVID-19 Pandemic.** Clin. Transplant. 2021; Jha PK, Yadav DK, Siddini V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255903>
5. **Impact of dexamethasone use to prevent from severe COVID-19-induced acute kidney injury.** Crit Care 2021; 25:249Orieux A, Khan P, Prevel R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271956>
6. **A COVID-19 Emergency Response for Remote Control of a Dialysis Machine with Mobile HRI.** Front Robot AI 2021; 8:612855Wazir HK, Lourido C, Chacko SM, Kapila V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262944>
7. **COVID-19: Zinc and Angiotensin-Converting Enzyme 2 (ACE2) Deficiencies as Determinants of Risk and Severity of Disease: A Narrative Review.** Infect Dis Ther 2021:1-11Salgo MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251655>
8. **[Kidney damage in COVID-19].** Nephrol. Ther. 2021; Burtey S, Sallée M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266783>
9. **[SFNDT in the heart of the COVID-19 epidemic].** Nephrol. Ther. 2021; Hourmant M, Frimat L, Moulin B, Vrtovsnik F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266784>
10. **[Why this special COVID issue?].** Nephrol. Ther. 2021; Vigneau C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274253>

Reviews (42 articles)

1. **Addressing Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following COVID-19 Vaccination: A Mini-Review of Practical Strategies.** Acta Cardiol Sin 2021; 37:355-364Chen PW, Tsai ZY, Chao TH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257485>
2. **Intention to COVID-19 vaccination and associated factors among health care workers: A systematic review and meta-analysis of cross-sectional studies.** Am. J. Infect. Control 2021; Luo C, Yang Y, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273461>
3. **Titres and neutralising capacity of SARS-CoV-2-specific antibodies in human milk: a systematic review.** Arch. Dis. Child. Fetal Neonatal Ed. 2021; Low JM, Low YW, Zhong Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257103>
4. **COVID-19 and loneliness: A rapid systematic review.** Aust. N. Z. J. Psychiatry 2021:48674211031489Pai N, Vella SL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256632>
5. **Covid-19 and the next outbreak: decreasing frailty by using mild stress?** Biogerontology 2021:1-5Le Bourg E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273015>

6. **Health authorities' health risk communication with the public during pandemics: a rapid scoping review.** BMC Public Health 2021; 21:1401Berg SH, O'Hara JK, Shortt MT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266403>
7. **Effectiveness of contact tracing apps for SARS-CoV-2: a rapid systematic review.** BMJ Open 2021; 11:e050519Jenniskens K, Bootsma MCJ, Damen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253676>
8. **An outline of SARS-CoV-2 pathogenesis and the complement cascade of immune system.** Bull Natl Res Cent 2021; 45:123Hembram P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257504>
9. **Plausible Positive Effects of Statins in COVID-19 Patient.** Cardiovasc. Toxicol. 2021:1-9Vitiello A, Ferrara F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255300>
10. **'It's history in the making all around us': examining COVID-19 through the lenses of HIV and epidemic history.** Cult Health Sex 2021:1-16Braksmajer A, London AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254890>
11. **Clinical-Pathological Correlation of the Pathophysiology and Mechanism of Action of COVID-19 - a Primer for Clinicians.** Curr. Allergy Asthma Rep. 2021; 21:38Chee J, Loh WS, Liu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259961>
12. **A Review on the Effectivity of the Current COVID-19 Drugs and Vaccines: Are They Really Working Against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants?** Curr Clin Microbiol Rep 2021:1-8Noor R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249605>
13. **COVID-19 Pandemic and the Convalescent Plasma Therapy: Possible Benefits and Risks.** Curr Clin Microbiol Rep 2021:1-5Noor R, Tasnim N, Saha C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249604>
14. **Diagnosis of COVID-19 Using Machine Learning and Deep Learning: A Review.** Curr Med Imaging 2021; Mondal MRH, Bharati S, Podder P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259149>
15. **Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021.** Euro Surveill 2021; 26Harder T, Koch J, Vygen-Bonnet S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269175>
16. **Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review.** Fam. Pract. 2021; van Kessel SAM, Olde Hartman TC, Lucassen P, van Jaarsveld CHM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268556>
17. **Review article on COVID-19 and Guillain-Barré syndrome.** Front Biosci (Schol Ed) 2021; 13:97-104Patnaik UJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256532>
18. **Prevention and Recovery of COVID-19 Patients With Kampo Medicine: Review of Case Reports and Ongoing Clinical Trials.** Front. Pharmacol. 2021; 12:656246Takayama S, Namiki T, Odaguchi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248620>
19. **Knowledge, Attitude, and Practice of Healthcare Providers Toward Novel Coronavirus 19 During the First Months of the Pandemic: A Systematic Review.** Front Public Health 2021; 9:606666Tegegne GT, Kefale B, Engidaw MT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249826>
20. **Relevance of vitamin D(3) in COVID-19 infection.** Gene Rep 2021; 24:101270UI Afshan F, Nissar B, Chowdri NA, Ganai BA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249826>

term=34250314

21. **Pattern and determinants of COVID-19 infection and mortality across countries: An ecological study.** Heliyon 2021; 7:e07504Asem N, Ramadan A, Hassany M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254048>
22. **The effectiveness of Colchicine as an anti-inflammatory drug in the treatment of coronavirus disease 2019: Meta-analysis.** Int. J. Immunopathol. Pharmacol. 2021; 35:20587384211031763Golpour M, Mousavi T, Alimohammadi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250834>
23. **Aspects of Epidemiology, Pathology, Virology, Immunology, Transmission, Prevention, Prognosis, Diagnosis, and Treatment of COVID-19 Pandemic: A Narrative Review.** Int. J. Prev. Med. 2021; 12:38Rahimi Pordanjani S, Hasanpour A, Askarpour H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249287>
24. **Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review.** Iran J. Public Health 2020; 49:18-29Sheikhshahrokh A, Ranjbar R, Saeidi E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268202>
25. **An Introduction to SARS Coronavirus 2; Comparative Analysis with MERS and SARS Coronaviruses: A Brief Review.** Iran J. Public Health 2020; 49:30-37Taherizadeh M, Tabibzadeh A, Panahi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268203>
26. **"Five-Early" Model: The Magic Weapon against COVID-19.** Iran J. Public Health 2020; 49:82-86Yi Q, Fang W, Lang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268209>
27. **Questions about COVID-19 associated coagulopathy: possible answers from the viscoelastic tests.** J. Clin. Monit. Comput. 2021; Pavoni V, Giancesello L, Pazzi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264472>
28. **Unraveling the role of liver sinusoidal endothelial cells in COVID-19 liver injury.** J Hepatol 2021; Saviano A, Baumert TF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274367>
29. **N-Acetylcysteine as Adjuvant Therapy for COVID-19 - A Perspective on the Current State of the Evidence.** J Inflamm Res 2021; 14:2993-3013Wong KK, Lee SWH, Kua KP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262324>
30. **Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.** J Microbiol Immunol Infect 2021; Lai CC, Chao CM, Hsueh PR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253490>
31. **Symptoms, complications and management of long COVID: a review.** J R Soc Med 2021;1410768211032850Aiyegbusi OL, Hughes SE, Turner G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265229>
32. **Venous and arterial thromboembolic disease in COVID-19.** J. Thromb. Thrombolysis 2021;1-3Ten Berg J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255267>
33. **Systematic Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients with Chronic Kidney Disease.** Kidney Int Rep 2021; Carr EJ, Kronbichler A, Graham-Brown M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250319>
34. **Effect of sanitizer on obliteration of SARS -CoV2/COVID 19: A mini review.** Mater Today Proc 2021; Andal V, Lakshmipathy R, Jose D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249617>

35. **eHealth solutions to fight against COVID-19: A scoping review of applications.** Med. J. Islam. Repub. Iran 2021; 35:43Eslami P, Niakan Kalhori SR, Taheriyani M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268231>
36. **Mucormycosis and COVID-19: An Epidemic within a Pandemic in India.** Mycoses 2021; Selarka L, Sharma S, Saini D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255907>
37. **A Narrative Review of Current Understanding and Classification of Dry Eye Disease with New Insights on the Impact of Dry Eye during the COVID-19 Pandemic.** Ophthalmol Ther 2021;1-13Barabino S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275088>
38. **Novel Respiratory Viruses in the Context of Mass-Gathering Events: A Systematic Review to Inform Event Planning from a Health Perspective.** Prehosp. Disaster Med. 2021;1-12Ranse J, Beckwith D, Khan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261546>
39. **COVID-19 and cardiovascular system-a comprehensive review.** Rev Cardiovasc Med 2021; 22:343-351AlShahrani I, Hosmani J, Shankar VG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258902>
40. **The effectiveness of non-contact thermal screening as a means of identifying cases of Covid-19: a rapid review of the evidence.** Rev Med Virol 2021; 31:e2192Cardwell K, Jordan K, Byrne P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260781>
41. **Population-based prevalence surveys during the Covid-19 pandemic: A systematic review.** Rev Med Virol 2021; 31:e2200Franceschi VB, Santos AS, Glaeser AB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260777>
42. **Immunity and inflammatory biomarkers in COVID-19: A systematic review.** Rev Med Virol 2021; 31:e2199Iwamura APD, Tavares da Silva MR, Hümmelgen AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260778>

Risk factors (75 articles)

1. **Incidence of COVID-19 in patients with rheumatic diseases.** Aktuelle Rheumatologie 2021; 46:225-227Kessing R.
2. **Myeloid phenotypes in severe COVID-19 predict secondary infection and mortality: a pilot study.** Ann Intensive Care 2021; 11:111Marais C, Claude C, Semaan N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259942>
3. **Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France.** Arthritis Res. Ther. 2021; 23:188Felten R, Scherlinger M, Guffroy A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256812>
4. **Asthma and COVID-19: a dangerous liaison?** Asthma Res Pract 2021; 7:9Lombardi C, Gani F, Berti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261543>
5. **Fatores associados ao óbito em casos confirmados de COVID-19 no estado do Rio de Janeiro.** BMC Infect. Dis. 2021; 21:687Cini Oliveira M, de Araujo Eleuterio T, de Andrade Corrêa AB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271868>
6. **Absolute mortality risk assessment of COVID-19 patients: the Khorshid COVID Cohort (KCC) study.** BMC Med. Res. Methodol. 2021; 21:146Marateb HR, von Cube M, Sami R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261439>

7. **Longitudinal trajectories of pneumonia lesions and lymphocyte counts associated with disease severity among convalescent COVID-19 patients: a group-based multi-trajectory analysis.** BMC Pulm. Med. 2021; 21:233Shi N, Huang C, Zhang Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256743>
8. **Coronary artery calcium score may be a novel predictor of COVID-19 prognosis: a retrospective study.** BMJ Open Respir Res 2021; 8Takehita Y, Terada J, Fujita R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272254>
9. **Is cancer a prognostic factor for severe COVID-19, especially for breast cancer patients?** Cancer Radiother. 2021; Allali S, Beddok A, Kirova Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274225>
10. **Complement activation and increased expression of Syk, mucin-1 and CaMK4 in kidneys of patients with COVID-19.** Clin Immunol 2021; 229:108795Jamaly S, Tsokos MG, Bhargava R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252574>
11. **Cardiovascular Risk Factors and the Severity of COVID-19 Disease.** Cureus 2021; 13:e15486Motaib I, Zbiri S, Elamari S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262822>
12. **Biomarkers Predictive of Extubation and Survival of COVID-19 Patients.** Cureus 2021; 13:e15462Topp G, Bouyea M, Cochran-Caggiano N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258124>
13. **The Role of Antiphospholipid Antibodies in COVID-19.** Curr. Rheumatol. Rep. 2021; 23:72Stelzer M, Henes J, Saur S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259944>
14. **Higher admission activated partial thromboplastin time, neutrophil-lymphocyte ratio, serum sodium, and anticoagulant use predict in-hospital COVID-19 mortality in people with Diabetes: Findings from Two University Hospitals in the U.K.** Diabetes Res Clin Pract 2021; 178:108955Iqbal A, Greig M, Arshad MF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273452>
15. **Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States.** Diabetes Ther. 2021:1-17Boye KS, Tokar Erdemir E, Zimmerman N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275115>
16. **Outcome and death risk of diabetes patients with Covid-19 receiving pre-hospital and in-hospital metformin therapies.** Diabetol. Metab. Syndr. 2021; 13:76Tamura RE, Said SM, de Freitas LM, Rubio IGS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256824>
17. **Risk models for predicting in-hospital mortality from COVID-19 pneumonia in the elderly.** Emergencias 2021; 33:282-291López-Izquierdo R, Ruiz Albi T, Bermejo-Martín JF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251141>
18. **Mortality risk model for patients with suspected COVID-19 based on information available from an emergency dispatch center.** Emergencias 2021; 33:265-272Martín-Rodríguez F, Sanz-García A, Alberdi Iglesias A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251139>
19. **Effects of chronic exposure to ambient air pollutants, demographic, and socioeconomic factors on COVID-19 morbidity: The Israeli case study.** Environ. Res. 2021:111673Levi A, Barnett-Itzhaki Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260961>
20. **Association of ABO and Rh blood groups with obstetric outcomes in SARS-CoV-2 infected pregnancies: A prospective study with a multivariate analysis.**

- Eur. J. Obstet. Gynecol. Reprod. Biol. 2021; 264:41-48 Sainz Bueno JA, Cerrillos González L, Abascal-Saiz A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271364>
21. **Dementia as Risk Factor for Severe Coronavirus Disease 2019: A Case-Control Study.** Front. Aging Neurosci. 2021; 13:698184 Pisaturo M, Calò F, Russo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267649>
 22. **Symptom Prediction and Mortality Risk Calculation for COVID-19 Using Machine Learning.** Front Artif Intell 2021; 4:673527 Jamshidi E, Asgary A, Tavakoli N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250465>
 23. **B-Type Natriuretic Peptide Concentrations, COVID-19 Severity, and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression.** Front Cardiovasc Med 2021; 8:690790 Zinellu A, Sotgia S, Carru C, Mangoni AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250044>
 24. **PNPLA3 and TLL-1 Polymorphisms as Potential Predictors of Disease Severity in Patients With COVID-19.** Front Cell Dev Biol 2021; 9:627914 Grimaudo S, Amodio E, Pipitone RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249902>
 25. **The Gut Microbiota of Critically Ill Patients With COVID-19.** Front Cell Infect Microbiol 2021; 11:670424 Gaibani P, D'Amico F, Bartoletti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268136>
 26. **Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 Severity.** Front. Endocrinol. (Lausanne) 2021; 12:658304 Moin ASM, Al-Qaissi A, Sathyapalan T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248840>
 27. **Dyslipidemia Is Related to Mortality in Critical Patients With Coronavirus Disease 2019: A Retrospective Study.** Front. Endocrinol. (Lausanne) 2021; 12:611526 Yue J, Xu H, Zhou Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248834>
 28. **EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients.** Front. Immunol. 2021; 12:634416 Luft T, Wendtner CM, Kosely F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248931>
 29. **SARS-CoV-2/ACE2 Interaction Suppresses IRAK-M Expression and Promotes Pro-Inflammatory Cytokine Production in Macrophages.** Front. Immunol. 2021; 12:683800 Pantazi I, Al-Qahtani AA, Alhamlan FS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248968>
 30. **Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning.** Front. Immunol. 2021; 12:700782 Patterson BK, Guevara-Coto J, Yogendra R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262570>
 31. **Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms.** Front. Microbiol. 2021; 12:698169 Proal AD, VanElzakker MB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248921>
 32. **Oral Microbiome Dysbiosis Is Associated With Symptoms Severity and Local Immune/Inflammatory Response in COVID-19 Patients: A Cross-Sectional Study.** Front. Microbiol. 2021; 12:687513 Soffritti I, D'Accolti M, Fabbri C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248910>
 33. **Liver dysfunction in COVID-19: a useful prognostic marker of severe disease?** Frontline Gastroenterol. 2021; 12:293-298 Lok J, Gess M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249314>

34. **Is obesity a risk factor in cancer patients with COVID-19?** Future Oncol 2021; Park R, Wulff-Burchfield E, Sun W, Kasi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254528>
35. **Validation of red cell distribution width as a COVID-19 severity screening tool.** Future Sci OA 2021; 7:Fso712Pouladzadeh M, Safdarian M, Choghakabodi PM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254030>
36. **Mortality rate and biomarker expression within COVID-19 patients who develop acute ischemic stroke: a systematic review and meta-analysis.** Future Sci OA 2021; 7:Fso713Yassin A, Ghzawi A, Al-Mistarehi AH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254031>
37. **Blood system ABO antigens as risk factor for severity of SARS-CoV-2 infection.** Gac Med Mex 2021; 157:174-180Torres-Alarcón CG, García-Ruiz A, Cañete-Ibáñez CR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34270530>
38. **Comorbidities predict 30-day hospital mortality of older adults with COVID-19.** Geriatr. Nurs. 2021; 42:1024-1028Pott Junior H, Cominetti MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256151>
39. **Frailty as a mortality predictor in older adults with COVID-19: A systematic review and meta-analysis of cohort studies.** Geriatr. Nurs. 2021; 42:983-992Saragih ID, Advani S, Saragih IS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256158>
40. **The hidden interplay between sex and COVID-19 mortality: the role of cardiovascular calcification.** Geroscience 2021;1-15Cereda A, Toselli M, Palmisano A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260010>
41. **Assessment of severity and mortality of COVID-19 with anti-A1 and B IgM isohemagglutinins, a reflection of the innate immune status.** Int J Clin Pract 2021:e14624Ozcelik F, Tanoglu A, Guven BB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251730>
42. **"Five-Early" Model: The Magic Weapon against COVID-19.** Iran J. Public Health 2020; 49:82-86Yi Q, Fang W, Lang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268209>
43. **Association Between Pediatric Asthma and Positive Tests for SARS-CoV-2 in the District of Columbia.** J Allergy Clin Immunol Pract 2021; Margolis RHF, Patel SJ, Sheehan WJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265448>
44. **Deaths of people with intellectual disabilities: Analysis of deaths in England from COVID-19 and other causes.** J Appl Res Intellect Disabil 2021; Heslop P, Byrne V, Calkin R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272793>
45. **Low serum level of apolipoprotein A1 may predict the severity of COVID-19: A retrospective study.** J. Clin. Lab. Anal. 2021:e23911Zhu Z, Yang Y, Fan L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260764>
46. **Mortality associated with early changes in ARDS severity in COVID-19 patients - Insights from the PRoVENT-COVID study.** J Crit Care 2021; 65:237-245Schuijt MTU, Martin-Loeches I, Schultz MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271294>
47. **Gut microbiota, inflammation, and molecular signatures of host response to infection.** J Genet Genomics 2021; Gou W, Fu Y, Yue L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257044>
48. **Association between Early Antibiotic Therapy and In-Hospital Mortality among Older Patients with SARS-CoV-2 Pneumonia.** J Gerontol A Biol Sci Med Sci 2021;

- Putot A, Bouiller K, Laborde C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272847>
49. **Does ABO Blood Groups Affect Outcomes in Hospitalized COVID-19 Patients?** J Hematol 2021; 10:98-105 Kumar G, Nanchal R, Hererra M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267846>
 50. **Blood cell morphology and COVID-19 clinical course, severity, and outcome.** J. Hematop. 2021;1-8 Pezeshki A, Vaezi A, Nematollahi P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249171>
 51. **Cross-sectional assessment of SARS-CoV-2 viral load by symptom status in Massachusetts congregate living facilities.** J Infect Dis 2021; Lennon NJ, Bhattacharyya RP, Mina MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255846>
 52. **Self-infection with speech aerosol may contribute to COVID-19 severity.** J Intern Med 2021; Kushalnagar P, Chow CC, Bax A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268819>
 53. **Mucormycosis or black fungus infection is a new scare in South Asian countries during COVID-19 pandemic: Associated risk factors and preventive measures.** J Med Virol 2021; Rahman FI, Islam MR, Bhuiyan MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260073>
 54. **Dexamethasone treatment may mitigate adverse effects of vitamin D deficiency in hospitalised Covid-19 patients.** J Med Virol 2021; Wenban C, Heer RS, Baktash V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273116>
 55. **Prevention and management of infections after exposure to ionizing radiation.** J. Radiol. Prot. 2021; Maher K, Bouligny IM, Yeager AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265748>
 56. **The CoVID-TE Risk Assessment Model for Venous Thromboembolism in Hospitalized Patients with Cancer and COVID-19.** J Thromb Haemost 2021; Li A, Kuderer NM, Hsu CY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260813>
 57. **Harmonized D-dimer levels upon admission for prognosis of COVID-19 severity: Results from a Spanish multicenter registry (BIOCOVID-Spain study).** J. Thromb. Thrombolysis 2021;1-10 García de Guadiana-Romualdo L, Morell-García D, Favaloro EJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272635>
 58. **Clinical utility of biochemical markers for the prediction of COVID-19-related mortality in kidney transplant recipients.** Kidney Int Rep 2021; Caillard S, Chavarot N, Francois H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254049>
 59. **Highly expressed ACE-2 receptors during pregnancy: A protective factor for SARS-COV-2 infection?** Med. Hypotheses 2021; 153:110641 Figueiro-Filho EA, Hobson SR, Farine D, Yudin MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256245>
 60. **Comparison of the effects of etomidate, ketamine, sodium thiopental, and midazolam on the mortality of patients with COVID-19 requiring intubation.** Med. J. Islam. Repub. Iran 2021; 35:49 Edalatkhah A, Kazemi MR, Samadi Khorshidi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268237>
 61. **Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis.** Microvasc. Res. 2021;104224 Andrianto, Al-Farabi MJ, Nugraha RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273359>
 62. **Visceral Adiposity and Severe COVID-19 Disease: Application of an Artificial Intelligence Algorithm to Improve Clinical Risk Prediction.** Open Forum Infect

- [Dis](#) 2021; 8:ofab275Goehler A, Hsu TH, Seiglie JA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34258315>
63. **Parkinson's disease patients may have higher rates of Covid-19 mortality in Iran.** [Parkinsonism Relat. Disord.](#) 2021; 89:90-92Salari M, Etemadifar M, Ashrafi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256334>
 64. **Platelet-leukocyte interactions in the pathogenesis of viral infections.** [Platelets](#) 2021;1-8Hottz ED, Quirino-Teixeira AC, Merij LB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34260328>
 65. **Exposing health inequities: Surreal snapshots from the Grand Canyon to global COVID-19 pandemic.** [Qual Soc Work](#) 2021; 20:90-96Balestrery JE.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34253957>
 66. **C-Reactive protein and SOFA scale: A simple score as early predictor of critical care requirement in patients with COVID-19 pneumonia in Spain.** [Rev. Esp. Anesthesiol. Reanim.](#) 2021; Vaquero-Roncero LM, Sánchez-Barrado E, Escobar-Macias D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247837>
 67. **Can Comorbidity Data Explain Cross-State and Cross-National Difference in COVID-19 Death Rates?** [Risk Manag. Healthc. Policy](#) 2021; 14:2877-2885Cegan JC, Trump BD, Cibulsky SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267565>
 68. **Characteristics and outcomes of patients with COVID-19 and liver injury: a retrospective analysis and a multicenter experience.** [Rom. J. Intern. Med.](#) 2021; Voiosu A, Roman A, Pop R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253002>
 69. **COVID-19 and aging: Identifying measures of severity.** [SAGE Open Med](#) 2021; 9:20503121211027462Neves MT, de Matos LV, Vasques AC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34249362>
 70. **Spatial-temporal generalized additive model for modeling COVID-19 mortality risk in Toronto, Canada.** [Spat Stat](#) 2021;100526Feng C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34249608>
 71. **Elevated glycohemoglobin is linked to critical illness in CoVID-19: a retrospective analysis.** [Ther Adv Infect Dis](#) 2021; 8:20499361211027390Windham S, Wilson MP, Fling C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249357>
 72. **Racial disparities in COVID-19 associated pulmonary embolism: A multicenter cohort study.** [Thromb Res](#) 2021; 205:84-91Metra B, Summer R, Brooks SE *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34274560>
 73. **Sinus bradycardia is associated with poor outcome in critically ill patients with COVID-19 due to the B.1.1.7 Lineage.** [Toxicol Rep](#) 2021; 8:1394-1398Chalkias A, Pantazopoulos I, Papagiannakis N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34258235>
 74. **Risk Factors and Clinical Phenotypes Associated with Severity in Patients with COVID-19 in Northeast Mexico.** [Vector Borne Zoonotic Dis.](#) 2021; García-Alvarado FJ, Muñoz-Hernández MA, Moran Guel E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34255563>
 75. **Admission Braden Scale Score as an Early Independent Predictor of In-Hospital Mortality Among Inpatients With COVID-19: A Retrospective Cohort Study.** [Worldviews Evid. Based Nurs.](#) 2021; Lovicu E, Faraone A, Fortini A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34275200>

Safety (35 articles)

1. **COVID-19 Vaccination Induced Lymphadenopathy in a Specialized Breast Imaging Clinic in Israel: Analysis of 163 cases.** Acad Radiol 2021; Faermann R, Nissan N, Halshtok-Neiman O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257025>
2. **Large hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: A case report.** Acta Neurol. Scand. 2021; de Melo Silva ML, Jr., Lopes DP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273119>
3. **Two Cases of Well Controlled Chronic Spontaneous Urticaria Triggered by the Moderna COVID-19 Vaccine.** Allergy Rhinol (Providence) 2021; 12:21526567211026271 Alflen C, Birch K, Shilian R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249404>
4. **Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar.** Ann Med Surg (Lond) 2021; 67:102540 Razok A, Shams A, Almeer A, Zahid M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249353>
5. **Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine.** BMJ Case Rep. 2021; 14 Malik B, Kalantary A, Rikabi K, Kunadi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261635>
6. **Intracerebral bleeding after janus-kinase inhibitor baricitinib for COVID-19.** Brain Hemorrhages 2021; Finsterer J, Scorza FA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250455>
7. **COVID-19 Vaccination-Induced Rash: Does the Choice of Vaccine Matter?** Cureus 2021; 13:e15490 Zafar M, Ewnetu B, Ahmed S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268022>
8. **Efficacy of frontline chemical biocides and disinfection approaches for inactivating SARS-CoV-2 variants of concern that cause coronavirus disease (COVID-19) with emergence of opportunities for green eco-solutions.** Curr Opin Environ Sci Health 2021:100290 Rowan NJ, Meade E, Garvey M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250323>
9. **Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections).** Curr. Rheumatol. Rep. 2021; 23:74 Varley CD, Winthrop KL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269903>
10. **Myocarditis after mRNA vaccination: Discussions about risks of the new COVID-19 vaccines for younger men.** Deutsche Apotheker Zeitung 2021; 161 Blasius H.
11. **The Meaning of SARS-CoV-2 Antibodies in a Patient with a Systemic Reaction to the mRNA-1273 SARS-CoV-2 Vaccine after Previous Natural Immunization.** Eur J Case Rep Intern Med 2021; 8:002617 Szagary L, Meienberg A, Berger CT, Mayr M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268264>
12. **Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT).** Eur J Intern Med 2021; Varona JF, García-Isidro M, Moeinvaziri M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256983>
13. **Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England.** Euro Surveill 2021; 26 Powell AA, Power L, Westrop S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269172>
14. **COVID-19 vaccination associated severe immune thrombocytopenia.** Exp Hematol Oncol 2021; 10:42 Shah SRA, Dolkar S, Mathew J, Vishnu P.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34266487>

15. **Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines.** Expert Opin. Drug Saf. 2021; Sessa M, Kragholm K, Hviid A, Andersen M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264151>
16. **NOTTO COVID-19 Vaccine Guidelines for Transplant Recipients.** Indian J. Nephrol. 2021; 31:89-91 Kute VB, Agarwal SK, Prakash J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267426>
17. **Adverse events and humoral response after two-dose SARS-CoV-2 mRNA vaccination in the hospital personnel of a cardiopulmonary tertiary care center.** Infect Control Hosp Epidemiol 2021;1-8 De Vita E, Sbrana F, Quattrone F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261574>
18. **Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine.** Int. J. Hematol. 2021; Waqar SHB, Khan AA, Memon S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264514>
19. **Adverse rare events to vaccines for COVID-19: From hypersensitivity reactions to thrombosis and thrombocytopenia.** Int. Rev. Immunol. 2021;1-10 Novak N, Tordesillas L, Cabanillas B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251972>
20. **N-Acetylcysteine as Adjuvant Therapy for COVID-19 - A Perspective on the Current State of the Evidence.** J Inflamm Res 2021; 14:2993-3013 Wong KK, Lee SWH, Kua KP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262324>
21. **Predicted and Observed Incidence of Thromboembolic Events among Koreans Vaccinated with ChAdOx1 nCoV-19 Vaccine.** J Korean Med Sci 2021; 36:e197 Huh K, Na Y, Kim YE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254476>
22. **SAFETY OF COVID-19 VACCINES.** J Med Virol 2021; Al Khames Aga QA, Alkhaffaf WH, Hatem TH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34270094>
23. **Relapse of microscopic polyangiitis after vaccination against COVID-19: a case report.** J Med Virol 2021; Conticini E, D'Alessandro M, Bergantini L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251683>
24. **Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.** J Med Virol 2021; Kalantari S, Fard SR, Maleki D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255369>
25. **Commentary: The spectrum of neurological manifestations related to COVID-19 and vaccinations.** J. Neuroimmunol. 2021; 358:577660 Samudralwar RD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274719>
26. **A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma.** J. Oncol. Pharm. Pract. 2021;10781552211031304 Demir E, Sütcüoğlu O, Demir B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255596>
27. **Coincidence of fever following COVID-19 vaccine and endemic tropical diseases: A challenge to clinicians during the global rollout of COVID-19 vaccination.** J Travel Med 2021; Asawapaithulsert P, Pisutsan P, Matsee W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272852>
28. **Acute facial paresis as a possible complication of vaccination against SARS-CoV-2.** Laryngo- Rhino- Otologie 2021; 100:526-528 Volk GF, Kutenreich AM,

Geitner M, Guntinas-Lichius O.

29. **A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine.** Neurol Sci 2021;1-3Nasuelli NA, De Marchi F, Cecchin M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272622>
30. **Early COVID-19 Therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in Outpatient Settings Significantly Improved COVID-19 outcomes compared to Known outcomes in untreated patients.** New Microbes New Infect 2021:100915Cadegiani FA, Goren A, Wambier CG, McCoy J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249367>
31. **Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis.** Open Forum Infect Dis 2021; 8:ofab176Gibson EG, Pender M, Angerbauer M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258310>
32. **AstraZeneca's COVID-19 vaccine: Vector vaccine with high protective effect.** Pharm. Ztg. 2020; 165:46-48Dingermann T.
33. **Convalescent plasma treatment for early post-kidney-transplant acquired COVID-19.** Transpl Infect Dis 2021; Kluger MA, Czogalla J, Schmidt-Lauber C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251081>
34. **Henoch-Schönlein purpura presenting post COVID-19 vaccination.** Vaccine 2021; Hines AM, Murphy N, Mullin C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247902>
35. **Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia.** Vaccine 2021; MacIntyre CR, Veness B, Berger D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272095>

Treatment options (69 articles)

1. **Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.** Acta Med Indones 2021; 53:194-201Syam AF, Pitoyo CW, Suhendro S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251348>
2. **Recent advances in developing small-molecule inhibitors against SARS-CoV-2.** Acta Pharm Sin B 2021; Xiang R, Yu Z, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249607>
3. **Response to: 'Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response' by Westhoff et al.** Ann. Rheum. Dis. 2021; Bonelli M, Aletaha D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272251>
4. **Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report.** Ann. Rheum. Dis. 2021; Golding B, Lee Y, Golding H, Khurana S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272252>
5. **Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.** Antiviral Res 2021; 193:105137Touret F, Driouich JS, Cochin M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265358>
6. **The rationale for the use of corticosteroids in early severe Guillain-Barré syndrome.** Autoimmun Rev 2021; 20:102907Berciano J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274541>
7. **Traditional medicines for COVID-19: Perspectives from clinical pharmacologists.** Br. J. Clin. Pharmacol. 2021; Yimer G, Ekuadzi E, Fasinu P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272755>

8. **Intracerebral bleeding after janus-kinase inhibitor baricitinib for COVID-19.** Brain Hemorrhages 2021; Finsterer J, Scorza FA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34250455>
9. **Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab-induced arthritis by methylprednisolone, baricitinib, and remdesivir.** Clin Case Rep 2021; 9:e04459 Oda N, Miyoshi K, Morichika D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257986>
10. **Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with COVID-19.** Clin Infect Dis 2021; Wong CKH, Lau KTK, Au ICH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265054>
11. **Efficient machine learning model for predicting drug-target interactions with case study for Covid-19.** Comput. Biol. Chem. 2021; 93:107536 El-Beheri H, Attia AF, El-Feshawy N, Torkey H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271420>
12. **Unravelling the therapeutic potential of marine drugs as SARS-CoV-2 inhibitors: An insight from essential dynamics and free energy landscape.** Comput. Biol. Med. 2021; 135:104525 Rampogu S, Gajula RG, Lee G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252682>
13. **Impact of dexamethasone use to prevent from severe COVID-19-induced acute kidney injury.** Crit Care 2021; 25:249 Orieux A, Khan P, Prevel R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271956>
14. **A Review on the Effectivity of the Current COVID-19 Drugs and Vaccines: Are They Really Working Against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants?** Curr Clin Microbiol Rep 2021:1-8 Noor R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249605>
15. **COVID-19 Pandemic and the Convalescent Plasma Therapy: Possible Benefits and Risks.** Curr Clin Microbiol Rep 2021:1-5 Noor R, Tasnim N, Saha C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249604>
16. **Drug repurposing: an alternative strategy to treat COVID-19.** Curr. Pharm. Biotechnol. 2021; Han P, Zheng H, Wen P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250872>
17. **Synopsis on Pharmotechnological Approaches in Diagnostic to Management Strategies in Fighting Against COVID-19.** Curr. Pharm. Des. 2021; Azhar A, Hassan N, Singh M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269664>
18. **Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections).** Curr. Rheumatol. Rep. 2021; 23:74 Varley CD, Winthrop KL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269903>
19. **Visualized analyses of investigations upon mesenchymal stem/stromal cell-based cytotherapy and underlying mechanisms for COVID-19 associated ARDS.** Curr. Stem Cell Res. Ther. 2021; Aitong W, Leisheng Z, Hao Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254927>
20. **Research cooperation reports initial successes: Lüdenschied pharmacy finances development of a phytotherapeutic agent against COVID-19.** Deutsche Apotheker Zeitung 2021; 161.
21. **Efficacy of Intratympanic Glucocorticoid Steroid Administration Therapy as an Initial Treatment for Idiopathic Sudden Sensorineural Hearing Loss During the COVID-19 Pandemic.** Ear Nose Throat J 2021:1455613211032534 Tsuda T, Hanada Y, Wada K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247535>

22. **Insulin therapy and outcome from coronavirus disease 2019 (COVID-19): A Systematic Review, Meta-Analysis, and Meta-Regression.** Endocr. Metab. Immune Disord. Drug Targets 2021; Hariyanto TI, Lugito NPH, Yanto TA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250875>
23. **The dynamics in applied COVID-19 pharmacotherapy and the influence of national guidance in The Netherlands: a quantitative and qualitative study.** Eur J Hosp Pharm 2021; Uitvlugt EB, Soeng DYF, van der Linden P, van de Garde EMW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272215>
24. **Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study.** Front Bioeng Biotechnol 2021; 9:646184Wang Q, Lin X, Xiang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249878>
25. **Differential Cytokine Responses in Hospitalized COVID-19 Patients Limit Efficacy of Remdesivir.** Front. Immunol. 2021; 12:680188Chan YH, Young BE, Fong SW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262564>
26. **Nutraceutical Approach to Preventing Coronavirus Disease 2019 and Related Complications.** Front. Immunol. 2021; 12:582556Derosa G, Maffioli P, D'Angelo A, Di Pierro F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262553>
27. **Interleukin-1- Receptor Kinase 4 Inhibition: Achieving Immunomodulatory Synergy to Mitigate the Impact of COVID-19.** Front. Immunol. 2021; 12:693085Gupta A, Chun HJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248990>
28. **A Computational Approach Identified Andrographolide as a Potential Drug for Suppressing COVID-19-Induced Cytokine Storm.** Front. Immunol. 2021; 12:648250Rehan M, Ahmed F, Howladar SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248936>
29. **Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection.** Front. Pharmacol. 2021; 12:575877Ayatollahi SA, Sharifi-Rad J, Tsouh Fokou PV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267652>
30. **Serratiopeptidase, A Serine Protease Anti-Inflammatory, Fibrinolytic, and Mucolytic Drug, Can Be a Useful Adjuvant for Management in COVID-19.** Front. Pharmacol. 2021; 12:603997Sharma C, Jha NK, Meeran MFN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248612>
31. **The Role of Pulmonary Surfactants in the Treatment of Acute Respiratory Distress Syndrome in COVID-19.** Front. Pharmacol. 2021; 12:698905Wang S, Li Z, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267664>
32. **Therapeutic prevention of COVID-19 in elderly: a case-control study.** Geroscience 2021;1-11Blanc F, Waechter C, Vogel T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273049>
33. **Mesenchymal stem cells: ideal seeds for treating diseases.** Hum. Cell 2021:1-16Gao G, Fan C, Li W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272720>
34. **Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial.** Int Immunopharmacol 2021; 99:107969Alavi Darazam I, Shokouhi S, Mardani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273635>
35. **Tocilizumab and Systemic Corticosteroids in the Management of COVID-19 Patients:A Systematic Review and Meta-Analysis.** Int J Infect Dis 2021; Alkofide H, Almohaizeie A, Almuhaiani S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273515>
36. **Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.** Intensive Care Med 2021:1-

- 20Arabi YM, Gordon AC, Derde LPG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251506>
37. **High-dose dexamethasone treatment for COVID-19 severe acute respiratory distress syndrome: a retrospective study.** *Intern Emerg Med* 2021;1-7Vecchié A, Batticciotto A, Tangianu F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275096>
 38. **Benralizumab: a potential tailored treatment for life-threatening DRESS in the COVID-19 era.** *J Allergy Clin Immunol Pract* 2021; Mesli F, Dumont M, Soria A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273579>
 39. **Tocilizumab in patients with COVID-19: which patient, time, and dose?** *J Anesth.* 2021; Hasanin A, Mostafa M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264384>
 40. **Computational drug repurposing study of antiviral drugs against main protease, RNA polymerase, and spike proteins of SARS-CoV-2 using molecular docking method.** *J. Basic Clin. Physiol. Pharmacol.* 2021; Jalalvand A, Khatouni SB, Najafi ZB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265888>
 41. **Clinical efficacy of low-dose emetine for patients with COVID-19: a real-world study.** *J BioX Res* 2021; 4:53-59Fan S, Zhen Q, Chen C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254034>
 42. **Clinical Features and Outcome of Low and High Corticosteroids in Admitted COVID-19 Patients.** *J Epidemiol Glob Health* 2021; AlBahrani S, Al-Tawfiq JA, Jebakumar AZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34270179>
 43. **N-acetylcysteine for the treatment of COVID-19 among hospitalized patients.** *J Infect* 2021; Avdeev SN, Gaynitdinova VV, Merzhoeva ZM, Berikkhanov ZG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252497>
 44. **The Impact of Corticosteroids on Secondary Infection and Mortality in Critically Ill COVID-19 Patients.** *J. Intensive Care Med.* 2021;8850666211032175Ritter LA, Britton N, Heil EL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247526>
 45. **Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.** *J Med Virol* 2021; Kalantari S, Fard SR, Maleki D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255369>
 46. **Dexamethasone treatment may mitigate adverse effects of vitamin D deficiency in hospitalised Covid-19 patients.** *J Med Virol* 2021; Wenban C, Heer RS, Baktash V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273116>
 47. **Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.** *J Microbiol Immunol Infect* 2021; Lai CC, Chao CM, Hsueh PR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253490>
 48. **Novel piperazine based compounds as potential inhibitors for SARS-CoV-2 Protease Enzyme: Synthesis and molecular docking study.** *J. Mol. Struct.* 2021; 1245:131020Omar AZ, Mosa TM, El-Sadany SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248201>
 49. **A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma.** *J. Oncol. Pharm. Pract.* 2021;10781552211031304Demir E, Sütçüoğlu O, Demir B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255596>

50. **Integrated vaccination and non-pharmaceutical interventions based strategies in Ontario, Canada, as a case study: a mathematical modelling study.** J R Soc Interface 2021; 18:20210009Betti M, Bragazzi NL, Heffernan JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255985>
51. **Synthetic Attempts Towards Eminent Anti-Viral Candidates of SARS-CoV.** Mini Rev. Med. Chem. 2021; Kundu S, Sarkar D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254915>
52. **Early COVID-19 Therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in Outpatient Settings Significantly Improved COVID-19 outcomes compared to Known outcomes in untreated patients.** New Microbes New Infect 2021:100915Cadegiani FA, Goren A, Wambier CG, McCoy J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249367>
53. **Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.** Open Forum Infect Dis 2021; 8:ofab254Bariola JR, McCreary EK, Wadas RJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250192>
54. **The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting.** Open Forum Infect Dis 2021; 8:ofab305Corwin DS, Ender PT, Sahu N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258324>
55. **Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients.** Open Forum Infect Dis 2021; 8:ofab292Piccicacco N, Zeidler K, Montero J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258319>
56. **Impact of nonpharmacological COVID-19 interventions in hospitalizations for childhood pneumonia in Brazil.** Pediatr Pulmonol 2021; Friedrich F, LC EG, Petry LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265188>
57. **A synthetic defective interfering SARS-CoV-2.** PeerJ 2021; 9:e11686Yao S, Narayanan A, Majowicz SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249513>
58. **Ultraviolet C Supported Novel Phototherapy Units at the Crossroads of the COVID-19 Pandemic.** Photobiomodul Photomed Laser Surg 2021; 39:437-438Kutlu Ö. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264764>
59. **Contribution of traditional Chinese medicine combined with conventional western medicine treatment for the novel coronavirus disease (COVID-19), current evidence with systematic review and meta-analysis.** Phytother. Res. 2021; Jiang F, Xu N, Zhou Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256418>
60. **Dexamethasone treatment for COVID-19 investigated.** Pneumologie 2021; 75:415Wagner A.
61. **Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: a timing challenge for clinicians.** Pulm. Pharmacol. Ther. 2021:102055Ji HL, Wagener BM, Ness TJ, Zhao R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271164>
62. **Low dose lung radiotherapy for COVID-19 pneumonia: A potential treatment.** Respir. Med. 2021; 186:106531Gupta S, Ahuja R, Sharma N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260977>
63. **Platelet lysate for COVID-19 pneumonia-a newer adjunctive therapeutic avenue.** Stem Cell Investig 2021; 8:11Jeyaraman M, Muthu S, Khanna M *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34268440>

64. **Combination of mesenchymal stem cells and nicorandil: an emerging therapeutic challenge against COVID-19 infection-induced multiple organ dysfunction.** Stem Cell. Res. Ther. 2021; 12:404Safari A, Lionetti V, Razeghian-Jahromi I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266486>
65. **Cell therapy in patients with COVID-19 using Wharton's jelly mesenchymal stem cells: a phase 1 clinical trial.** Stem Cell. Res. Ther. 2021; 12:410Saleh M, Vaezi AA, Aliannejad R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271988>
66. **Sequential dosing of convalescent COVID-19 plasma with significant temporal clinical improvements in a persistently SARS-COV-2 positive patient.** Transfus. Apher. Sci. 2021:103180Mirihagalle N, Parajuli P, Sundareshan V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247970>
67. **Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: A meta-review of systematic reviews and an updated meta-analysis.** Travel Med Infect Dis 2021; 43:102135Chivese T, Musa OAH, Hindy G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265436>
68. **Fluorescence of ocular surface in a Covid -19 patient after Favipiravir treatment: a case report.** Virol J 2021; 18:146Doran MA, Aytogan H, Ayıntap E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256791>
69. **Review of the potential of mesenchymal stem cells for the treatment of infectious diseases.** World J. Stem Cells 2021; 13:568-593Sharma A, Chakraborty A, Jaganathan BG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=3424922>

Trials (26 articles)

1. **French Multicentre Observational Study on SARS-CoV-2 infections Intensive care initial management: the FRENCH CORONA Study.** Anaesth Crit Care Pain Med 2021:100931Roger C, Collange O, Mezzarobba M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256165>
2. **Practice of adjunctive treatments in critically ill COVID-19 patients-rational for the multicenter observational PROAcT-COVID study in The Netherlands.** Ann Transl Med 2021; 9:813Valk CMA, Swart P, Boers LS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268426>
3. **A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae.** BMC Infect. Dis. 2021; 21:677LaVergne SM, Stromberg S, Baxter BA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256735>
4. **Absolute mortality risk assessment of COVID-19 patients: the Khorshid COVID Cohort (KCC) study.** BMC Med. Res. Methodol. 2021; 21:146Marateb HR, von Cube M, Sami R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261439>
5. **Development and validation of the Oxford Pandemic Attitude Scale-COVID-19 (OPAS-C): an internet-based cross-sectional study in the UK and USA.** BMJ Open 2021; 11:e043758Kantor BN, Kantor J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261678>
6. **Design, implementation and initial findings of COVID-19 research in the Rotterdam Study: leveraging existing infrastructure for population-based investigations on an emerging disease.** Eur. J. Epidemiol. 2021:1-6Licher S, Terzikhan N, Splinter MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34275020>

7. **Prevention and Recovery of COVID-19 Patients With Kampo Medicine: Review of Case Reports and Ongoing Clinical Trials.** Front. Pharmacol. 2021; 12:656246Takayama S, Namiki T, Odaguchi H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34248620>
8. **Expanded principles of ethics and its implementation during COVID-19 vaccine trials: A scoping evidence based research synthesis.** Hum Vaccin Immunother 2021:1-7Kumar V, Aranha V, Rajgarhia R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34264174>
9. **COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge.** Immunity 2021; DiPiazza AT, Leist SR, Abiona OM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34270939>
10. **NOTTO COVID-19 Vaccine Guidelines for Transplant Recipients.** Indian J. Nephrol. 2021; 31:89-91Kute VB, Agarwal SK, Prakash J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34267426>
11. **Adverse events and humoral response after two-dose SARS-CoV-2 mRNA vaccination in the hospital personnel of a cardiopulmonary tertiary care center.** Infect Control Hosp Epidemiol 2021:1-8De Vita E, Sbrana F, Quattrone F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261574>
12. **Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial.** Int Immunopharmacol 2021; 99:107969Alavi Darazam I, Shokouhi S, Mardani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273635>
13. **SARS-CoV-2 seroprevalence and associated factors in Manaus, Brazil: baseline results from the DETECTCoV-19 cohort study.** Int J Infect Dis 2021; Lalwani P, Salgado BB, Filho IVP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273518>
14. **Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.** Intensive Care Med 2021:1-20Arabi YM, Gordon AC, Derde LPG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251506>
15. **Placebo-controlled trials with COVID-19 vaccines: participants first.** J. Clin. Epidemiol. 2021; Dal-Ré R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271109>
16. **Clinical Trials in COVID-19 Management & Prevention: A Meta-epidemiological Study examining.** J. Clin. Epidemiol. 2021; Honarmand K, Penn J, Agarwal A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274489>
17. **Participation in ENSEMBLE phase III multicenter clinical trial of Ad26.CoV2.S, a COVID-19 vaccine: An investigational drug services perspective.** J. Clin. Pharm. Ther. 2021; Li N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254358>
18. **Mortality associated with early changes in ARDS severity in COVID-19 patients - Insights from the PRoVENT-COVID study.** J Crit Care 2021; 65:237-245Schuijt MTU, Martin-Loeches I, Schultz MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271294>
19. **Vitamin D supplementation and COVID-19 risk: a population-based, cohort study.** J. Endocrinol. Invest. 2021:1-13Oristrell J, Oliva JC, Casado E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273098>
20. **Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19**

- patients.** *J Med Virol* 2021; Kalantari S, Fard SR, Maleki D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34255369>
21. **The landscape of COVID-19 trials in Australia.** *Med. J. Aust.* 2021; 215:58-61.e51 Seidler AL, Aberoumand M, Williams JG *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34275134>
 22. **Early COVID-19 Therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in Outpatient Settings Significantly Improved COVID-19 outcomes compared to Known outcomes in untreated patients.** *New Microbes New Infect* 2021:100915 Cadegiani FA, Goren A, Wambier CG, McCoy J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34249367>
 23. **Cell therapy in patients with COVID-19 using Wharton's jelly mesenchymal stem cells: a phase 1 clinical trial.** *Stem Cell. Res. Ther.* 2021; 12:410 Saleh M, Vaezi AA, Aliannejad R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271988>
 24. **A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial.** *Trials* 2021; 22:451 Sharma A, Sharma C, Raina S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266452>
 25. **Admission Braden Scale Score as an Early Independent Predictor of In-Hospital Mortality Among Inpatients With COVID-19: A Retrospective Cohort Study.** *Worldviews Evid. Based Nurs.* 2021; Lovicu E, Faraone A, Fortini A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34275200>
 26. **German registry www.Covid19-Rheuma.de: Status report after 1 year of the pandemic.** *Z. Rheumatol.* 2021; Hasseli R, Pfeil A, Hoyer BF *et al.*

Vaccines (91 articles)

1. **COVID-19 Vaccination Induced Lymphadenopathy in a Specialized Breast Imaging Clinic in Israel: Analysis of 163 cases.** *Acad Radiol* 2021; Faermann R, Nissan N, Halshtok-Neiman O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257025>
2. **Addressing Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following COVID-19 Vaccination: A Mini-Review of Practical Strategies.** *Acta Cardiol Sin* 2021; 37:355-364 Chen PW, Tsai ZY, Chao TH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34257485>
3. **[Immune Response to Single-Dose Moderna Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2].** *Acta Med Port* 2021; Moreira-Pinto J, Gregório S, Camarinha J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256902>
4. **Large hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: A case report.** *Acta Neurol. Scand.* 2021; de Mélo Silva ML, Jr., Lopes DP.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34273119>
5. **Two Cases of Well Controlled Chronic Spontaneous Urticaria Triggered by the Moderna COVID-19 Vaccine.** *Allergy Rhinol (Providence)* 2021; 12:21526567211026271 Alflen C, Birch K, Shilian R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34249404>
6. **Unique Predictors of Intended Uptake of a COVID-19 Vaccine in Adults Living in a Rural College Town in the United States.** *Am. J. Health Promot.*

- 2021:8901171211026132Lennon RP, Small ML, Smith RA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34269077>
7. **Intention to COVID-19 vaccination and associated factors among health care workers: A systematic review and meta-analysis of cross-sectional studies.** Am. J. Infect. Control 2021; Luo C, Yang Y, Liu Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34273461>
 8. **Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar.** Ann Med Surg (Lond) 2021; 67:102540Razok A, Shams A, Almeer A, Zahid M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249353>
 9. **Response to: 'Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response' by Westhoff et al.** Ann. Rheum. Dis. 2021; Bonelli M, Aletaha D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34272251>
 10. **Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report.** Ann. Rheum. Dis. 2021; Golding B, Lee Y, Golding H, Khurana S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34272252>
 11. **Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.** Ann. Rheum. Dis. 2021; Westhoff TH, Seibert FS, Anft M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34272253>
 12. **[Human resource management and vaccination strategies in primary care in Europe during COVID-19 pandemic].** Aten. Primaria 2021; 53:102132Ares-Blanco S, Astier-Peña MP, Gómez-Bravo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256236>
 13. **Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine.** BMJ Case Rep. 2021; 14Malik B, Kalantary A, Rikabi K, Kunadi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34261635>
 14. **Decolonising human rights: how intellectual property laws result in unequal access to the COVID-19 vaccine.** BMJ Glob Health 2021; 6Sekalala S, Forman L, Hodgson T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253631>
 15. **Intention to have the seasonal influenza vaccination during the COVID-19 pandemic among eligible adults in the UK: a cross-sectional survey.** BMJ Open 2021; 11:e049369Sherman SM, Sim J, Amlôt R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34257095>
 16. **Efficacy information influences intention to take COVID-19 vaccine.** Br. J. Health Psychol. 2021; Davis CJ, Golding M, McKay R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34250684>
 17. **Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses.** Cell 2021; Nathan A, Rossin EJ, Kaseke C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34265281>
 18. **Evaluating Vaccine Efficacy Against SARS-CoV-2 Infection.** Clin Infect Dis 2021; Lin DY, Gu Y, Zeng D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260716>
 19. **Deliberation, Dissent, and Distrust: Understanding distinct drivers of COVID-19 vaccine hesitancy in the United States.** Clin Infect Dis 2021; Tram KH, Saeed S, Bradley C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272559>
 20. **Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in health care workers: an observational study**

- using surveillance data. Clin Microbiol Infect 2021; Paris C, Perrin S, Hamonic S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265462>
21. **The SARS-CoV-2 Vaccine Hesitancy Among the General Population: A Large Cross-Sectional Study From Kuwait.** Cureus 2021; 13:e16261Burhamah W, AlKhayyat A, Oroszlányová M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268064>
 22. **COVID-19 Vaccination-Induced Rash: Does the Choice of Vaccine Matter?** Cureus 2021; 13:e15490Zafar M, Ewnetu B, Ahmed S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268022>
 23. **A Review on the Effectivity of the Current COVID-19 Drugs and Vaccines: Are They Really Working Against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants?** Curr Clin Microbiol Rep 2021;1-8Noor R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249605>
 24. **A half measure: Every COVID-19 single-dose vaccination offers only suboptimal protection.** Deutsche Apotheker Zeitung 2021; 161.
 25. **Impfung im EU-Ausland Digitale Zertifikate möglich.** Deutsche Apotheker Zeitung 2021; 161.
 26. **Myocarditis after mRNA vaccination: Discussions about risks of the new COVID-19 vaccines for younger men.** Deutsche Apotheker Zeitung 2021; 161Blasius H.
 27. **Leave of absence for COVID-19 vaccination?: Labor law in times of corona.** Deutsche Apotheker Zeitung 2021; 161Van Den Heuvel M.
 28. **Lack of vaccination and associated comorbidities predispose to the need for intensive care in individuals infected with the delta variant - A case cohort study from a tertiary care hospital in New Delhi, India.** Diabetes Metab Syndr 2021; 15:102203Vaishya R, Sibal A, Sharma H, Singh SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34265494>
 29. **The Meaning of SARS-CoV-2 Antibodies in a Patient with a Systemic Reaction to the mRNA-1273 SARS-CoV-2 Vaccine after Previous Natural Immunization.** Eur J Case Rep Intern Med 2021; 8:002617Sazgary L, Meienberg A, Berger CT, Mayr M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268264>
 30. **COVID-19 mRNA Vaccine and Myocarditis.** Eur J Case Rep Intern Med 2021; 8:002681Singh B, Kaur P, Cedeno L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268277>
 31. **Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT).** Eur J Intern Med 2021; Varona JF, García-Isidro M, Moeinvaziri M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256983>
 32. **Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021.** Euro Surveill 2021; 26Harder T, Koch J, Vygen-Bonnet S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269175>
 33. **Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England.** Euro Surveill 2021; 26Powell AA, Power L, Westrop S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269172>
 34. **Current vaccine technology with an emphasis on recombinant measles virus as a new perspective for vaccination against SARS-CoV-2.** EuroMediterr J

- Environ Integr 2021; 6:61Jbeli R, Jelassi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250222>
35. **COVID-19 vaccination associated severe immune thrombocytopenia.** Exp Hematol Oncol 2021; 10:42Shah SRA, Dolkar S, Mathew J, Vishnu P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34266487>
 36. **Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines.** Expert Opin. Drug Saf. 2021; Sessa M, Kragholm K, Hviid A, Andersen M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264151>
 37. **COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines?** Expert Rev Vaccines 2021;1-13Cooper S, van Rooyen H, Wiysonge CS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34252336>
 38. **Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets.** Front. Immunol. 2021; 12:694857Riddell S, Goldie S, McAuley AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248993>
 39. **Socio-Demographics Correlate of COVID-19 Vaccine Hesitancy During the Second Wave of COVID-19 Pandemic: A Cross-Sectional Web-Based Survey in Saudi Arabia.** Front Public Health 2021; 9:698106Al-Mohaithef M, Padhi BK, Ennaceur S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249851>
 40. **Ethical Considerations for Unblinding and Vaccinating COVID-19 Vaccine Trial Placebo Group Participants.** Front Public Health 2021; 9:702960Stoehr JR, Hamidian Jahromi A, Thomason C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249853>
 41. **Efficacy of Covid-19 vaccines: several modes of expression should be presented in scientific publications.** Fundam. Clin. Pharmacol. 2021; Montastruc JL, Biron P, Sommet A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250637>
 42. **Safety, efficacy and acceptability of SARS-CoV-2 vaccines in patients with cancer.** Future Virol. 2021; Chebel R, Labaki C, Farhat M, Kattan J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34249141>
 43. **COVID outbreak after the 1st dose of COVID vaccine among the nursing home residents: What happened?** Geriatr. Nurs. 2021; 42:1105-1108Ye P, Fry L, Liu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274688>
 44. **Effects of COVID-19 vaccination on FDG-PET/CT imaging: A literature review.** Glob Health Med 2021; 3:129-133Minamimoto R, Kiyomatsu T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250287>
 45. **Determinants of COVID-19 vaccine acceptance in the Arab world: a cross-sectional study.** Glob Health Res Policy 2021; 6:23Kaadan MI, Abdulkarim J, Chaar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253254>
 46. **COVID-19 Vaccination: crucial roles and opportunities for the mental health professionals.** Glob Ment Health (Camb) 2021; 8:e25Banerjee D, Mukhopadhyay S, Sahana Asmeen M, Javed A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258020>
 47. **Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.** Hematol. Oncol. 2021; Cuneo A, Rigolin GM, Coscia M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258787>
 48. **Assessing licensed nurses COVID-19 vaccine attitudes and intentions: a cross-sectional survey in the state of Hawaii.** Hum Vaccin Immunother 2021;1-

- 8Fontenot HB, Mattheus D, Lim E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254888>
49. **Landscape and progress of global COVID-19 vaccine development.** Hum Vaccin Immunother 2021;1-5Huang HY, Wang SH, Tang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254894>
 50. **Expanded principles of ethics and its implementation during COVID-19 vaccine trials: A scoping evidence based research synthesis.** Hum Vaccin Immunother 2021;1-7Kumar V, Aranha V, Rajgarhia R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264174>
 51. **COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients' Association.** Inflamm. Bowel Dis. 2021; Costantino A, Noviello D, Conforti FS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34259844>
 52. **Prosociality and Social Responsibility Were Associated With Intention of COVID-19 Vaccination Among University Students in China.** Int J Health Policy Manag 2021; Yu Y, Luo S, Mo PK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34273931>
 53. **Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine.** Int. J. Hematol. 2021; Waqar SHB, Khan AA, Memon S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264514>
 54. **Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case.** Int J Infect Dis 2021; Connor BA, Couto-Rodriguez M, Barrows JE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271202>
 55. **Adverse rare events to vaccines for COVID-19: From hypersensitivity reactions to thrombosis and thrombocytopenia.** Int. Rev. Immunol. 2021;1-10Novak N, Tordesillas L, Cabanillas B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251972>
 56. **Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review.** Iran J. Public Health 2020; 49:18-29Sheikhshahrokh A, Ranjbar R, Saeidi E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268202>
 57. **Young Adult Perspectives on COVID-19 Vaccinations.** J. Adolesc. Health 2021; Adams SH, Schaub JP, Nagata JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274212>
 58. **Placebo-controlled trials with COVID-19 vaccines: participants first.** J. Clin. Epidemiol. 2021; Dal-Ré R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271109>
 59. **Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know?** J. Clin. Med. Res. 2021; 13:317-325Vasireddy D, Vanaparthi R, Mohan G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267839>
 60. **Participation in ENSEMBLE phase III multicenter clinical trial of Ad26.CoV2.S, a COVID-19 vaccine: An investigational drug services perspective.** J. Clin. Pharm. Ther. 2021; Li N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254358>
 61. **Attitudes and intentions towards COVID-19 vaccines and associated factors among Egyptian adults.** J Infect Public Health 2021; Omar DI, Hani BM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247946>
 62. **Predicted and Observed Incidence of Thromboembolic Events among Koreans Vaccinated with ChAdOx1 nCoV-19 Vaccine.** J Korean Med Sci 2021; 36:e197Huh K, Na Y, Kim YE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254476>

63. **Emergency Department Utilization by In-hospital Healthcare Workers after COVID-19 Vaccination.** J Korean Med Sci 2021; 36:e196Park MJ, Choi YJ, Choi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254475>
64. **COVID-19 vaccination and the right to take risks.** J. Med. Ethics 2021; Huang PH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253621>
65. **SAFETY OF COVID-19 VACCINES.** J Med Virol 2021; Al Khames Aga QA, Alkhaffaf WH, Hatem TH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34270094>
66. **Relapse of microscopic polyangiitis after vaccination against COVID-19: a case report.** J Med Virol 2021; Conticini E, D'Alessandro M, Bergantini L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34251683>
67. **Public awareness about coronavirus vaccine, vaccine acceptance, and hesitancy.** J Med Virol 2021; Elgendy MO, Abdelrahim MEA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255346>
68. **Commentary: The spectrum of neurological manifestations related to COVID-19 and vaccinations.** J. Neuroimmunol. 2021; 358:577660Samudralwar RD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274719>
69. **COVID-19 Vaccination in Pregnancy: The Benefits Outweigh the Risks.** J. Obstet. Gynaecol. Can. 2021; 43:814-816Chavan M, Qureshi H, Karnati S, Kollikonda S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253304>
70. **Integrated vaccination and non-pharmaceutical interventions based strategies in Ontario, Canada, as a case study: a mathematical modelling study.** J R Soc Interface 2021; 18:20210009Betti M, Bragazzi NL, Heffernan JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255985>
71. **COVID-19: Perceived Infection Risk and Barriers to Uptake of Pfizer-BioNTech and Moderna Vaccines Among Community Healthcare Workers.** J Racial Ethn Health Disparities 2021; Famuyiro TB, Ogunwale A, des Bordes J, Raji M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264506>
72. **Coincidence of fever following COVID-19 vaccine and endemic tropical diseases: A challenge to clinicians during the global rollout of COVID-19 vaccination.** J Travel Med 2021; Asawapaithulsert P, Pisutsan P, Matsee W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272852>
73. **Systematic Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients with Chronic Kidney Disease.** Kidney Int Rep 2021; Carr EJ, Kronbichler A, Graham-Brown M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250319>
74. **Acute facial palsy as a possible complication of vaccination against SARS-CoV-2.** Laryngo- Rhino- Otologie 2021; 100:526-528Volk GF, Kutenreich AM, Geitner M, Guntinas-Lichius O.
75. **Reprint of: The Dark Side of the Moon: Global challenges in the distribution of vaccines and implementation of vaccination plans against COVID-19.** Maturitas 2021; 150:61-63Mesa-Vieira C, Botero-Rodríguez F, Padilla-Muñoz A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274076>
76. **Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines.** Mol. Pharm. 2021; Chatzikleanthous D, O'Hagan DT, Adamo R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264684>
77. **A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine.** Neurol Sci 2021;1-3Nasuelli NA, De Marchi F, Cecchin M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272622>

78. **Is it possible to ensure COVID19 vaccine supply by using plants?** Nucleus (Calcutta) 2021;1-5Bhar A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248208>
79. **COVID-19 infection, progression, and vaccination: Focus on obesity and related metabolic disturbances.** Obes Rev 2021; Westheim AJF, Bitorina AV, Theys J, Shiri-Sverdlov R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269511>
80. **Impact of Previous Coronavirus Disease 2019 on Immune Response After a Single Dose of BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.** Open Forum Infect Dis 2021; 8:ofab299Velasco M, Galán MI, Casas ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258322>
81. **SARS-CoV-2 vaccination for adolescents and young adult patients treated at a specialist pediatric oncology unit.** Pediatr Blood Cancer 2021:e29240Nigro O, Sironi G, Bergamaschi L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264546>
82. **AstraZeneca's COVID-19 vaccine: Vector vaccine with high protective effect.** Pharm. Ztg. 2020; 165:46-48Dingermann T.
83. **COVID-19 vaccines: Unanswered questions about effectiveness.** Pharm. Ztg. 2020; 165:38-40Hohmann-Jeddi C.
84. **COVID-19 pandemics Stage II - Energy and environmental impacts of vaccination.** Renew Sustain Energy Rev 2021; 150:111400Klemeš JJ, Jiang P, Fan YV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248390>
85. **[Explanatory factors on the acceptance of SARS-CoV-2 vaccine from consumer's behaviour perspective.].** Rev. Esp. Salud Pública 2021; 95de Andrés Sánchez J, Arias-Oliva M, Pelegrín-Borondo J, Lima Rua O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267176>
86. **Safety and Tolerability of SARS-CoV-2 Emergency-Use Authorized Vaccines Allogeneic Hematopoietic Stem Cell Transplant Recipients.** Transplant Cell Ther 2021; Ali H, Ngo D, Aribi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274492>
87. **Significance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation.** Vaccine 2021; Fujimoto AB, Keskinocak P, Yildirim I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274126>
88. **One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model.** Vaccine 2021; Gooch KE, Smith TRF, Salguero FJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253420>
89. **Henoch-Schönlein purpura presenting post COVID-19 vaccination.** Vaccine 2021; Hines AM, Murphy N, Mullin C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34247902>
90. **Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia.** Vaccine 2021; MacIntyre CR, Veness B, Berger D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272095>
91. **Initial impact of SARS-Cov-2 vaccination on healthcare workers in Italy- Update on the 28th of March 2021.** Vaccine 2021; Mateo-Urdiales A, Del Manso M, Andrianou X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253419>

Women – pregnancy (35 articles)

1. **Changes in obstetric interventions and preterm birth during COVID-19: A nationwide study from Iceland.** Acta Obstet Gynecol Scand 2021; Einarsdóttir K, Swift EM, Zoega H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34255860>
2. **Titres and neutralising capacity of SARS-CoV-2-specific antibodies in human milk: a systematic review.** Arch. Dis. Child. Fetal Neonatal Ed. 2021; Low JM, Low YW, Zhong Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34257103>
3. **Elevated risk for obsessive-compulsive symptoms in women pregnant during the COVID-19 pandemic.** Arch Womens Ment Health 2021; Mahaffey BL, Levinson A, Preis H, Lobel M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34269873>
4. **Clinical relevance of SARS-CoV-2 infection in late pregnancy.** BMC Pregnancy Childbirth 2021; 21:505Ruggiero M, Somigliana E, Tassis B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253173>
5. **[Adaptation of Health Care Organization in a level III Maternity Hospital during the COVID-19 pandemic].** Bull. Acad. Natl. Med. 2021; Hascoët JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248144>
6. **Cerebral Vasculitis in a COVID-19 Confirmed Postpartum Patient: A Case Report.** Case Rep. Neurol. 2021; 13:324-328Chua AMU, Jamora RDG, Jose ACE, Anlacan VMM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248564>
7. **COVID-19 in a pregnant patient with beta-thalassemia major: A case report.** Clin Case Rep 2021; 9:e04331Hailan YMA, Sayed G, Yassin MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34267898>
8. **Women's Sexual Health During the Pandemic of COVID-19: Declines in Sexual Function and Sexual Pleasure.** Curr Sex Health Rep 2021;1-13de Oliveira L, Carvalho J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248426>
9. **Investigating the impact of asymptomatic or mild SARS-CoV-2 infection on female fertility and in vitro fertilization outcomes: A retrospective cohort study.** EClinicalMedicine 2021; 38:101013Wang M, Yang Q, Ren X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250457>
10. **Association of ABO and Rh blood groups with obstetric outcomes in SARS-CoV-2 infected pregnancies: A prospective study with a multivariate analysis.** Eur. J. Obstet. Gynecol. Reprod. Biol. 2021; 264:41-48Sainz Bueno JA, Cerrillos González L, Abascal-Saiz A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271364>
11. **Impact of innovative pelvic floor muscle training on quality-adjusted life years (QALYs) in women with stress urinary incontinence treated by duloxetine.** Eur. J. Obstet. Gynecol. Reprod. Biol. 2021; 264:25-30Svihra J, Hagovska M, Breza J, Jr. *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271362>
12. **Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines.** Expert Opin. Drug Saf. 2021; Sessa M, Kragholm K, Hviid A, Andersen M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34264151>
13. **One Year Into the Pandemic: A Systematic Review of Perinatal Mental Health Outcomes During COVID-19.** Front Psychiatry 2021; 12:674194Iyengar U, Jaiprakash B, Haitsuka H, Kim S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34248710>
14. **Breastfeeding and COVID-19.** Gac Med Mex 2021; 157:194-200Galindo-Sevilla NDC, Contreras-Carretero NA, Rojas-Bernabé A, Mancilla-Ramírez J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34270527>
15. **COVID-19 during pregnancy.** Geburtshilfe Frauenheilkd. 2021; 81:588Lorenz J.

16. **The hidden interplay between sex and COVID-19 mortality: the role of cardiovascular calcification.** Geroscience 2021;1-15Cereda A, Toselli M, Palmisano A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260010>
17. **COVID-19 infection in pregnancy: a single center experience with 75 cases.** Ginek. Pol. 2021; Damar Çakırca T, Torun A, Hamidanoğlu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263921>
18. **The impact of COVID-19 pandemic on reproductive intentions among the Polish population.** Ginek. Pol. 2021; Sienicka A, Pisula A, Pawlik KK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263917>
19. **Did the SARS-CoV-2 effect pregnancy complications?** Ginek. Pol. 2021; Yucel Celik O, Çelen Ş, Engin Üstün Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34263916>
20. **Oncophone20 study: Patients' perception of telemedicine in the COVID-19 pandemic during follow-up visits for gynecological and breast cancers.** Int J Gynaecol Obstet 2021; Picardo E, Baù MG, Anatrone C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34258764>
21. **Clinical Features and Outcomes of COVID-19 Infection among Pregnant Women in South Africa.** Int J MCH AIDS 2021; 10:1-9Basu JK, Chauke L, Magoro T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262795>
22. **Prenatal Stress and Psychiatric Symptoms During Early Phases of the COVID-19 Pandemic in Italy.** Int J Womens Health 2021; 13:653-662Colli C, Penengo C, Garzitto M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34262355>
23. **Obstetrics and Neonatal Outcomes in Pregnant Women with COVID-19: A Systematic Review.** Iran J. Public Health 2020; 49:38-47Banaei M, Ghasemi V, Saei Ghare Naz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34268204>
24. **Psychometric properties of the Italian version of the Pandemic-Related Pregnancy Stress Scale (PREPS) and its correlation with anxiety and depression.** J. Affect. Disord. 2021; 294:48-53Penengo C, Colli C, Garzitto M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34271249>
25. **Evaluation of clinical outcomes of neonates born to mothers with coronavirus (COVID-19) in Shahid Beheshti Hospitals.** J Educ Health Promot 2021; 10:173Hosseini MS, Hosseini A, Ghaffari E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34250107>
26. **Probable viremia and positive placental swabs for SARS-CoV-2 in a preterm pregnant woman with mild COVID-19.** J Med Virol 2021; Akdemir Y, Haciseyitoglu D, Celebi G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260081>
27. **COVID-19 Vaccination in Pregnancy: The Benefits Outweigh the Risks.** J. Obstet. Gynaecol. Can. 2021; 43:814-816Chavan M, Qureshi H, Karnati S, Kollikonda S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34253304>
28. **Maternal deaths due to COVID-19 disease: The cases in a single center pandemic hospital in the south east of Turkey.** J. Obstet. Gynaecol. Res. 2021; Bağlı İ, Öcal E, Yavuz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254718>
29. **Does time change the anxiety and depression scores for pregnant women on Covid-19 pandemic?** J. Obstet. Gynaecol. Res. 2021; Geren A, Birge Ö, Bakır MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34254394>
30. **Physician Experiences in Management of COVID-19-Associated Coagulopathy in Pregnancy: Communication from the ISTH SSC Subcommittee on Women's Health Issues in Thrombosis and Haemostasis.** J Thromb Haemost 2021; Jevtic

- SD, Malinowski AK, Othman M, Kadir RAA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34260818>
31. **Highly expressed ACE-2 receptors during pregnancy: A protective factor for SARS-COV-2 infection?** Med. Hypotheses 2021; 153:110641 Figueiro-Filho EA, Hobson SR, Farine D, Yudin MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34256245>
 32. **Delivery management of suspected or confirmed COVID-19 positive mothers.** Pediatr. Neonatol. 2021; Lin C, Chu SM, Hsu JF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34272199>
 33. **COVID-19: Increased mortality among pregnant women.** Pharm. Ztg. 2021; 166:52-53 Dinger mann T.
 34. **Validation of the French IVF guidelines during the COVID-19 pandemic.** Reprod. Biomed. Online 2021; Poulain M, Fossard C, Benammar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=34274240>
 35. **COVID-19: The pandemic has serious consequences for mother and child.** Z. Geburtshilfe Neonatol. 2021; 225:198 Lorenz J.

to subscribe click [here](#)

mailing address is:
lansberg@gmail.com

© P.J. Lansberg